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Abstract 
GPR40, GPR41 and GPR43 are a small family of GPCRs.  Fatty acids were identified as 
the ligands for these receptors in 2003.  High levels of circulating fatty acids have been 
linked to a variety of diseases, including type 2 diabetes mellitus, cancer, and high levels of 
fatty acids are produced by anaerobic bacteria at the site of infection.  High levels of 
GPR40 have been detected in the β cells of the pancreas and all three receptors have been 
shown to be expressed in immune cells.  Due to the recent identification of the ligand for 
these receptors, their pharmacology, function and oligomerisation was investigated during 
this study. 
A [35S]GTPγS binding assay was developed to monitor the activation of GPR41 using a 
GPR41-Gαi3 Cys
351Ile fusion protein.  Using the fusion protein improved the signal to 
background ratio and allowed the potency of a variety of short chain fatty acids to be 
determined.  A GPR40-Gαq fusion protein was also generated, but basal levels of 
[35S]GTPγS binding in Gαq immunoprecipitates was high and did not increase significantly 
upon the addition of long chain fatty acids.  Treatment of membranes expressing GPR40-
Gαq with fatty acid free BSA reduced the basal [
35S]GTPγS binding in a concentration 
dependent manner and allowed the responsiveness of GPR40 to fatty acids to be 
uncovered.  This also allowed the potency of a variety of thiazolidinediones and small 
molecule agonists to be determined.  It was found that troglitazone was the most potent 
thiazolidinedione tested.  Rosiglitazone also acted as an agonist of GPR40, albeit with 
lower potency than troglitazone, whereas ciglitazone and pioglitazone displayed little 
potency.  Using clones of Flp-In TREx HEK293 cells where GPR40-eYFP was cloned into 
the Flp-In locus, the expression of GPR40-eYFP could be controlled by the addition of 
doxycycline.  Using this cell line confirmed that GPR40 mediated the rise in [Ca2+]i 
induced by the addition of troglitazone.  The expression of GPR40 was detected in the rat 
β cell line, INS-1E.  Addition of lauric acid or troglitazone to these cells induced a large, 
transient rise of [Ca2+]i.  Membranes prepared from INS-1E cells also displayed high basal 
[35S]GTPγS binding, which could be reduced by fatty acid free BSA.  The combination of 
fatty acid free BSA and lauric acid or troglitazone increased [35S]GTPγS binding.  The 
high levels of [35S]GTPγS binding observed in membranes expressing GPR40 may reflect 
the binding of an endogenous ligand to GPR40. 
Homology models of all three receptors based on the crystal structure of rhodopsin 
indicated that a conserved Arg residue in TM 5 may co-ordinate the carboxylate group of 
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the fatty acid.  To confirm this observation a series of mutant receptors were generated, 
with the Arg residue in TM5 mutated to alanine.  Neutralisation of the charge in TM5 in 
GPR41 and GPR43 resulted in receptors that were unable to respond to short chain fatty 
acids.  Further mutants of GPR43 were generated in which the Arg in TM5 was replaced 
by Lys, Leu or Ser.  None of these mutants were able mediate a rise in [Ca2+]i  in response 
to short chain fatty acids.  The equivalent mutation in GPR40 did not abolish the receptors 
ability to respond to long chain fatty acids.  There are two further conserved basic residues 
in TM regions of the receptors; an Arg/Lys in TM2 and a His in TM4.  These residues 
were also mutated to alanine.  In GPR41 and GPR43, both mutants had similar function to 
the wild type receptors.  Both GPR40 mutants were also able to respond to a variety of 
fatty acids measured by their ability to mediate a rise in [Ca2+]i in a FLIPR based assay 
system.  A series of further GPR40 mutants were generated where two of the three basic 
TM residues were mutated.  The most striking observation was found with the mutant in 
which the His in TM4 and Arg in TM5 mutated to alanine, this mutant was unable to 
mediate a rise in [Ca2+]i in response to a variety of saturated fatty acids.  This may indicate 
that upon loss of charge in TM5 the His in TM4 compensates and vice versa.  None of the 
small molecule agonists or thiazolidinediones were able to activate the TM4 or TM5 
mutants.  This indicated that the synthetic agonists of GPR40 require a more conserved 
binding pocket which may be due to their more rigid structure. 
The ability of GPR40 and GPR43 to form homo-oligmers was also investigated.  It was 
found that GPR40 and GPR43 formed homo-oligomers as monitored by co-
immunoprecipitation, FRET in single, living cells and by time resolved FRET.   
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1 Introduction 
1.1 General introduction 
To allow communication between cells, tissues and organs, receptors are found on the cell 
surface that specifically recognise a huge variety of signals ranging from light to proteins.  
Cell surface receptors are divided into different classes depending on their amino acid 
sequence and their homology to other receptors.  The largest family is called the G protein 
coupled receptor (GPCR) family and in human is encoded by over 800 genes (Hill, 2006).  
GPCRs serve to transduce a signal from outside to inside a cell.  They achieve this by 
activating proteins within the cell which can trigger multiple signal transduction pathways.  
GPCR dysfunction has been shown to be associated with a variety of human diseases 
ranging from allergic rhinitis to schizophrenia.  Around 30% of drugs in clinical use are 
targeted against GPCRs, although these drugs only act on approximately 30 receptors 
(Wise et al., 2004).  This makes the GPCR superfamily an attractive target for the 
development of new pharmaceutical medicines and for gaining a greater understanding of 
many disease processes (Hill, 2006). 
1.2 G protein coupled receptors 
1.2.1 Structure of GPCRs 
GPCRs can be identified by their seven transmembrane (TM) spanning α-helices.  These 
helices lead to a distinctive hydrophobicity pattern in the amino acid sequence, which 
makes the identification of putative GPCRs fairly easy.  Seven TM spanning helices results 
in the N- and C- terminus of the protein being at different sides of the membrane, and for 
GPCRs the N-terminus is extracellular and consequently the C-terminus is intracellular.  
The TM helices are joined by three intracellular and three extracellular loops.  GPCRs vary 
enormously in their length, with the shortest receptors consisting of around 300 amino 
acids (e.g. GPR40) and the longest of around 1000 amino acids (e.g. GABA receptors).  
Differences in the length of the N- and C- terminal domains and the intracellular and 
extracellular loops contribute to this wide range of sequence length.   
The first crystal structure of a GPCR was presented by Palczewski et al (2000), which 
showed the ground state structure of the light activated receptor, bovine rhodopsin, at 2.8Å 
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resolution.  This structure provided a wealth of information about the structural 
organisation of the receptor and gave clues to the mechanisms involved during receptor 
activation and the relay of the signal inside the cell.  The structure revealed a highly 
organised arrangement of the TM regions, which was in agreement with lower resolution 
data generated using electron microscopy, with the seven TM regions being arranged in a 
counter clockwise orientation with the core of the receptor being primarily comprised of 
TMs 2, 3, 5, 6 and 7 with TMs 1 and 4 being peripherally sequestered and more exposed to 
the lipid bilayer (Unger et al., 1997; Palczewski et al., 2000).   
The TM domains in rhodopsin vary in length from 19 to 34 residues and the crystal 
structure of bovine rhodopsin confirmed that they can be both kinked and/or tilted.  TM1 
and 2 were found to be tilted from the plane of the membrane by 25o.  TM1 contains a 12o 
bend within it, which is caused by a proline residue and TM2 deviates 30o from the ideal 
helix due to two glycine residues at the top of the helix.  TM3 is the longest helix and is the 
most tilted from the plane of the membrane, showing a 33o tilt.  This TM region also 
contains two internal bends, one due to a proline within the sequence and the other occurs 
at a serine, which does not usually cause a bend in a helix and appears to be related to the 
packing of the helices.  The C-terminal end of TM3, which occurs near the intracellular 
face of the receptor, contains the highly conserved D(E)RY (Asp/Glu-Arg-Tyr) motif 
found in nearly all rhodopsin-like receptors (see section 1.2.2), and has been linked to the 
stabilisation of the inactive receptor and to the activation of the receptor (see section 
1.2.4.2).  TM regions 4 and 6 both run almost perpendicularl to the membrane but the 
presence of two proline residues in TM4 and one in TM6 cause both of the helices to be 
kinked.  The proline residue in TM6 is one of the most conserved residues in GPCRs.  
TM5 tilts at 26o and contains two internal kinks that occur at phenylalanine and histidine 
residues.  TM7 possesses the highly conserved NPXXY motif, which is thought to be 
involved in forming structural domains that facilitate interactions with TM6, which are 
important in holding the receptor in the inactive state.  The crystal structure also 
highlighted the presence of another short helix in the cytoplasmic surface, which is termed 
helix 8.  It is an extension of TM7 and two cysteine residues at the end of the helix are 
modified by the attachment of palmitic acid moieties which insert into the membrane.   
The extracellular domains of rhodopsin, as shown by the crystal structure, form a compact 
lid and parts of this fold inwards to enclose the covalently bound retinal molecule.  The 
extracellular loops also contain two cysteine residues which are highly conserved in the 
GPCR family.  They are thought to form a disulphide bond which stabilises the receptor 
structure.  Within the N-terminal region and the extracellular loops of nearly all GPCRs 
Leigh Ann Stoddart, 2007   18 
can be found one or more N-linked glycosylation sites (Asn-X-Ser/Thr), where X can be 
any amino acid except proline or asparagine (Kristainsen et al., 2004).  For several GPCRs, 
the prevention of glycosylation results in reduced cell surface expression but has limited 
effect on ligand binding or the function of the receptors that are successfully delivered to 
the cell surface (Davidson et al., 1995; Ray et al., 1998).  This indicates that this region of 
a GPCR is important in the correct trafficking of the receptor to the plasma membrane.   
The intracellular loops were poorly defined in the crystal structure of bovine rhodopsin 
which indicates that they have a high degree of flexibility (Palczewski et al., 2000).  Other 
studies have indicated that they play an important role in G protein coupling (see section 
1.2.4.3).  The third intracellular loop contains serine and threonine resides that provide 
recognition sites for protein kinases that are involved in receptor desensitisation and 
internalisation (see section 1.2.6). 
1.2.2 GPCR family subtypes 
GPCRs function to transduce signals, in the form of ligands, into intracellular responses.  
GPCRs can be activated by a wide variety of ligand types, including light, ions, amino 
acids, nucleotides, peptides, biogenic amides, lipids and proteins.  Activation of a receptor, 
by ligand binding, can trigger a variety of responses within a cell.  Classically, these 
signals are generated through activation of heterotrimeric G proteins but there are a 
growing number of other proteins that can interact with GPCRs such as β-arrestins and 
neurochondrin.  The GPCR superfamily can be subdivided into three major subfamiles 
(Families A-C) and three small subfamilies (D-F) based on sequence homology and the 
pharmacological nature of the ligand. 
Family A is the largest class in the GPCR family and is the most studied.  Members of this 
family contain residues that are highly conserved although their overall homology is low.  
The conserved residues are mainly found in the TM regions and include the D(E)RY motif 
in TM3 and the NPXXY motif in TM7 as mentioned in section 1.2.1.  Other residues 
commonly found in TM regions of family A GPCRs, include an asparagine in TM1, an 
aspartic acid in TM2, a tryptophan in TM4 and a proline in TM6.  As mentioned in section 
1.2.1, extracellular loops 1 and 2 often contain cysteine residues that are connected by a 
disulphide bond.  The arginine residue of the D(E)RY motif is the only residue that is 
conserved in all family A receptors (Probst et al., 1992).  
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Family A receptors can be divided into three subgroups on the basis of their mechanisms 
for ligand binding.  Family Aα includes rhodopsin and the biogenic amine receptors, such 
as the adrenergic and dopamine receptors, and bind their ligands within a core formed by 
their TM helices.  Members of subfamily Aβ use their N-terminal region and extracellular 
loops as well as the TM helices to make up their ligand binding domain.  The ligands for 
this subfamily are usually peptides and the subfamily includes the receptors for 
chemokines, opioids and somatostatin.  The receptors that make up subfamily Aγ usually 
contain a longer N-terminal region which has been found to be very important in ligand 
binding, although some residues in the extracellular loops have also been implicated.  
Receptors within this subfamily include those for glycoprotein hormones such as lutenising 
hormone.   
Family B receptors are characterised by the presence of a large extracellular domain which 
is involved in ligand binding.  This family does not contain any of the conserved residues 
that are found in family A receptors.  They do contain conserved prolines in TM regions 
although these differ from those conserved in family A.  They also do not contain the 
D(E)RY motif.  The N-terminal region of these receptors contains several cysteine residues 
which form a network of disulphide bridges.  Family B is a smaller family and only 
contains about 20 different receptors.  The receptors in this family include those for 
calcitonin, vasoactive intestinal polypeptide, glucagon and glucagon like peptide.   
The receptors that make up family C all contain an extremely long N-terminus, which is 
usually 500-600 amino acids long.  They contain little sequence homology across the 
family but do contain cysteine residues in extracellular loops 2 and 3 which may form a 
disulphide bond.  The ligand binding domain of these receptors is proposed to be formed 
exclusively by the N-terminal region (Conn and Pin, 1997).  The crystal structure of the 
ligand binding domain of the metabolic glutamate receptor has been elucidated.  It forms a 
homodimer through both disulphide bonds and hydrophobic interactions (Kunishima et al., 
2000; Tsuchiya et al., 2002).   
The three additional families of GPCRs derive from genes that code for the pheromone 
receptors that bind to the Gαi/o family of G proteins (Dulac and Axel, 1995), the 
frizzled/smoothened receptors (Foord et al., 2002) and a family of cAMP-receptors found 
in Dictyostelium discoideum (Herald et al., 1992).  The frizzled/smoothened receptors are 
involved in embryonic development and in mammals there are 10 frizzled and 1 
smoothened receptors which are structurally similar to family B GPCRs (Foord et al., 
2002). 
Leigh Ann Stoddart, 2007   20 
The crystal structure for bovine rhodopsin is the only detailed structural information that 
exists for mammalian GPCRs and it is thought that all family A receptors will share a high 
degree of structural homology to rhodopsin even though their sequences are divergent.  As 
mentioned above, family B receptors do not have any of the conserved residues found in 
family A receptors but a similar overall morphology to family A receptor has been 
proposed.  The TM regions are likely to be kinked and tilted to different degrees than in 
family A receptors and due to the lack of a palmitoylation site within the C-terminal region 
they are unlikely to have an intracellular helix 8.  There is little structural information on 
the TM regions of other families of GPCRs so their arrangement is unknown. 
1.2.3 G proteins 
The structural changes within a GPCR that occur upon ligand binding allow the receptor to 
interact more effectively with guanine nucleotide binding proteins (G proteins).  G proteins 
consist of three different polypeptides, giving a heterotrimeric protein made up of an α, β, 
and γ subunit.  In the inactive state guanosine 5’diphosphate (GDP) is bound to the α 
subunit.  The GPCR acts as a guanine nucleotide exchange factor which promotes the 
release of GDP from the α subunit and its replacement with guanosine 5’triphosphate 
(GTP).  GTP is present in the cell at higher concentrations that GDP.  The exchange of 
GDP for GTP results in the dissociation of the α subunit from the β and γ subunits, which 
are tightly associated.  Both the α and βγ subunits are then able to interact with and 
regulate effector systems, in effect transducing the signal from the receptor to the cell.  The 
α subunit has intrinsic GTPase activity, which catalyses the hydrolysis of the terminal 
phosphate of the GTP; this returns the α subunit into an inactive state with GDP bound and 
promotes the re-association of the βγ subunits.  Early biochemical studies on G proteins 
found that rates of hydrolysis of GTP to GDP in purified α subunits were too slow to 
explain the rapid turnover seen in physiological systems.  This led to the discovery of 
RGS, or regulators of G protein signalling, proteins which act as GTP-ase activating 
proteins.  They have been shown to interact with G α subunits and promote the hydrolysis 
of GTP which therefore inactivates the G protein within a shorter time scale (De Vries et 
al., 1999).   
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1.2.3.1 G protein α subunit 
There are 16 different genes for G protein α subunits which through alternative splicing 
results in at least 28 distinct α subunits.  The α subunits can be classified into four 
subfamilies; Gαs, Gαi/o, Gαq/11 and Gα12/13 (Milligan and Kostenis, 2006). 
The Gαs family consists of Gαs(s), Gαs(L), Gαs(XL), which are alternatively spliced products 
of the Gαs gene, and Gαolf.  Gαs is known as the stimulatory G protein as its activation 
stimulates production of cyclic AMP (cAMP) through activation of adenylyl cyclase.  The 
Gαs family have also been shown to activate maxi K
+ channels, Src tyrosine kinases and 
the tubulin GTPase (Popova et al., 1994).  Expression of the Gαs splice variants is 
ubiquitous and there is some evidence that they are alternatively expressed under various 
conditions (Novotny and Svoboda, 1998).  Gαolf is only found mainly in olfactory neurons 
and certain CNS ganglia (Drinnan et al., 1991; Herve et al., 1993).   
The Gαi/o family includes Gαo1, Gαo2, Gαi1-3, Gαz, Gαt1/2 and Gαgust.  Many of the members 
of this family act to inhibit the production of cAMP by adenylyl cyclase and were 
originally identified as the inhibitory G proteins (Bokoch et al., 1984).  Other functions of 
this family include activation of K+ channels, inhibition of Ca2+ channels, activation of 
Rap1GAPII-dependent ERK/MAP kinase (Mochizuki et al., 1999) and activation of Src 
tyrosine kinases (Milligan and Kostenis, 2006).  Gαt1/2 stimulate cGMP phosphodiesterases 
(Granovsky et al., 2001).  Gαi1-3 are widely expressed, although preferential expression is 
found in neuronal systems.  Gαo1/2 are specifically expressed in neurons and 
neuroendrocrine cells.  Gαt1 and Gαt2 have a highly restricted distribution and are only 
found in retinal rod and cone outer segments respectively (Lerea et al., 1986), although 
expression has also been reported in taste buds (McLaughlin et al., 1994).  Gαgust also has 
limited expression and is found in sweet and bitter taste buds and chemoreceptor cells in 
the airways and it is responsible for sensing bitter taste via activation of 
phosphodiesterases (Margolskee, 2002).   
The Gαq/11 family is composed of Gαq, Gα11, Gα14, Gα15 and Gα16.  All members of this 
family activate phospholipase Cβ (PLCβ) isoforms.  Active PLCβ hydrolyses phosphatidyl 
inositol 4,5 bisphosphate into sn 1,2 diacylglycerol and inositol 1,4,5 trisphosphate (IP3).  
PLCβ can also be activated by βγ subunits but this occurs mainly in haemapoietic cells.  
IP3 binds to specific IP3 gated Ca
2+ release channels (IP3 receptors) that are found on the 
smooth endoplasmic reticulum.  These channels are show high specificity for inositiol 
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1,4,5 trisphosphate.  IP3 receptors are regulated by positive feedback as released Ca
2+ binds 
to IP3 receptors to further increase Ca
2+ release.  Released Ca2+ can activate ryanodine 
receptors which are also Ca2+ channels.  This Ca2+ activated Ca2+ release give a rapid all or 
nothing Ca2+ signalling response.  This rise in intracellular [Ca2+] ([Ca2+]i) is transient. Ca
2+ 
levels are returned to normal via multiple mechanisms which include Ca2+ ATPases that 
are found on the plasma membrane and endoplasmic reticulum and Na+Ca2+ antiporters.     
Gαq/11 are widely expressed, whereas Gα14, Gα15 and Gα16 are expressed in haematopoietic 
cells.  Gα14, Gα15 and Gα16 are naturally promiscuous Gα subunits.  Most GPCRs couple 
to a family of α subunits whereas promiscuous G proteins couple to a wide range of 
GPCRs that do not couple to Gαq or Gα11.  This allows them to be used to link a variety of 
predominately Gαs and Gαi/o coupled receptors to the PLCβ pathway (Kostenis et al., 
2005).   
Gα12 and Gα13 form a separate G protein α subunit family.  They are both widely 
expressed and are associated with communications involved between heterotrimeric G 
proteins and the cellular responses mediated by monomeric GTP-binding proteins, 
including morphology and cell proliferation (Riobo and Manning, 2005).  They mediate 
this crosstalk by activating a range of signalling proteins including phospholipase D and 
PLCε (Wing et al., 2003).   
The crystal structure of a variety of G protein α subunits has been elucidated, either on 
their own or complexed with βγ, effector or regulatory proteins (Noel et al., 1993; 
Coleman et al., 1994; Wall et al., 1995; Tesmer et al., 1997; Chen et al., 2005).  As 
expected with proteins that share at least 50% homology across the family, they all have 
highly similar structures.  The α subunit is composed of two main domains; the first 
domain is responsible for binding and hydrolyzing GTP to GDP while the second 
comprises of a unique helical domain that buries the GTP in the core of the protein (Noel 
et al., 1993; Coleman et al., 1994).  The GTPase domain of the α subunit is composed of 5 
α helices surrounding a 6-stranded β sheet (Coleman et al., 1994).  The α subunits are not 
transmembrane proteins but undergo modifications to allow them to attach to the 
membrane.  The widely expressed members of the Gαi/o family undergo N-myristoylation, 
which co-translationally attaches myristic acid (C14:0) to the N-terminal glycine following 
removal of the initiating methionine.  All G protein α subunits, apart from Gαt1/2, contain a 
cysteine near the N-terminus which is within the target site for post-translational addition 
of palmitic acid (C16:0) via a reversible thio-ester linkage (Wedegaertner et al., 1995).  It 
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has been shown that these modifications are important for plasma membrane targeting and 
for the association of the α subunit with the βγ subunits (Linder et al., 1991; Milligan et 
al., 1995).   
Endo-toxins produced by Vibrio cholerae and Bordetella pertussis use G protein α 
subunits as their target.  Both toxins are mono-ADP-ribosyltransferases; cholera toxin 
(CTX) is a N-linked transferase whereas pertussis toxin (PTX) is a C-linked transferase.  
The CTX target is an arginine residue within the GTPase domain of the α subunit of Gαs 
family, and modification of this residue prevents the α subunit from hydrolysing GTP to 
GDP and therefore results in a constitutively active protein.  The PTX target is a cysteine 
residue four residues from the end of Gαi/o family α subunits.  The incorporation of the 
ADP-ribose onto the α subunit prevents it from interacting with the receptor and therefore 
can no longer be activated (Hepler and Gilman, 1992).  Gαi/o α subunits can be modified to 
prevent ADP-ribosylation by mutation of the target cysteine to any other residue (Bahia et 
al., 1998).  CTX and PTX have proved to be very useful in defining the roles of Gαi/o and 
Gαq.  A specific inhibitor of Gαq/11 has recently been described by Takasaki et al., (2004), 
which was isolated from the culture broth of Chromobacterium sp. and named YM254890.  
It is thought that it prevents the exchange of GDP for GTP on the α subunit and its 
specificity makes it an important and useful tool for studying Gαq/11 mediated events.   
The action of PTX on Gαi/o α subunits has led to the finding that the C-terminal tail of the 
α subunit is important for receptor recognition (Kostenis et al., 2005).  This resulted in the 
creation of chimeric G proteins α subunits in which the terminal 5 amino acids have been 
replaced with the corresponding sequence of another α subunit.  These chimeric G proteins 
allow the switching of the pathway that a receptor activates.  The most common chimeric 
G proteins have a Gαq backbone and the last 5 residues of another α subunit such as Gαs or 
Gαi1 and they are widely used in the screening for ligands at orphan GPCRs (see section 
1.3).  It is now appreciated that there are additional regions within the α subunit that are 
involved in GPCR interaction, including the N-terminal domain (Kostenis et al., 2005). 
1.2.3.2 G protein βγ subunits 
There are five different β and 12 different γ subunits that have been identified.  Most cell 
types express multiple β and γ subtypes, although β3 and γ8 are only found in retinal cone 
cells and β1 and γ1 are only found in retinal rod cells.  β5 is found in neurons in 
neuroendocrine organs and β5(L) is only found in the retina (Milligan and Kostenis, 2006).  
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The large number of β and γ subunits give rise to numerous possible combinations but it is 
likely that the subtle expression patterns of the subunits limit the likelihood of pairings.  
For example, it has been shown that β2 cannot form a functional dimer with γ1 (Spring et 
al., 1994).  Most pairs can interact with similar affinity to α subunits.  An exception is the 
β1γ1 pair as it forms better interactions with αt1 than the other βγ pairs (Hamm, 1998). 
The G protein β subunits have a β propeller structure based on a seven WD (tryptophan-
aspartate)-40 repeats (Lambright et al., 1994; Wall et al., 1995; Sondek et al., 1996).  The γ 
subunit interacts with the β subunit via N-terminal coiled-coil interactions and through a 
series of extensive contacts along the base of β subunit.  The association between β and γ 
subunits is very strong and dissociation can usually only be achieved through protein 
denaturation.  The exception to this rule is found in the β5 subunit which has been shown to 
dissociate from the γ subunit, which allows it to interact with a number of RGS proteins 
that contain a γ-subunit-like domain (Levay et al., 1999).  The βγ dimer interacts with the 
α subunit via a hydrophobic pocket present when the α subunit has GDP bound.  The 
conformational changes that occur in the α subunit upon GTP binding results in a loss of 
the hydrophobic pocket and therefore dissociation of βγ (Lambright et al., 1996). 
Lipid modifications are also found on the γ subunits.  For most of the γ subunits it is a 
geranylgeranyl (C20) modification, apart from γ1 which is farnesylated (C15).  The 
modifications occur at the extreme C-terminus of the subunit through a stable thioether 
bond on the cysteine found in the ‘CAAX’ box motif.  The three terminal residues are 
subsequently cleaved resulting in the cysteine becoming the new C-terminus.  There are no 
lipid modifications found on the β subunits (Wedegaertner et al., 1995). 
It was originally thought that the presence of βγ was to suppress the activity of the α 
subunit when not in the GTP bound form and to tether it to the membrane before lipid 
modifications on the α subunits were identified (Milligan and Kostenis, 2006).  It is now 
appreciated that βγ have their own role within the cell and can bind to and activate a range 
of effector proteins.  Target proteins for βγ include PLCβ isoforms, adenylyl cyclases, G 
protein receptor kinases (GRK), K+ channels and Ca2+ channels.  Not all βγ dimer pairs 
function equivalently and some have more affinity for certain effectors than others.  For 
example, β1γ2 has been shown to stimulate one of the adenylyl cyclase isoforms, adenylyl 
cyclase II, but β5γ1 inhibits the activity of the same enzyme (Bayewitch et al., 1998).  The 
conformation of the βγ subunits does not undergo major structural changes upon activation 
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and it has now been proposed that the α subunits act to suppress the activity of the βγ 
subunits (Cabrera-Vera et al., 2003).  
1.2.4 Signal transduction and ligand binding 
1.2.4.1 Ligand binding 
The means by which a GPCR binds its ligand differs for the different families of receptors.  
Even within family A there are major differences in the areas important in ligand binding.  
As mentioned previously, detailed structural information exists only for rhodopsin.  The 
ligand for rhodopsin, 11-cis-retinal, is covalently attached to the receptor through the 
formation of a Schiff base with lysine296 in TM7 within a binding crevice formed by the 
TM helices.  11-cis-retinal acts as an inverse agonist (see section 1.2.5) which keeps the 
receptor inactive in the absence of light, and exposure to light results in isomerisation of 
11-cis-retinal to all-trans-retinal, which acts as the agonist to activate the receptor (Sakmar, 
1998).  Interactions between 11-cis-retinal and the receptor also occur between the C9 of 
retinal and glycine121 in TM3 and with aromatic residues in the outer portion of TM6 (Han 
et al., 1997; Nakayama et al., 1991).   
Apart from rhodopsin, the best studied receptor-ligand interactions are those of the 
biogenic amine receptors.  The ligands for these receptors also bind within a crevice 
formed by the TM regions and the main ligand-receptor interactions occur within TMs 3, 5 
and 6.  It has been found that the positively charged amine of catecholamines forms a salt 
bridge with an aspartic acid residue within TM3.  The aspartic acid residue is conserved 
within the biogenic amine receptors.  The importance of this residue has been 
demonstrated by mutagenesis studies on the β2 adrenergic receptor (Strader et al., 1991), 
α1A adrenergic receptor (Hwa et al., 1995), histamine H2 receptor (Gantz et al., 1992) and 
the muscarinic acetylcholine receptors (Spalding et al., 1994).  In the β2 adrenergic 
receptor, important interactions also occur between the catechol ring of adrenaline and two 
serine residues that occur one α helical turn apart in TM5.  Further studies on this receptor 
have identified two residues in TM6, phenylalanine290 and asparagine293 which are thought 
to stabilise the catechol ring and hydrogen bond with the β-hydroxyl of adrenaline 
respectively (Tota et al., 1990; Wieland et al., 1996).  Receptors that interact with 
eicosanoids, such as leukotrienes and prostanoids, have a similar mechanism for binding 
their ligands.  The important residues in the binding crevice are from TMs 3, 6 and 7.  
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There is also a conserved arginine at the top of TM7, near the extracellular surface, that is 
proposed to coordinate the carboxyl head group of these ligands (Funk et al., 1993).   
The members of GPCR family A whose ligands are peptides have a slightly different 
mechanism for ligand binding.  These receptors include the angiotensin receptors, 
chemokine receptors and the opioid receptors.  For these receptors, the ligands make 
important interactions with the N-terminus of the receptor and extracellular loops 1 and 2.  
Residues within the TM domains have also been shown to be important but these often lie 
at the top of the α helices (Gether, 2000).  Family A GPCRs that are activated by 
nucleosides, such as the adenosine receptors, have ligand binding domains that are largely 
made up by the TM regions but the second extracellular loop also contributes (Ji et al., 
1998).  The protease activated receptors have a unique mechanism for activation.  Their N-
terminus contains a recognition sequence for proteases such as thrombin, and when this is 
cleaved the shortened N-terminus acts as a tethered agonist for the receptor through 
interactions with the extracellular loops (Nanevicz et al., 1996), much like those observed 
for the peptide GPCRs. 
As mentioned above, family B GPCRs commonly contain a longer N-terminus that family 
A receptors.  This long N-terminus has been shown to be very important in binding of 
ligands to the receptor.  In a similar way to the family A receptors that are activated by 
peptides, the extracellular loops also play a role but none of the residues within the TM 
domains have been shown to be important in agonist binding (Gether, 2000).  The family C 
receptors contain a very long N-terminus and this region forms the whole of the ligand 
binding domain.  The crystal structure of the extracellular domain of the metabotropic 
glutamate mGluR1 receptor has been resolved, which demonstrated that the ligand binding 
domain forms a disulphide-linked dimer.  The dimer formation of this domain has been 
likened to a Venus flytrap which opens and closes in response to agonist binding 
(Kunishima et al., 2000).   
1.2.4.2 Signal transduction 
To allow transduction of the signal from an agonist into a cell via a GPCR the receptor 
must be able to activate intracellular effectors.  This is achieved by the receptor undergoing 
a series of conformational changes upon ligand binding that allow the effectors to bind and 
be activated.  The changes that occur have been best studied for rhodopsin due to the 
covalent attachment of the 11-cis-retinal, which acts as an antagonist to keep the receptor 
in a inactive state whilst the absorption of a photon of light isomerises the 11-cis-retinal to 
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all-trans-retinal which induces several conformational changes within the receptor (Meng 
et al., 2001; Teller et al., 2001).   
In the inactive state, a GPCR has various molecular constraints within the TM regions 
which prevent it from spontaneously activating.  Many of these constraints involve 
interactions between residues that are found to be highly conserved within family A 
GPCRs (Urizar et al., 2005).  The release of these constraints induces positional changes of 
certain TM helices.  One of the regions that is heavily implicated as being very important 
in receptor activation is the DRY motif found at the bottom of TM3.  The arginine in this 
triplet is conserved throughout family A GPCRs and is thought to form ionic interactions 
with a partly conserved aspartic acid/glutamic acid residue in the cytoplasmic end of TM6.  
The crystal structure of rhodopsin supports this idea as it shows a network of interactions 
between the glutamic acid and arginine of the ERY in TM3 and the glutamic acid of TM6 
which is proposed to sustain the cytoplasmic ends of these two helices immobilized 
(Palczewski et al., 2000).  This interaction has also been proposed for a variety of other 
family A GPCRs, including the β2 adrenergic receptor (Ballesteros et al., 2001).  
Disruption of the ionic interactions between the arginine in TM3 and the glutamic acid in 
TM6 in rhodopsin is accompanied by the uptake of two protons (Arnis et al., 1994) which 
results in a change of environment for the residues and the movement of TM3 and TM6.  
The importance of the disruption of the ionic bond has been demonstrated by the 
introduction of mutations which neutralise the charge of the Asp/Glu.  This results in a 
constitutively active receptor.  This has been observed for many GPCRs, including 
rhodopsin (Cohen et al., 1993), β2 adrenergic receptor (Rasmussen et al., 1999), α1A 
adrenergic receptor (Scheer et al., 1996) and M1 muscarinic receptor (Lu et al., 1997).  The 
movement of these TM regions is thought to be a critical step in the creation of an active 
GPCR (Gether, 2000).  Analysis of the crystal structure of rhodopsin shows that TM6 
exists in a highly bent configuration due to a conserved proline within the α helix; it is 
thought that the movement of TM6 occurs around this hinge region in the absence of the 
interactions between TM6 and TM3.   
1.2.4.3 Regions of GPCRs involved in interaction with G protein 
A variety of different approaches have been used to decipher the regions within a GPCR 
that are involved in interacting and activating the G protein.  These include site directed 
mutagenesis (Wess et al., 1990; Blin et al., 1995), the engineering of chimeric receptors to 
attempt to switch the G protein signalling to an alternative pathway (Hwa et al., 1996) and 
the use of synthetic peptides to mimic the regions within the receptor that are thought to 
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activate the G protein (Higashijima et al., 1990).  These studies, and others, have shown 
that the second and third intracellular loops and the membrane proximal part of the 
carboxy terminus each play important roles in G protein coupling and activation (Gether, 
2000).  Each intracellular loop plays different roles; intracellular loop 3 appears to be the 
region important in G protein coupling specificity and intracellular loop 2 has been shown 
to be important for efficient G protein activation (Bluml et al., 1994; Burstein et al., 1995).  
The arginine in the DRY triplet had been proposed to interact directly with the G protein 
(Wess, 1998) but recent studies have shown that the arginine does not interact with the G 
protein and its function is to stabilise the inactive and activated conformations of the 
receptor (Flanagan, 2005).  As mentioned above, the carboxy terminus of the G protein α 
subunit is one of the regions involved in interaction with the receptor.  It has been 
proposed that the movement of TM3 and TM6 during receptor activation may allow 
insertion of the C-terminus of the α subunit into a cavity formed by the TM helices and 
this interaction induces the release of GDP (Gether, 2000). 
1.2.5 Receptor theory and constitutive activation 
The covalent attachment of 11-cis-retinal to rhodopsin holds the receptor in an inactive 
state and isomerisation of 11-cis-retinal to all-trans-retinal causes the receptor to undergo 
conformational changes that result in the receptor being in a conformation that allows 
activation of downstream effectors.  Rhodopsin is unique within the GPCR superfamily as 
11-cis-retinal prevents activation of the receptor in the absence of light as spontaneous 
isomerisation is a rare event, but measurable spontaneous activation of virtually all GPCRs 
can be recorded in the absence of agonist and this is termed constitutive activity (Milligan, 
2003).   
Models to explain the activation of GPCRs have been proposed and modified as our 
knowledge of receptor activation has expanded (Rang, 2006).  The most widely accepted 
model for GPCR activation is the extended ternary complex model, which is an extension 
of a 2-state model.  A 2-state model states that a receptor exists in equilibrium between an 
inactive conformation (R) and an active conformation (R*).  In the absence of agonist the 
majority of the receptor population exists in the R state but as the energy barrier between 
the R and R* is sufficiently low it allows a small portion of the receptors to spontanously 
switch to the R* state in which down stream effectors can be activated.  The presence of an 
agonist serves to alter the equilibrium between R and R* and agonists are hypothesised to 
have higher affinity for the R* state, thus, in the presence of an agonist a larger portion of 
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the population will now be in the active state to generate a signal within the cell.  The 
extended ternary complex model takes into account the interactions between the receptor 
and the G protein in addition to the interactions between the receptor and the agonist.  
Using these models and functional observations, the basic division of compounds into 
agonists and antagonists is no longer sufficient .  Compounds that act as agonists can be 
described as full agonists, which produce a maximal effect in a given assay system under 
specific conditions, or partial agonists which produce a detectable but submaximal effect 
under the same conditions.  Traditionally, an antagonist was defined as a compound that 
blocked the effect of agonists but monitoring the effects of these compounds on 
constitutive activity it was found that many were able to block some of the constitutive 
activity of a receptor by holding the receptor in the R state (Costa and Herz, 1989).  This 
resulted in antagonists that block constitutive activity being defined as inverse agonists as 
they have higher affinity for R.  As with agonists, inverse agonists can be termed full 
inverse agonists or partial inverse agonists.  A neutral antagonist has equal affinity for R 
and R*, thus producing no change in the equilibrium but blocks the effects of both agonists 
and inverse agonists.  Recent developments have found that the same receptor can activate 
several different signal transduction pathways depending on the agonist.  It is likely that 
different agonists stabilise different active conformations of the receptor and this can result 
in agonist directed-trafficking of the signal (Perez and Karnik, 2005). 
The degree of constitutive activity of a receptor can be altered by mutations.  As mentioned 
previously, neutralisation of the charge of the aspartic acid/glutamic acid of the DRY motif 
at the bottom of TM3 often results in an increase of constitutive activity (Ballesteros et al., 
2001; Montanelli et al., 2004).  This residue is thought to interact with a residue in TM6 
and mutation of this region also results in elevated levels of constitutive activity (Pauwels 
and Wurch, 1998; Seifert and Wenzel-Seifert, 2002), which supports the theory that this 
region is important in the movement of the TM helices associated with activation of the 
receptor.  Naturally occurring mutations in this region are associated with several inherited 
and acquired diseases, mainly in the endocrine system, and result in constitutively active 
GPCRs (Parnot et al., 2002). 
1.2.6 GPCR regulation 
Following activation of a GPCR, a series of events occur to desensitise the receptor to 
prevent chronic receptor over stimulation.  In the seconds following receptor activation, the 
receptor is phosphorylated at serine and threonine residues found within the C terminus 
and third intracellular loop.  GPCRs can be phosphorylated by kinases that are activated by 
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the second messengers produced by GPCR activation, such as protein kinase A (PKA) and 
protein kinase C (PKC) and by G protein receptor kinases (GRKs) (Krupnick and Benovic, 
1998).  GRKs only phosphorylate agonist activated GPCRs whereas agonist activation is 
not required for second messenger phosphorylation (Ferguson, 2001).  Phosphorylation of 
a GPCR serves to increase the affinity of the receptor for cytosolic cofactors termed 
arrestins.  Arrestins preferentially bind to receptors phosphorylated by GRKs over those 
phosphorylated by second messenger dependent kinases (Lohse et al., 1990; Lohse et al., 
1992).  Arrestin binding sterically hinders G protein coupling, serving to uncouple the 
receptor from the G protein.  Arrestins also function as endocytic adaptor proteins which 
can target a receptor for internalisation via clathrin-coated vesicles.  Internalisation 
removes the receptor from the cell surface into intracellular membrane vesicles and once 
internalised a receptor can either be recycled back to the cell surface or targeted to 
lysosomes for degradation.  Recycling involves the receptor becoming resensitised through 
dissociation from both the arrestin and the ligand and dephosphorylation by protein 
phosphatases.  Receptors that are targeted for degradation can result in a reduction in the 
total number of receptors within a cell, which can also be achieved at the transcriptional 
level (Luttrell and Lefkowitz, 2002). 
1.3 Orphan GPCRs 
In humans, about 360 genes for GPCRs are thought to encode non-sensory receptors.  Of 
these receptors the natural ligand has been identified for approximately 210, which leaves 
150 receptors with no known ligand or function: these are termed orphan GPCRs (Wise et 
al., 2004).  Many orphan GPCRs share low levels of homology with other receptors whose 
ligands have been identified, and subsequently cannot be classed within known specific 
sub-families.  It has been found that many orphan GPCRs share greater levels of homology 
with each other and form new sub-families.  These subfamilies are distributed throughout 
the GPCR superfamily tree, which implies they may be activated by a range of novel 
ligands and have a diverse range of function (Wilson et al., 1998).  It is estimated that 
although about 50% of all drugs with known mechanisms exert their biological effects by 
targeting GPCRs, these drugs target only 30 of the known GPCRs.  The potential of 
finding new drug targets and consequently new pharmaceutically active compounds has 
been a lure for many pharmaceutical companies to attempt to identify the activating 
ligands of orphan GPCRs.   
Leigh Ann Stoddart, 2007   31 
There are two general strategies used for the identification of ligands for orphan GPCRs; 
reverse pharmacology and orphan receptor strategy.  Reverse pharmacology uses 
compound libraries comprising of a variety of known endogenous ligands for other 
GPCRs, putative GPCR agonists and purified tissue extracts, and screens these compounds 
against a GPCR of unknown function.  This approach is often used by pharmaceutical 
companies due to its high throughput capability.  The more classic approach starts with the 
identification of a biologically active substance, usually a tissue extract which leads to the 
discovery of the receptor it activates.  This is often termed the orphan receptor strategy.  In 
contrast to reverse pharmacology, this technique is often used by smaller, mainly 
academic, laboratories.   
To identify activation of a GPCR by a putative ligand, a functional assay must be utilised.  
More than half of all identifications of ligands at orphan GPCRs have been accomplished 
using techniques that monitor changes in intracellular Ca2+ [Ca2+]i levels.  Changes in 
[Ca2+]i are a result of activation of the Gαq/11 proteins.  As only a proportion of GPCRs 
couple to Gαq/11, the introduction of chimeric or promiscuous G proteins are required as 
these redirect signalling of a wide range of GPCRs into the Ca2+ pathway.  As mentioned 
previously, an area of G proteins shown to be important in their interaction with GPCRs 
the extreme C-terminus.  The replacement of the five carboxy terminal amino acids of Gαq 
with the corresponding residues of another G protein results in a chimeric G protein which 
is able to couple to a non Gαq/11 receptor but activate the Gαq/11 pathway.  Mixtures of 
chimeric and promiscuous G proteins, often termed a ‘G protein cocktail’, are co-expressed 
with an orphan receptor.  However, there are several reports that question the overall 
applicability of the G protein cocktail strategy to all GPCRs.  A variety of other assay 
systems have been used in deorphanisation programmes, including reporter gene assays, 
assays monitoring the production of cAMP, yeast based assays and electrophysiological 
assays using oocytes.  There are advantages and disadvantages to each assay system, 
factors such as costs and its conversion to a high throughput platform are key to many 
pharmaceutical companies, whereas for academic laboratories sensitivity is often more 
important.   
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1.4 GPR40 family of fatty acid receptors 
1.4.1 Identification of genes encoding for the receptors 
GPR40, GPR41, GPR42 and GPR43 were identified by Sawzdargo et al., (1997) as a 
tandemly encoded group of intronless genes located at chromosome 19q13.1.  They were 
identified during a search for novel galanin receptors using sets of degenerate primers 
based on conserved sequences in human and rat galanin receptors.  They contain seven TM 
domains characteristic of GPCRs, along with other features common to the GPCR family 
and without knowledge of their activating ligands were classed as orphan GPCRs 
(Sawzdargo et al., 1997).  cDNA homologous to human GPR41 was cloned from rat lung 
(Bonini et al., 1997) and mouse GPR43 was cloned from leukaemia inhibitory factor 
stimulated M1 myeloid leukaemia cells (Senga et al., 2003).  GPR40-43 represent a family 
of receptors and they are more closely related to each other than to other GPCRs.  GPR41 
and GPR42 share about 98% homology and differ by only six amino acids (corresponding 
to seven nucleotide differences).  Only one receptor corresponding to GPR41/GPR42 can 
be identified in rodents (Brown et al., 2003) and GPR42 is now thought to be open reading 
frame pseudogene (Brown et al., 2005).  The other three receptors share 34-42% similarity, 
with GPR41 and GPR43 being the most similar.  The next most closely related receptors 
are the protease activated receptors, although GPR40-43 lack the long N-terminal 
extracellular domain which is cleaved to activate the protease activated receptors.  
1.4.2 Identification of GPR40 as a receptor for fatty acids 
GPR40 remained an orphan GPCR until 2003 when three papers were independently 
published that identified a range of medium and long chain saturated and unsaturated fatty 
acids as ligands for this receptor (Briscoe et al., 2003; Itoh et al., 2003; Kotarsky et al., 
2003).  Briscoe et al., (2003) identified an unsaturated long chain fatty acid, elaidic acid, as 
the only compound from a large library to act as an agonist at GPR40 in an assay system 
measuring the release of intracellular Ca2+.  They went on to demonstrate that over 40 
different fatty acids were able to activate GPR40 in the micro-molar range and of these 
fatty acids, eicosatrienoic acid was the most potent with an pEC50 of 5.71±0.11 (Briscoe et 
al., 2003).  Itoh et al., (2003) used a similar method to also identify long chain fatty acids 
as agonists at GPR40 with similar potency as described by Briscoe et al.  The lack of 
specificity of the receptor for different fatty acids may indicate that selectivity of the 
activating fatty acid is determined by local tissue specific environments.  They also showed 
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that methyl linoleate, a non-carboxyl containing compound related to linoleic acid, was 
unable to activate the receptor hence indicating that a carboxyl group was required for 
agonist function (Itoh et al., 2003).  Kotarsky et al., (2003) identified fatty acids as agonists 
of GPR40 by measuring the activation of a reporter gene.  Using this method they found 
fatty acids to be less potent than as detailed by Briscoe et al., (2003) and Itoh et al., (2003).  
In this study they also described non-fatty acid agonists of GPR40.  These were the insulin 
sensitising thiazolidinediones, rosiglitazone and MCC-555, and an experimental anti-
obesity compound, MEDICA16.   
1.4.2.1 Tissue distribution of GPR40 
All three initial reports on GPR40 found high levels of mRNA in the pancreas (Briscoe et 
al., 2003; Itoh et al., 2003; Kotarsky et al., 2003).  Briscoe et al., (2003) found by 
quantitative RT-PCR ubiquitous expression in all regions of the brain, with highest 
expression in the substantia nigra and medulla oblongata.  This was not supported by the 
tissue distribution study carried out by Kotarsky et al., (2003) using northern blot analysis 
on human samples.  In addition, Itoh et al., (2003) were unable to detect GPR40 mRNA in 
rat brain.  Kotarsky et al., (2003) detected expression of GPR40 in the human liver, heart 
and skeletal muscle but this was not seen in human or rat tissue by Briscoe et al., (2003) or 
by Itoh et al., (2003).  GPR40 expression has also been reported in human immune cells, 
with the highest levels of mRNA detected in monocytes (Briscoe et al., 2003).  Functional 
GPR40 has also been detected in the human breast cancer cell lines, MCF-7 (Yonezawa et 
al., 2004) and MDA-MB-231 (Hardy et al., 2005).  Further analysis of the expression of 
GPR40 in the pancreas found mRNA levels enriched in islets and in particular in the 
insulin producing β-cells (Briscoe et al., 2003, Itoh et al., 2003).  GPR40 expression has 
also been detailed in various pancreatic cell lines, including MIN6, β-TC-3, HIT-T15 and 
INS-1E (Briscoe et al., 2003; Itoh et al., 2003; Kotarsky et al., 2003; Sharipo et al., 2005).  
Tomita et al., (2005) demonstrated expression of GPR40 in human islets and in islet cell 
tumours.  Expression has also been detected in rat islets (Feng et al., 2005; Salehi et al., 
2005).   
1.4.2.2 GPR40 modes of signal transduction 
The initial studies on GPR40 suggested that the receptor coupled to the Ca2+ mobilising G 
proteins, Gαq and Gα11.  The study by Briscoe et al., (2003) did not use chimeric or 
promiscuous G proteins and found that in a reporter cell line which indicates 
responsiveness to Gαi/o and Gαq/11 pathways, a signal could be generated via GPR40 and 
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treatment with PTX did not affect the signal suggesting that the signal was generated via 
Gαq/11 activation (Briscoe et al., 2003).  Itoh et al., (2003) and Kotarsky et al., (2003) both 
concluded that GPR40 is predominately coupled to Gαq/11 but they also suggested that the 
receptor could also weakly couple to Gαi/o.  Studies on cells endogenously expressing 
GPR40 support the Gαq/11 coupling of the receptor (Hardy et al., 2005; Fujiwara et al., 
2005).  In particular, Shapiro et al., (2005) used the Gαq/11 specific inhibitor, YM254890 
(Takasaki et al., 2004) on the β-cell line, INS-1E, and this significantly reduced palmitic 
acid-induced mobilisation of [Ca2+]i.  However, in the breast cancer cell line, MCF-7, 
treatment with PTX blocked the long chain fatty acid induced elevation of [Ca2+]i 
(Yonezawa et al., 2004).   
1.4.2.3 Dual role of FAs in β cells 
Insulin secretion is stimulated by an increase in blood glucose.  Glucose is taken up into 
the β cells through the non insulin dependent glucose transporter, GLUT 2 and metabolised 
to acetyl CoA.  The resulting change in ATP/ADP ratio causes the closure of ATP 
sensitive K+ channels, which in turn depolarises the plasma membrane.  This 
depolarisation opens voltage dependent Ca2+ channels.  The Ca2+ influx triggers insulin 
granule exocytosis.  This Ca2+ influx is considered to be the major trigger for glucose-
stimulated insulin secretion (GSIS) (Ashcroft et al., 1990; Prentki et al., 1996). 
Fatty acids play an important role in normal β cell function.  An increase in free fatty acid 
concentrations augments GSIS (Seyffert and Madison, 1967; Stein et al., 1997).  The 
absence of circulating fatty acids causes loss of GSIS, which is reversible by replacement 
with exogenous fatty acids, and suggests that fatty acids are required for basal insulin 
secretion (Stein et al., 1996).  In contrast to the augmentation of GSIS by short term 
elevated plasma fatty acids levels, chronically raised levels of fatty acids has been shown 
to impair insulin secretion (Prentki et al., 2002) and induce β cell apoptosis (Lee et al., 
1994; El Assaad et al., 2003).  There is a strong link between obesity, non-insulin 
dependent diabetes mellitus (NIDDM), and circulating plasma levels of fatty acids.   
The mechanism by which fatty acids act as signalling molecules within β cells is complex.  
Fatty acids can cross the plasma membrane and be converted into long chain acyl-CoA 
(LC-CoA) in the cytosol.  During glucose metabolism, malonyl Co-A is produced which 
inhibits carnitine palmitoyltransferase (CPT-1) on the mitochondrial membrane.  This 
prevents the oxidation of fatty acids and produces a build of LC-CoA in the cytosol 
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(DeFronzo, 1997).  The LC-CoA then acts as an effector molecule to enhance insulin 
release (Prentki and Corkey, 1996).  Other mechanisms have been suggested such as 
triglyceride/free fatty acid cycling via lipolysis (Nolan et al., 2006). 
1.4.2.4 Could the effects of FAs on β cells be explained through action 
on GPR40 
The endogenous expression of GPR40 in a range of transformed pancreatic β-cell lines and 
in pancreatic β-cells has initiated a series of studies into the function of the receptor in 
these cells.  Initial studies in MIN6 cells whereby GPR40 was silenced using siRNA 
demonstrated that fatty acids were then unable to amplify insulin release (Itoh et al., 2003).  
This was also shown by Salehi et al. (2005).  Treatment of INS-1E cells with siRNA 
corresponding to GPR40 resulted in a significant reduction in insulin secretion in the 
presence of fatty acids and a rise in [Ca2+]i in response to palmitic acid could no longer be 
detected (Shapiro et al., 2005; Schnell et al., 2006).  The mechanism of GPR40-mediated 
insulin secretion from rat β-cells appears to involve a reduction in current through voltage 
gated K+ channels and an increase in PKA activity (Feng et al., 2006).   
An important finding by Salehi et al., (2005) was the possible antagonist effects of 2-
bromo palmitate (2BrP) on GPR40.  They showed that 2BrP inhibited linoleic acid 
mediated phosphatidyl inositol hydrolysis in human embryonic kidney, HEK293, cells 
transiently expressing mouse GPR40 and in MIN6 cells.  2BrP also showed partial agonist 
properties, by causing a slight activation of PI hydrolysis, although no attempt at 
quantification was undertaken (Salehi et al., 2005).  2BrP is classically described as an 
inhibitor of CPT-1 and therefore of mitochondrial long chain fatty acid oxidation.  This 
supports the malonyl-CoA hypothesis of insulin release and has been shown to stimulate 
insulin secretion (Prentki et al., 1992).  The interaction of this compound with GPR40 
complicates its support to the malonyl-CoA hypothesis.  
The most compelling evidence implicating GPR40 in the development of NIDDM comes 
from work carried out by Steneberg et al., (2005) using mouse models of GPR40.  They 
developed GPR40 knockout mice and found that islets isolated from these mice were 
unable to increase insulin secretion in response to treatment with palmitic acid.  Mice 
expressing GPR40, when fed a high fat diet, become obese and this leads to high plasma 
fatty acid levels, insulin resistance, hyperinulinemia and glucose intolerance, in short all 
the factors associated with NIDDM.  By contrast, the GPR40 knockout mice, although they 
became obese, they did not develop glucose intolerance and became less insulin resistant.  
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To investigate the contribution of GPR40 overstimulation in the development of NIDDM, 
GPR40 was over expressed under the control of the Ipf1/PDX-1 promoter in transgenic 
mice.  In contrast to the knockout mice, those overexpressing GPR40 were glucose 
intolerant and hypoinsulinemic on a normal diet (Stenberg et al., 2005).  This development 
of diabetes is comparable to the chronic effects of fatty acids on β cells (Haber et al., 
2003).  
The mechanisms of action of fatty acids in normal β cell function and in the development 
NIDDM are not fully understood.  The studies on GPR40 in recombinant cell systems, β 
cell lines, isolated islets and in transgenic mice point towards this receptor being involved.  
It has been proposed that GPR40 interacts with the systems involving fatty acid 
metabolism within the β cells (Nolan et al., 2006).   
Dissection of the role of GPR40 in pancreatic β-cells is hampered by the lack of high 
affinity, specific agonists and antagonists.  The incentive of possible pharmacological 
intervention at this receptor for the treatment of NIDDM has lead to the recent publication 
of a range of GPR40 agonists based on a 3-(4-{[N-alkyl]amino}phenyl)propanoic acid 
template (Garrido et al., 2006).  Using a reporter gene assay they found compounds with 
potencies in the nanomolar range.  They also showed that a carboxylic moiety was not 
essential for agonist action at the receptor, with no effect on potency and a slight reduction 
in efficacy.  The structure of six of these compounds is shown in Figure 1.2 (a-g).  Further 
studies were carried out on one of the compounds, GW9508X (Compound (a) in Figure 
1.2, and called GW839508X herein) (Briscoe et al., 2006).  They observed similar potency 
of the compound to that observed in the reporter gene assay when measuring the release of 
[Ca2+]i in HEK293 cells transiently expressing GPR40.  GW839508X was also able to 
increase GSIS in MIN6 cells in a concentration dependent manner, although not to the 
same levels as linoleic acid.  In addition to the characterisation of the agonist, they also 
described a GPR40 specific antagonist, GW1100 (Figure 1.2 (f)).  This compound 
inhibited the enhancement of GSIS by GW839508X in MIN6 cells but only partially 
inhibited the GSIS achieved by linoleic acid.   
Two polymorphisms in the open reading frame of human GPR40 have been reported, 
Arg211His (Hamid et al., 2005; Ogawa et al., 2005) and a rare Asp175Asn polymorphism 
(Hamid et al., 2005).  Hamid et al., (2005) found that the allelic frequency of the Arg211His 
polymorphism was similar in normal patients and patients with NIDDM.  In a recombinant 
cell system, they found no difference in the potency of eicosatriynoic acid for GPR40 
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Arg211His or GPR40 Asp175Asn but the Asp175Asn receptor showed a reduction in maximal 
efficacy.  However, studies on Japanese men have indicated that the Arg211His 
polymorphism is linked to insulin secretory capacity (Ogawa et al., 2005).  They also 
found that serum insulin levels were higher in His/His homozygotes compared to Arg/Arg 
homozygotes.  The full effects of these polymorphisms have yet to be studied in detail.   
1.4.2.5 Possible role of GPR40 in other tissues 
There is a large amount of literature on the effects of long chain fatty acids on a variety of 
tissues.  Some of these effects may be mediated by action on GPR40.  The expression and 
function of GPR40 in areas other than pancreatic β cells and the known effects on fatty 
acids on these tissues are detailed below. 
In addition to the role of free fatty acids in the potentiation of GSIS, recent observations 
indicate that free fatty acids also potentiate glucagon release from the α cells (Bollheimer 
et al., 2004; Olofsson et al., 2004; Hong et al., 2005).  Flodgren et al., (2007) were able to 
detect GPR40 mRNA in a hamster glucagonoma cell line, In-R1-G9 and found that the 
receptor co-localised with glucagon in the periphery of mouse islets.  Treatment of both In-
R1-G9 cells and isolated mouse islets with linoleic acid increased glucose stimulated 
glucagon release in a concentration dependent manner.  Knockdown of GPR40 expression 
significantly reduced the ability of linoleic acid to increase glucagon exocytosis and pre-
treatment of the cells with linoleic acid to remove existing receptor from the cell surface 
rendered additional fatty acid unable to increase glucagon secretion (Flodgren et al., 2007).  
Using in-situ hybridization, Briscoe et al., (2003) and Itoh et al., (2003) were both unable 
to detect GPR40 in the periphery of rat islet and GPR40 mRNA could not be detected in 
human glucagonoma tissue (Tomita et al., 2005).  The reasons for these discrepancies are 
unclear but it may be due to the comparatively small number of α cells within the islets 
(Flodgren et al., 2007).  The previous studies on mouse islets found that a release of [Ca2+]i 
was induced upon addition of palmitic acid and the increase in [Ca2+]i was required for 
fatty acid stimulated glucagon release (Olofsson et al., 2004).  The study on GPR40 by 
Flodgren et al., (2007) did not monitor fatty acid mediated release of [Ca2+]i, but as 
GPR40-mediated [Ca2+]i release has been observed in β cells (Shapiro et al., 2005) it is 
possible that the release of [Ca2+]i in α cells may also be mediated through GPR40.   
Expression of GPR40 on immune cells has only been demonstrated by Briscoe et al., 
(2003).  They detected GPR40 mRNA specifically in human monocytes, although the 
expression of GPR40 was significantly lower than that of the related receptor, GPR43, 
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which is activated by short chain fatty acids (see section 1.5.3.3).  Fatty acids are known to 
exert diverse effects on the immune system and various immune cell subtypes (Hwang, 
2000). In obese patients, who have increased levels of plasma free fatty acids, an increased 
secretion of proinflammatory cytokines and infiltration of monocytes and macrophages has 
been reported (Dandona et al., 2004) although the exact mechanisms behind this are 
unclear and the contribution of GPR40 activation has not be examined.   
As detailed above, expression of GPR40 has been detected in breast cancer cell lines in 
two separate studies (Yonezawa et al., 2004; Hardy et al., 2005).  Previous epidemiological 
studies have indicated that women in countries with a high-fat diet have a significantly 
higher risk of developing breast cancer than those in countries with a low fat diet (Cohen et 
al., 1993; Rose, 1997).  The increased risk of a high fat diet has been confirmed in a 
number of studies using animal models and cultured breast cancer cells (reviewed in 
Cohen et al., 1993).  Recent studies on the breast cancer cell line, MDA-MB-231 have 
shown that oleic acid stimulated cell proliferation but palmitic acid induced apoptosis 
(Hardy et al., 2000; Hardy et al., 2003).  Yonezawa et al., (2004) demonstrated that oleic 
acid and linoleic acid, both unsaturated fatty acids, were able to mediate a rapid, transient 
rise of [Ca2+]i in the human breast cancer cell line, MCF-7, but palmitic acid and stearic 
acid, both saturated fatty acids, were unable to cause a rise in [Ca2+]i.  They found that the 
effect of oleic acid and linoleic acid was PTX sensitive (Yonezawa et al., 2004).  Hardy et 
al., (2005) found similar results with MDA-MB-231 cells.  To dissect the role of GPR40 in 
these cells, they reduced the levels of GPR40 by siRNA treatment and found that the 
proliferatory effects of GPR40 were reduced (Hardy et al., 2005).  The role of GPR40 in 
other types of cancer is yet to be assessed.   
1.4.2.6 PPARγ and thiazolidinediones 
Kotarsky et al., (2003) found that the thiazolidinedione, rosiglitazone, can act as an agonist 
of GPR40.  The thiazolidinediones are classically described as agonists of peroxisome 
proliferator activated receptor γ (PPARγ).  PPARγ belongs to a family of ligand activated 
transcription factors called peroxisome proliferator activated receptors (PPARs), of which 
there are three major subtypes; α, β/δ and γ.  They display distinct expression patterns; 
PPARα is present in the liver, kidney and heart, PPARδ is ubiquitously expressed and 
PPARγ is predominately expressed in adipocytes, with lower levels found in skeletal 
muscle and liver tissue (Kliewer et al., 1994; Fajas et al., 1997).  All three PPAR receptor 
subtypes are also found in pancreatic islet cells.  PPARγ is activated by high concentrations 
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of fatty acids and by prostaglandin J2 derivatives (Kliewer et al., 1995) as well as a range 
of thiazolidinediones.   
The thiazolidinediones are orally-available insulin sensitising agents that act to reverse 
insulin resistance in target tissues, which therefore makes them a treatment for NIDDM.  
They act by promoting fatty acid storage in adipocytes, which lowers the levels of plasma 
fatty acids, and they affect the expression of adipocyte secreted hormones that are 
important in glucose homeostasis (Rangwala et al., 2004).  Lehmann et al., (1995) 
demonstrated that thiazolidinediones could act in the nanomolar range as agonists at 
PPARγ.  The effectiveness of these compounds at reducing insulin resistance has led to a 
large range of compounds being developed, tested and licensed for use in the treatment of 
NIDDM.  Troglitazone was the first thiazolidinedione to be used clinically, although a rare 
but serious side effect of liver toxicity resulted in it being removed from the market 
(Graham et al., 2003).  Two further thiazolidinediones have been licensed clinically, 
rosiglitazone and pioglitazone and to date, do not cause as serious side effects (Tolman et 
al., 2003).  The structures of the four thiazolidinediones used in this study are shown in 
Figure 1.3.   
There has been a growing amount of literature published over the last few years that 
indicates that not all of the effect of the thiazolidinediones can be explained through action 
on PPARγ.  It is now well appreciated that thiazolidinediones have anti-proliferative 
effects on a variety of human cancer lines and the role of PPARγ in cell cycle regulation 
and the mechanism by which they inhibit growth is unclear (Weng et al., 2006).  A study 
on embryonic stem cells lacking expression of PPARγ (PPARγ-/-) demonstrated that the 
anti-proliferative effects of troglitazone and ciglitazone were the same as in PPARγ+/+ cells 
(Palakurthi et al., 2001).  They also demonstrated that both thiazolidinediones were able to 
mediate a rapid, transient rise in [Ca2+]i in both PPARγ
+/+ and PPARγ-/- cells (Palakurthi et 
al., 2001).  As mentioned above, the highest level of expression of PPARγ is found in 
adipose tissue (Fajas et al., 1998) although the target tissue for thiazolidinedione is 
unknown and candidates include adipose tissue, skeletal muscle, liver tissue and the β cell 
(Evans et al., 2004).  Although, the validity of adipose tissue as the target tissue has been 
brought into question by studies on mice that have been engineered to lack virtually all 
white and brown fat (Burant et al., 1997).  In these mice it was found that troglitazone 
retained its insulin sensitising properties and reduced circulating levels of free fatty acids, 
which indicates a mode of action independent of adipose tissue (Burant et al., 1997).  As 
transcription factors, PPARs act to regulate expression of specific genes that contain PPAR 
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DNA binding elements (PPRE) within the promoter regions (Tugwood et al., 1992).  It has 
been found that thiazolidinediones rapidly induce phosphorylation of MAPK family 
members, effects which are too rapid to be due to new protein synthesis (Gardner et al., 
2005).  Shiau et al., (2005) developed a set of thiazolidinedione analogs, in which a double 
bond was introduced before the thiazolidine-2,4-dione ring, to give ∆2 thiazolidinediones.  
The introduction of the double bond abrogated their PPARγ activity as measured by a 
PPARγ transcription factor ELISA and a reporter gene assay (Shiau et al., 2005).  ∆2-
troglitazone and ∆2-ciglitazone were shown to retain the ability to induce apoptosis in 
prostate cancer cells (Shiaue et al., 2005) and down regulate cyclin D1 in breast cancer 
cells (Huang et al., 2005).  
1.4.3 Identification of GPR41 and GPR43 as receptors for short 
chain fatty acids 
At a similar time to the publication of long chain fatty acids as agonists of GPR40, short 
chain fatty acids were described as the potential endogenous agonists for GPR41 (Brown et 
al., 2003; Le Poul et al., 2003) and GPR43 (Brown et al., 2003; Le Poul et al., 2003; 
Nilsson et al., 2003).  Brown et al., (2003) used a series of recombinant cell systems to 
confirm that GPR43 was activated by the carboxylic acid, acetate, and went on to show 
that the receptor was activated by a range of short chain fatty acids with similar potency in 
a [Ca2+]i mobilisation and [
35S]GTPγS binding assay.  This was also confirmed by Le Poul 
et al., (2003) in a Ca2+ based assay system and cAMP assay and by Nilsson et al., (2003) in 
both a reporter gene assay and a Ca2+ based assay system.  The rank order of potency was 
generally consistent between these different studies, with acetate (C2), propionate (C3) 
being equipotent followed by butyrate (C4), then valerate (C5), and formate (C1) (Brown 
et al., 2003; Le Poul et al., 2003; Nilsson et al., 2003).  Due to the high sequence homology 
between GPR43 and GPR41, Brown et al., (2003) and Le Poul et al., (2003) also found 
that short chain fatty acids were agonists of GPR41.  The potencies for short chain fatty 
acids at GPR41 were in a similar range to GPR43, although a different structure-activity 
relationship was identified.  Propionate, valerate and butyrate were equipotent at GPR41, 
with acetate and hexanoate showing a measurably lower potency (Brown et al., 2003; Le 
Poul et al., 2003).  Short chain fatty acids activate GPR41 and GPR43 with relatively low 
potency, generally in the mid micromolar range.  The low potency of these ligands has led 
to suggestions that they may not be the endogenous agonists for the receptors (Milligan et 
al., 2006). 
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1.4.3.1 GPR42 is likely to be a pseudo gene 
As mentioned previously, GPR41 and GPR42 share high sequence homology and differ by 
only six amino acid residues.  Brown et al., (2003) found that GPR42 was unable to 
respond to short chain fatty acids.  As only one ortholog of human GPR41 and GPR42 was 
found in rodent and bovine lineages, they undertook a mutagenesis study to replace the 
differing residues in GPR41 with the corresponding residues in GPR42.  They found that 
mutation of Arg174 in GPR41 to Trp resulted in the receptor being unable to respond to 
short chain fatty acids.  The equivalent mutation in GPR42 (Trp174Arg) was able to confer 
short chain fatty acid activity to the receptor.  In addition to the lack of function of GPR42, 
no expression of the receptor could be detected in a range of normal human tissues (Brown 
et al., 2003).  Due to its inability to respond to short chain fatty acids and no expression 
being detected, GPR42 is now considered to be a pseudo-gene (Brown et al., 2005). 
1.4.3.2 Signalling and G protein coupling 
GPR41 and GPR43 have distinct G protein coupling specificities.  GPR41 couples 
efficiently to the PTX sensitive G protein, Gαo1 and agonist function can be measured in 
[35S]GTPγS binding assays (Brown et al., 2003; Le Poul et al., 2003).  Le Poul et al., 
(2003) found that it was necessary to co-express GPR41 with the promiscuous G protein, 
Gα16 to measure the release of [Ca
2+]i.  It has also been shown that mouse GPR41 can 
reduce forskolin-induced cAMP production in CHO-K1 cells (Xiong et al., 2004).  GPR43 
has been shown to couple to both PTX sensitive and insensitive G proteins (Brown et al., 
2003; Le Poul et al., 2003, Nilsson et al., 2003).  Although Nilsson et al., (2003) concluded 
that the receptor coupled mainly through PTX sensitive G proteins as they observed a 70% 
reduction in the signal generated by GPR43 in a [Ca2+]i mobilisation assay upon PTX 
treatment.  Neither GPR41 nor GPR43 has been tested for their ability to interact with a 
full panel of mammalian G protein.  GPR43 has been tested for its ability to interact with a 
wide panel of chimeric yeast-mammalian G protein α subunits and it was found to interact 
with Gα12, Gα13, Gα14, Gαi1 and Gαi3 (Brown et al., 2003).  It therefore appears that 
GPR43 is a more promiscuous receptor that GPR41.   
1.4.3.3 Expression pattern 
The initial studies on GPR41 detected high levels of mRNA in a range of normal human 
tissues with highest levels of expression found in adipose tissue (Brown et al., 2003).  High 
levels of expression were also seen in the pancreas, spleen, lymph nodes, bone marrow and 
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peripheral blood mononuclear cells (Brown et al., 2003; Le Poul et al., 2003).  GPR41 
mRNA was detected in 3T3-L1 and 3T2-F442A adipose cell lines, and levels increased 
upon differentiation, although absolute levels remained low (Brown et al., 2003).  The 
expression of GPR41 in adipose cells was confirmed by Xiong et al., (2004).  They were 
able to identify mRNA corresponding to GPR41 in human adipose tissue, mouse white 
adipose tissue and in differentiated cells from the mouse adipogenic cell line, Ob-Luc.  The 
expression of GPR41 in adipose cells was brought into question by Hong et al., (2005).  
They were unable to detect GPR41 expression in human adipose tissue, cultured pre-
adipocytes or adipocytes, or in 3T3-L1 cells.  The discrepancy of GPR41 expression in 
these studies is unknown, as Hong et al., (2005) used the same probes for detecting the 
receptor as Xiong et al., (2004).   
GPR43 has a more specific expression pattern than GPR41.  Levels of GPR43 mRNA can 
be detected in a variety of tissues but highest expression can be found in immune cells such 
as neutrophils, monocytes, peripheral blood mononuclear cells, B-lymphocytes and 
polymophonuclear cells.  Considerable levels of GPR43 were detected in bone marrow and 
spleen but this is thought to reflect the expression of the receptor on immune cells (Brown 
et al., 2003; Le Poul et al., 2003; Nilsson et al., 2003).  The expression of GPR43 on 
immune cells is not surprising as mouse GPR43 was first identified from leucocytes 
(Senga et al., 2003).  GPR43 has also been detected in neutrophils and eosinophils by 
hybridisation to high-density oligonucleotide arrays (Nakajima et al., 2004).  Nilsson et al., 
(2003) also found expression of the receptor in skeletal muscle and heart.  GPR43 has also 
been reported in adipose tissue (Hong et al., 2005), the breast cancer cell line, MCF-7 
(Yonezawa et al., 2006) and rat distal ileum and colon (Karaki et al., 2006).   
Two recent patents by Arena Pharmaceuticals indicated that both GPR41 and GPR43 may 
also be expressed in pancreatic islet cells and both receptors subject to up-regulation in 
db/db diabetic mice.  
1.4.3.4 Role of short chain fatty acids in the immune response – could 
this response be mediated by GPR41 and GPR43 
The initial studies on GPR43 and GPR41 all indicated that GPR43 was expressed at high 
levels and GPR41 to a lesser extent in a variety of immune cells (Brown et al., 2003; Le 
Poul et al., 2003; Nilsson et al., 2003).  Le Poul et al., (2003) demonstrated that treatment 
of polymophonuclear cells with acetate or propionate induces a rise in [Ca2+]i and 
chemotaxis.  This confirms various other studies in which short chain fatty acids mediate 
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the activation of leukocytes by Ca2+ mobilisation (Naccache et al., 1998; Nakao et al., 
1992; Cavaglieri et al., 2003) and implicates GPR43 in the well known effects of short 
chain fatty acids on monocyte chemotaxis and movement towards sites of bacterial 
infection.  High concentrations of short chain fatty acids have been reported in connection 
with severe anaerobic infections, which have the potential to activate GPR43 and mediate 
the recruitment of leukocytes to the site of infection. 
Normal blood concentrations of short chain fatty acids are 100-150µM acetate, 4-5µM 
propionate and 1-3µM butyrate (Cummings et al., 1987) but increased levels of fatty acids 
are associated with some disease states.  The genetic condition propionic acidemia results 
in the accumulation of propionate in the blood due to mutations in propionyl-CoA 
carboxylase.  The disease is characterised by a low blood pH due to the build up of 
propionate and the impairment of immune function leading to frequent infections (Feliz et 
al., 2003).  It has been suggested that the immunosuppressive factor in propionic acidemia 
is propionate.    
Alcohol consumption has been shown to increase circulating acetate concentrations by 
250% (Siler et al., 1999) and levels of acetate may reach those required to activate GPR43.  
In patients with alcoholic hepatitis and cirrhosis it is common to find polymorphonuclear 
neutrophils at the site of disease (Bautista, 2002).  Alcohol is metabolised to acetate by the 
liver which may explain the recruitment of polymorphonuclear neutrophils.  Acute and 
chronic alcohol intake increases the susceptibility to bacterial and viral infections 
(Corberand et al., 1989; Bautista, 2002).  The defective inflammatory response may be due 
to the desensitisation of the immune response through activation by excess acetate.  To 
date no studies have been undertaken to examine the contribution activation of GPR43 
makes towards the immune response. 
1.4.3.5 Role of GPR41 and GPR43 in adipocytes 
As detailed above, there is some debate about the expression of GPR41 in adipocytes.  
Brown et al., (2003), Le Poul et al., (2003) and Xiong et al., (2004) were all able to detect 
GPR41 mRNA in adipose tissue.  Xiong et al., (2004) undertook studies to determine the 
function of GPR41 in adipocytes.  Using the Ob-Luc cell line, in which one allele of the 
leptin gene is knocked in with a luciferase cassette which allows the expression of the 
leptin gene to be monitored via luciferase bioluminescence, they demonstrated that the 
addition of short chain fatty acids to these cells increased luciferase activity in a 
concentration dependent manner.  They found a similar rank order of potency as observed 
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by Brown et al., (2003) and Le Poul et al., (2003), with acetate being significantly less 
potent than propionate or butyrate.  To examine the contribution of GPR41 to the 
production of leptin, as they also detected GPR43 in these cells, they used siRNA 
treatment to knockdown the expression of GPR41.  The knockdown of GPR41 almost 
completely abolished the ability of propionate to induce luciferase expression, and 
consequently leptin production.  PTX treatment of Ob-Luc cells rendered short chain fatty 
acids unable to stimulate leptin production.  The production of leptin has been linked to 
another Gαi/o coupled receptor, the adenosine A1 receptor (Rice et al., 2000).  They 
therefore concluded that activation of GPR41 in adipocytes is coupled to the production of 
leptin.  Leptin is known as a potent suppressor of appetite through its action on the CNS 
(Cohen et al., 2001).  The effects of propionate on appetite have been observed previously.  
Sodium propionate supplemented diets or infusion have been shown to reduce food intake 
in chickens and sheep through an unknown mechanism (Farningham and Whyte, 1993; 
Pinchasov and Elmaliah. 1995).  Xiong et al., (2003) also found that mice fed on a diet 
containing 3% sodium propionate ate less than control animals fed with an equimolar 
amount of sodium chloride.   
In contrast to the findings by Xiong et al., (2003), Hong et al., (2005) came to a different 
conclusion as to the important short chain fatty acid receptors in adipocytes.  They were 
unable to detect GPR41 mRNA in any cell line or tissue tested and decided to study the 
role of GPR43 in the differentiation of adipocytes.  Using 3T3-L1 adipocytes, they 
demonstrated that treatment of the cells with acetate or propionate increased GPR43 
expression and oil red O staining, which indicates the accumulation of lipids within the 
cells.  Knockdown of GPR43 expression by siRNA treatment and subsequent treatment 
with short chain fatty acid resulted in a reduction in oil red O staining compared to wild 
type cells, which indicated that GPR43 is involved in the differentiation of adipocytes.  
Treatment of 3T3-L1 cells with acetate or propionate also inhibited isoproterenol 
stimulated lipolysis in a concentration dependent manner and this was abolished when 
GPR43 expression was reduced by siRNA treatment (Hong et al., 2005).  This indicates 
that activation GPR43 plays a role in the inhibition of lipolysis.  The role of GPR41 and 
GPR43 in adipose tissue and leptin production needs to be further examined.  If GPR41 
mediates leptin production in adipose tissue, it may prove to be a new target in the 
treatment of obesity and diabetes.   
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1.4.3.6 Role of short chain fatty acids in the colon 
Large amounts of bacteria are present in a healthy colon which serves to digest 
polysaccharides, oligosaccharide and proteins in the gut.  A by-product of this fermentation 
is the production of high concentrations of short chain fatty acids.  In human colon, the 
total concentration of short chain fatty acids reaches between 60 and 130mmol L-1, of 
which acetate is the most common and butyrate and propionate found in approximately 
similar concentration, with a molar ratio of 60:20:20 respectively (Cummings et al., 1987).  
They are produced by anaerobic bacterial fermentation of undigested dietary carbohydrates 
and fibre polysaccharides and been proposed to play a key role in the maintenance of 
colonic homeostasis (Wong et al., 2006).  The development of irritable bowel disease 
(IBD) has been linked to a reduction of colonic short chain fatty acid production (Galvez et 
al., 2005), as levels of short chain fatty acids are decreased in the lumens of patients with 
ulcerative colitis (Vernia et al., 1988) and butyrate enemas have been reported to alleviate 
the symptoms of ulcerative colitis (Steihart et al., 1994; Patz et al., 1996), although their 
effectiveness has been questioned (Breuer et al., 1997).  Butyrate is also linked to the 
inhibition of proliferation of a variety of cancer cell lines and it may have preventative 
effects in the development of colon cancer (Wong et al., 2006).  The exact mechanism by 
which butyrate affects proliferation is unknown but it has been shown to be an inhibitor of 
histone deacetylase.   
GPR43 mRNA has been detected in rat distal ileum and colon (Karaki et al., 2006).  A 
recent study by Dass et al., (2007) attempted to uncover the role of GPR43 in intestinal 
motility.  They also found that GPR43 mRNA was present in the rat gut, with highest 
levels detected in the colon and they investigated the contribution of GPR43 to the effects 
of the fatty acids in the gut.  Electrical field stimulation evokes relaxation of rat distal 
colon and removal of the stimulation causes the colon to contract.  The post stimulation 
contraction could be inhibited in a concentration-dependent manner by formate, butyrate, 
acetate, propionate and valerate.  They found that butyrate, acetate and propionate were the 
most potent followed by valerate then formate.  Using guinea-pig ileum, it was found that 
the fatty acids stimulated peristaltic motility, with a similar rank order of potency. Similar 
effects of fatty acids were observed in mouse gut, with short chain fatty acid inhibiting the 
post electrical field stimulation contraction of the colon.  The rank order of potency of the 
fatty acids corresponds to that seen at GPR43 in HEK293 cells and to investigate the 
contribution of GPR43 to this effect they used GPR43 knockout mice.  In the GPR43-/- 
mice they found the same rank-order of inhibitory effects evoked by short chain fatty acids 
(Dass et al., 2007).  To date, there have been no reports of GPR41 being expressed in the 
Leigh Ann Stoddart, 2007   46 
gut, so it is unlikely to be up-regulated in the knockout mice and the rank order of potency 
of the short chain fatty acids at GPR41 is different in recombinant systems than that seen in 
this study.  The data generated using the knockout mice suggests that GPR43 does not 
mediate the effects short chain fatty acids have on intestinal motility. 
An area in which GPR41 and GPR43 are still proposed to be involved in is the 
development of IBD.  IBD is characterised by chronic and spontaneously relapsing 
inflammation of the gut.  The precise etiology of disease progression is still unknown and 
is proposed to involve a number of factors including environmental, genetic, microbial and 
immunological factors (Fiocchi et al., 1998).  It has been proposed that the exacerbated 
inflammatory response towards the intestine results from an inappropriate reaction towards 
a luminal agent (Farrell et al., 2002).  The intestinal epithelium acts as a barrier between 
the gut and the rest of the body but during the development of IBD the luminal wall can be 
compromised and this leads to the further up regulation of the immune response towards 
the gut.  Neutrophils are proposed to play a key role in the development of IBD and other 
inflammatory processes in the gut.  They are recruited to the colon and undergo activation 
to produce reactive oxygen intermediates and chemokines (Le Poul et al., 2003).  The 
release of the short chain fatty acids from the gut into the blood stream may act as an 
erroneous signal to the immune system via activation of GPR43.  If the activation of 
GPR43 is show to play a role in the development of IBD it could lead to the development 
of new therapeutics in the treatment of this disease.   
1.4.4 Two further GPCRs that are activated by free fatty acids 
Recently, two further orphan GPCRs have been shown to be activated by free fatty acids; 
GPR84 and GPR120 (Hirasawa et al., 2005; Wang et al., 2006).  GPR84 responds to 
medium chain fatty acids, C9 to C14, and GPR120 is activated by saturated, C14 to C18, 
and unsaturated, C16 to C22, long chain fatty acids. 
1.4.4.1 GPR84 
Previous studies on GPR84 identified the receptor as being expressed in neutrophils, 
eosinophils and phorbol ester activated peripheral blood mononuclear cells (Yousefi et al., 
2001).  Diindolylmethane was found to be a surrogate ligand for the receptor (Takeda et 
al., 2003) but a natural ligand was not identified until 2006 by Wang et al., (2006).  Using 
a reverse pharmacology approach in combination with an assay to measure the release of 
[Ca2+]i, medium chain fatty acids were shown to activate GPR84.  They found that 
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saturated fatty acids containing between 9 and 14 carbons were able to activate the receptor 
in a concentration-dependent manner in two different assay systems, one measuring the 
inhibition of forskolin stimulated cAMP production and the other measuring the activation 
of the G protein through binding of the non-hydolysable analogue of GTP, [35S]GTPγS.  
Of the fatty acids that were able to activate the receptor, capric acid (C10), undecanoic acid 
(C11) and lauric acids (C12) were shown to be the most potent (Wang et al., 2006).  The 
potencies of medium chain fatty acids at GPR84 are comparable to that seen at GPR40, 
with fatty acids activating GPR84 in the micro-molar range.  Unlike GPR40, GPR84 
shows more selectivity in regards to fatty acid chain length and is likely to couple 
predominately through the Gαi/o family of G proteins whereas GPR40 is a predominately 
Gαq/11 coupled receptor (Briscoe et al., 2003; Wang et al., 2006).  Wang et al., (2006) 
found that GPR84 was primarily expressed in monocytes and neutrophils.  Stimulation of a 
human monotypic leukaemia cell line, THP-1, and a mouse monocytes/macrophage cell 
line, RAW264.7, with lipopolysaccaride (LPS) resulted in an upregulation of GPR84 
mRNA, which suggests that GPR84 may play a pivotal role in monocyte and macrophage 
activation.  The treatment of LPS stimulated cells with capric acid, undecanoic acid, lauric 
acid and diindolylmethane increased the secretion of interleukin-12 p40 subunit (IL-12 
p40) in a concentration dependent manner.  IL-12 plays an important role in promoting cell 
mediated immunity to eradicate pathogens by inducing and maintaining T helper 1 
responses and inhibiting T helper 2 responses (Hsieh et al., 1993).  Venkataraman and Kuo 
(2005) studied the role of GPR84 in the immune system by generating a GPR84 knockout 
mouse.  They found that GPR84-/- mice specifically produced higher levels of IL-4 upon 
stimulation but no other phenotype could be detected (Venkatarman and Kuo, 2005).  As 
mentioned in Section 1.4.2.5, medium and long chain fatty acids are known to exert 
diverse effects on the immune system (Hwang, 2000; Wanten, 2000).  The expression 
pattern of GPR84 and its ability to be activated by medium chain fatty acids may provide a 
link between the activation of immune cells by fatty acids and the development of 
autoimmune diseases.   
1.4.4.2 GPR120 
GPR120 was deorphanised using a unique strategy in which the receptor was fused to a 
fluorescent protein and the levels of internalised receptor were monitored in response to a 
library of compounds.  Using this technique they found that long chain fatty acids evoked 
specific internalisation of GPR120 and the ability of fatty acids to activate the receptor in a 
concentration-dependent manner was confirmed in a Ca2+ release assay.  Most of fatty 
acids shown to activate GPR120 are also able to activate GPR40.  For most of the fatty 
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acids both receptors show similar potencies, apart from α-linolenic acid and γ-linolenic 
acid which both are 10 times more potent at GPR120 than GPR40 (Briscoe et al., 2003; 
Hirasawa et al., 2005).  The main area of GPR120 expression is the intestinal tract and 
lung in both mice and humans (Hirasawa et al., 2005).  Expression of GPR120 is also 
found in the intestinal endocrine cell line STC-1 (Hirasawa et al., 2005; Katsuma et al., 
2005).  The activation of GPR120 by free fatty acids in STC-1 cells has been reported to 
inhibit cellular apoptosis initiated by serum deprivation (Katsuma et al., 2005).  Using 
STC-1 cells, Hirasawa et al., (2005) demonstrated that the secretion of glucagon-like 
peptide-1 (GLP-1) was mediated through activation of GPR120 by fatty acids.  STC-1 cells 
also express GPR40, so to identify which receptor was being activated by the fatty acids 
they reduced the expression of each receptor by siRNA treatment.  Cells transfected with 
GPR40 siRNA showed no change in their ability to secrete GLP-1, whereas a significant 
reduction in GLP-1 secretion was observed in cells transfected with GPR120 siRNA.  
Increased plasma insulin and GLP-1 levels were also shown in the portal vein and the 
inferior vena cava in mice in response to α-linolenic acid but not to stearic acid or octanoic 
acid, which were unable to activate GPR120 in vitro (Hirasawa et al., 2005).  Iakoubov et 
al., (2006) found that the atypical protein kinase C, PKCξ, was required for oleic acid 
induced GLP-1 secretion via GPR120 in the murine GLUTag L cell line.  GLP-1 is a well 
characterised natural modulator of glucose dependent insulin secretion and its receptor is 
found on pancreatic β cells and is therefore a target in the treatment of diabetes (Rotella et 
al., 2005).  The GLP-1 receptor is a family B GPCR but it has proved to be a difficult 
target for clinical intervention as exogenous GLP-1 has a short half life (D’Alessio et al., 
2005) and small molecule agonists for the GLP-1 receptor have only recently been 
described (Knudsen et al., 2007).  Therefore targeting GPR120 rather than the GLP-1 
receptor may prove to be an alternative strategy in the treatment of diabetes.   
As detailed in section 1.4.2.4 , there have recently been two papers describing GPR40 
specific small molecule agonists (Garrido et al., 2006; Briscoe et al., 2006) and a GPR40 
specific antagonist (Briscoe et al., 2006).  The similarities between GPR40 and GPR120 in 
their activation by long chain fatty acids also means that the small molecule agonist 
described in detail by Briscoe et al., (2006), GW839508X, is an agonist of GPR120 
although with less potency than at GPR40 (pEC50 for GPR40 = 7.32±0.03 and for GPR120 
= 5.46±0.09).  The small molecule antagonist, GW1100, was unable to block a GPR120 
mediated rise in [Ca2+]i, indicating that it is a specific GPR40 antagonist.  To date, the 
effect of these compounds on GPR84 has not been reported.   
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1.5 GPCR oligomerisation 
Traditional models of GPCR ligand binding and signal transduction always portrayed 
GPCRs as monomeric signalling units.  The finding that the functional γ-aminobutyric acid 
receptor (GABAb receptor) was an obligate heterodimer of two distinct GPCR subunits 
GABAbR1 and GABAbR2 (Jones et al., 1998; Kaupmann et al., 1998; White et al., 1998; 
Sullivan et al., 2000) triggered immense interest into the possibility that GPCRs were not 
monomeric signalling units and were able to interact with each other.   
There are a variety of techniques that can be used to demonstrate protein-protein 
interactions between GPCRs and some are covered below in section 1.5.2.  Many of these 
techniques are not able to distinguish between a simple dimer and a higher order 
oligomeric structure.  Therefore, I will refer to oligomerisation rather than dimerisation.   
1.5.1 Methods to monitor GPCR oligomerisation 
1.5.1.1 Co-immunoprecipitation  
The starting point of many studies into the oligomerisation of GPCRs is their ability to be 
co-immunoprecipitated.  Co-immunoprecipitation refers to the ability of one epitope 
tagged GPCR to be immunoprecipitated with another differentially tagged receptor and to 
be detected by western blotting.  The commercial availability of a variety of specific 
antibodies for epitope tags has made this technique widespread (Milligan and Bouvier, 
2005).  Co-immunoprecipitation data has been subject to much scrutiny and has raised 
questions regarding the possibility of results being an artefact of the experimental 
procedure.  During preparation of samples, the receptors have to be solubilised from the 
membrane upon which these membrane proteins may aggregate.  To address this detergent 
extracts of membranes each expressing only one of the tagged receptors are combined 
prior to immunoprecipitation.  These samples generally do not result in co-
immunoprecipitation and therefore exclude the possibility of non-specific aggregation 
(Jordan and Devi, 1999).   
1.5.1.2 Resonance energy transfer (RET) techniques 
Techniques based on the energy transfer between a donor molecule and acceptor molecules 
have been extensively used to monitor the formation and existence of GPCR oligomers in 
living cells.  Energy is transferred in a non-radiative manner as a result of a dipole-dipole 
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coupling mechanism and is referred to as resonance energy transfer (RET).  The energy 
transfer is based on the Föster theory which demonstrates that energy transfer is highly 
dependent on the proximity of the donor and acceptor moieties (Föster, 1948).  The donor 
and acceptor have to be within 100Å of each other to generate a significant energy transfer 
and this short distance is indicative of direct protein-protein interactions (Wu and Brand, 
1994).  The donor molecule can be a fluorescent or luminescent protein.  Direct excitation 
of a fluorescent protein results in energy transfer to an acceptor fluorescent protein and is 
referred to as fluorescence resonance energy transfer (FRET).  Whereas when the donor 
protein is a luminescent protein, the oxidisation of a substrate results in energy transfer to a 
fluorescent protein and this technique is called bioluminescence resonance energy transfer 
(BRET).  In both techniques, the energy is re-emitted by the acceptor protein at a 
wavelength that is characteristic of the acceptor moiety.  The energy transfer is dependent 
on the overlap of the donor and acceptor excitation spectra, although significant overlap 
results in a reduction in the resolution of the RET signal generated.  Additional factors that 
affect the energy transfer include the quantum yield of the donor and acceptor excitation 
spectra and the orientation of the donor and acceptor moieties.  The bioluminescent or 
fluorescent proteins can be N- or C-terminally fused to the receptors of interest to allow 
expression in heterologous systems to investigate their interaction.  
1.5.1.3 Bioluminescence energy transfer (BRET) 
BRET utilises the bio-luminescent protein luciferase from the sea pansy, Renilla reniformis 
(Rluc) and a fluorescent acceptor protein.  The technique is based on the natural 
phenomenon of bioluminescence found in marine animals such as Renilla reniformis and 
the jellyfish, Aequora vicotria.  Energy transfer results for the oxidation of the Rluc 
substrate coelenterazine and the transfer of energy from Rluc to the acceptor protein, green 
fluorescent protein (GFP) (Xu et al., 1999).   
Originally, BRET systems used Rluc as the donor and a red shifted mutant of GFP, termed 
enhanced yellow fluorescent protein (eYFP).  The spectral properties of Rluc overlap 
significantly with that of eYFP resulting in a poor signal to noise ratio (Xu et al., 1999).  
To address this issue, a modified version of this assay has been developed and termed 
BRET2.  It utilises a modified form of coelenterazine called DeepBlueC (PerkinElmer), 
which when oxidised by Rluc produces a different spectra which is transferred to a 
modified form of GFP termed GFP2.  The use of DeepBlueC and GFP2 allows much higher 
spectral resolution between donor and acceptor and vastly improves the signal to noise 
ratio.  This technique has been extensively used to detect protein-protein interactions and 
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in particular has been used to investigate the properties of receptor oligomerisation and the 
interaction of GPCRs with intracellular protein such as arrestins.  By expressing different 
amounts of energy donor and energy acceptor-linked GPCRs, saturation curves can be 
generated that resemble ligand binding curves (Mercier et al., 2002).  This can provide 
useful measurements of the relative interaction affinities of the GPCRs to form oligomers 
(Mercier et al., 2002; Ramsay et al., 2004; Wilson et al., 2005).  
1.5.1.4 Fluorescence resonance energy transfer (FRET) 
FRET utilises the ability of fluorescent donor and acceptor proteins that have overlapping 
donor emission and acceptor excitation spectra.  Energy transfer occurs upon the excitation 
of the donor protein by an external light source.  As mentioned above, mutations in GFP 
can alter its spectral properties and provide energy transfer pairs.  The most widely used 
pairing is enhanced cyan fluorescent protein (eCFP) as the energy donor and eYFP as the 
acceptor.  Several other combinations of different variants of GFP can also be used 
(Milligan and Bouvier, 2005).  There are several variations of the FRET technique but one 
of the advantages is it can be used to monitor protein-protein interactions within living 
cells.  To monitor protein-protein interactions within living cells, the proteins of interest 
have to be fused to the fluorescent proteins and expressed in heterologous systems.  
Imaging of the FRET within the cells requires three measurements to be recorded; 
sensitised fluorescence and donor and acceptor fluorescence.  Recent advances have 
allowed FRET to be used to examine the existence of higher order GPCR oligomerisation. 
It utilises three component FRET systems based on serial energy transfer from cyan to 
yellow to red fluorescent proteins (He et al., 2004), and has been used to confirm the 
presence of higher order oligomers of the α1b adrenergic receptor (Lopez-Gimenez et al., 
2007).   
A variation of FRET, called time resolved FRET (Tr-FRET) can be used to specifically 
detect the presence of interacting proteins at the surface of cell.  This technique utilises 
antibodies directed at epitope tags, which can be introduced onto the N-terminus of a 
GPCR.  The antibodies are labelled with donor and acceptor moieties suitable for FRET.  
The donor moiety is commonly europium chelate which has long-lived fluorescence 
(Bazin et al., 2002).  Excitation of the europium results in the excitation of endogenous 
fluorophores, but this fluorescence is short lived.  A time delay of over 50µs between 
excitation and measurement of FRET allows the fluorescence from the endogenous 
fluorophores to decay and results in improved signal-to-noise ratios.  The acceptor 
moieties commonly used include allophycocyanin and Alexa Fluor 647 (Pfleger and Eidne, 
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2005).  Attaching the epitope tags to the N-terminus of a GPCR ensures that the antibodies 
directed at the epitopes only have access to cell surface expressed GPCRs, and has been 
used in studies to detect GPCR oligomers at the cell surface (McVey et al., 2001; Canals et 
al., 2004).   
1.5.1.5 Functional reconstitution 
A further technique that has been used to investigate GPCR oligomerisation is termed 
functional reconstitution.  In this technique two non-functional but different GPCR 
mutants, which are unable to signal when singly expressed, are coexpressed and if ligand 
binding or functionality can be restored it strongly suggests protein-protein interactions.  
This has been demonstrated for the angiotensin AT1 receptor (Monnot et al., 1996), the α1b 
adrenergic receptor (Carrillo et al., 2003) and the opioid receptors (Pascal and Milligan, 
2005)  
1.5.2 Functional significance of GPCR oligomerisation 
Using the techniques described in section 1.5.2 and other complementary techniques, a 
large range of Family A GPCRs have been shown to homo-oligomerise and to heter-
oligomerise with both closely related receptors and to ones that they share little homology 
(Milligan, 2006).  The functional significance of hetero-oligomerisation is poorly 
understood but roles have been proposed in protein folding, correct membrane delivery and 
interactions with G proteins. 
There is a growing amount of evidence to suggest that GPCR oligomer formation occurs 
during protein synthesis and is important for correct cell surface delivery of the receptor 
(Bulenger et al., 2005).  This has been demonstrated by the introduction of endoplasmic 
reticulum retention (ER) motifs which result in the modified receptor being retained in the 
ER along with a co-expressed, unmodified receptor.  This has been demonstrated for the β2 
adrenergic receptor (Salahpour et al., 2004) and for the CXCR1 and CXCR2 chemokine 
receptors (Wilson et al., 2005).  In the case of the GABAbR1 and GABAbR2 receptors, the 
GABAbR1 receptor contains an ER retention sequence within its carboxy terminus and is 
not delivered to the cell surface when expressed alone.  The GABAbR2 can mask the ER 
retention sequence to enable the complex to be delivered to the cell surface (Sullivan et al., 
2000). 
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An important proposed role for oligomerisation of GPCRs is in binding of G proteins.  
Models of rhodopsin and its associated G protein transducin have demonstrated that a 
dimer of rhodopsin provides an ideal footprint for a single heterotrimeric G protein to bind.  
The monomeric cytoplasmic surface of rhodopsin is too small to accommodate interactions 
with the α and βγ subunits simultaneously (Fotiadis et al., 2004; Fotiadis et al., 2006).  
Biophysical studies using the BLT1 leukotriene B4 receptor also found that the basic 
signalling unit was composed of two receptors and the three subunits of the G protein 
(Baneres et al., 2003).   
The effect of hetero-oligomerisation on ligand pharmacology and function has been 
investigated in a growing number of studies (Bulenger et al., 2005; Milligan, 2006).  
Studying the effect of hetero-oligomerisation is complicated by the probable presence of 
homo-oligomers, as only if the hetero-oligomer has a much higher affinity to form will 
there be just hetero-oligomers at the cell surface.  There have been some examples of 
hetero-oligomerisation having an effect on the function of GPCRs.  Two opioid receptor 
subtypes, MOP and DOP, when expressed singly each couple to PTX sensitive G protein 
but on co-expression they can generate signals that are in-sensitive to PTX treatment 
(George et al., 2000).  These signals have been shown to be generated by activation of Gz, 
which reflects a switch in the G protein coupling of these receptors (Fan et al., 2006).  This 
may reflect the hetero-oligomer being able to generate a unique interface that allows a 
different G protein to bind.  The ability of a hetero-oligomer to activate different G 
proteins has also been demonstrated for the D1 and D2 dopamine receptors (Lee et al., 
2004).  Difference in the potency of ligands has also been demonstrated upon the co-
expression of two receptors.  For example, the co-expression of the orexin-1 receptor and 
the cannabinoid CB1 receptor enhances the potency of orexin-A 100 fold and this effect 
could be blocked by CB1 receptor antagonists (Hilairet et al., 2003).  These effects could 
have wide reaching effects on the development of new clinically relevant compounds 
(Milligan, 2006).  The physiological existence of hetero-oligomers has only been 
demonstrated for a handful of receptors.  A selective agonist for the DOP-KOP opioid 
receptor hetero-oligomer displays similar effects in vivo as in vitro which supports the 
existence of opioid receptor hetero-oligomers in physiological systems (Waldhoer et al., 
2005).   
Rhodopsin is the only GPCR for which high resolution structural information is available.  
The initial crystal structure of rhodopsin did not contain any information regarding the 
quaternary structure of the receptor.  This is due to the requirement to extract the receptors 
from the membranes by detergent treatment before the crystallisation process.  The high 
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expression of rhodopsin in rod outer segments allowed investigations into the organisation 
of the receptor in its native state.  This has been carried out on mouse outer rod segments 
by atomic force microscopy (Fotiadis et al., 2003; Liang et al., 2003).  These studies 
clearly demonstrate the arrangement of the receptors in para-cystalline arrays with densely 
packed, double rows of the receptor.  Data from studies on 2-dimentional crystals of squid 
rhodopsin also demonstrates a higher order of the receptors (Davies et al., 2001).  
Computational models based on the observations from these studies have been generated to 
determine the key contacts between the receptor monomers (Fotiadis et al., 2004; Fotiadis 
et al., 2006).  From these models, TM4 and 5 have been implicated to play key role in the 
formation of receptor oligomers, and this has been supported by mutagenesis studies (Kota 
et al., 2006).  Studies on other Family A GPCRs, such as the dopamine D2 receptor (Guo 
et al., 2003; Guo et al., 2005) and the α1b adrenergic receptor (Carrillo et al., 2004) have 
also demonstrated that TM region 4 is important for oligomer formation.  Although it 
appears that TM4 is important for oligomer formation, other regions have been implicated 
and there may not be a consensus across Family A receptor (Milligan, 2006). 
1.6 Project aims 
The aim of this study was to gain a greater understanding of the pharmacology and 
function of GPR40, GPR41 and GPR43.  Due to their status as newly de-orphaned GPCRs, 
robust assays to monitor their activation were developed.  The development of a 
[35S]GTPγS binding assay to monitor the activation of GPR40 allowed the pharmacology 
of synthetic small molecule agonists, antagonists and thiazolidinediones to be investigated.  
Using predictions from models of GPR40, GPR41 and GPR43, which were based on the 
crystal structure of rhodopsin, mutagenesis studies were undertaken to investigate residues 
that were implicated in binding fatty acids and the fatty acid chain length specificity of 
GPR40 and GPR43.  The formation of GPR40 and GPR43 homo-oligomers was also 
investigated using several techniques including co-immunoprecipitation, Tr-FRET and 
FRET.  
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Figure 1.1 Diversity of GPCR signalling 
Activation of GPCRs can mediate a variety of cellular responses via G protein and G 
protein independent mechanisms. 
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Figure 1.2 Chemical structures of synthetic agonists and an antagonist used in my 
studies 
(a-g) Chemical structures of GPR40 synthetic agonists as detailed in Garrido et al., (2006).  
The above structures are termed: (a) GW839508X (2A), (b) GSK248257A (14A), (c) 
GSK250089A (14B), (d) GSK223112A (16A), (e) GSK272235A (18A), (f) GSK269778A 
(18B).  Numbers in parenthesis refer to the compound numbers in Garrido et al., (2006).  
Compound (f) is the GPR40 antagonist GW1100 as described in Briscoe et al., (2006).  
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Figure 1.3 Structure of thiazolidinediones 
Chemical structures of (a) ciglitazone, (b) troglitazone, (c) rosiglitazone and (d) 
pioglitazone. 
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2 Material and Methods 
2.1 Materials 
2.1.1 General reagents, enzymes and kits 
Amersham Pharmacia Biotech UK Ltd., Little Chalfont, Buckinghamshire, UK 
Full range RainbowTM molecular weight markers, 1st strand DNA synthesis kit, protein G 
Axxora (UK) Ltd., Nottingham, UK 
Ciglitazone, pioglitazone, rosiglitazone, troglitazone 
BDH, Lutterworth, Leicestershire, UK 
22mm coverslips, microscope slides 
Chemicon Europe Ltd., Chandlers Ford, UK 
ReBlot Plus solution 
Fisher Scientific UK Ltd, Loughborough, Leicestershire, UK 
NaCl, KCl, KH2PO4, Na2HPO4, Tris, Hepes, EDTA, SDS, CaCl2, D-glucose, DTT, urea, 
glacial acetic acid, sucrose, bactotryptone, yeast extract, C2H3O2K, MnCl2, glycerol, 
MOPS, bactoagar, ethylene glycol, methanol, isopropanol, ethanol 
Flowgen Bioscience Ltd., Nottingham, UK 
Agarose 
Invitrogen Ltd., Paisley, UK 
NuPage Novex pre-cast 8-12% Bis-Tris gels, NuPage MOPS SDS running buffer, 
deoxyribonuclease 
Konica Europe, Hohenbrunn, Germany 
X-ray film 
Merck Chemicals Ltd., Nottingham, UK 
Nonident P-40, pansorbin 
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Molecular Devices, Sunnyvale, CA 
Brilliant Black, Fluo 4  
New England Biolabs, MA, USA 
Restriction enzymes 
Pierce, Perbio Science UK Ltd., Tattenhall, Cheshire, UK 
Supersignal West Pico chemiluminescent substrate 
Promega UK Ltd., Southampton, UK 
Miniprep kit, Pfu DNA polymerase, restriction enzymes, T4 DNA ligase 
Qiagen, Crawley, West Sussex, UK 
Qiafilter maxiprep kit, QiaQuick gel extraction kit, QiaQuick PCR purification kit, RNeasy 
kit 
Roche Applied Science, Lewes, East Sussex, UK 
DNA molecular weight marker X, shrimp alkaline phosphatase, fatty acid free BSA, BSA, 
complete EDTA-free protease inhibitor tablet, dNTPs 
Sigma-Aldrich Company Ltd., Poole, Dorset, UK 
Probenecid, Triton X-100, Na-deoxycholate, MgCl2, bromophenol blue, BCA solution A, 
CuSO4, RbCl2, ampicillin, M2-anti Flag antibody, Tween-20, ascorbic acid, GTPγS, NaF, 
GDP, Fura-2, all fatty acids 
Stratagene, Amsterdam, The Netherlands 
QuikChange site directed mutagenesis kit 
Thermo Fisher Scientific, Ulm, Germany 
All oligonucleotides used for PCR reactions 
2.1.2 Tissue culture plasticware and reagents 
American Tissue Culture Collection, Rockville, USA 
HEK293T cells 
BD Bioscience, Cowley, UK 
75cm2 Falcon tissue culture flasks 
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Costar, Cambridge, MA, USA 
5ml, 10ml and 25ml pipettes, 75cm2 vented tissue culture flasks, 6 well plates, 10cm2 
dishes 
Invitrogen, Paisley, UK 
MEM with Earle’s Salt and L-Glutamine, MEM non-essential amino acids, foetal bovine 
serum, lipofectamine, geneticin G418, new born calf serum, RPMI, 2-mercaptoethanol, 
lipofectamine, HEPES, Flp-In T-REx HEK293 cells 
Greiner Bio-One, Kremsmünster, Austria  
Poly-D-lysine coated 384-well black-wall, clear-bottom microtiter plates 
Nalgene Nunc International, Rochester, NY 
175 cm2 tissue culture flasks 
Roche Applied Science, Lewes, East Sussex, UK 
Hygromycin B 
Sigma-Aldrich Company Ltd., Poole, Dorset, UK 
DMEM, L-glutamine, sodium pyruvate, 0.25% trypsin-EDTA, poly-D-lysine, doxycyline  
2.1.3 Radiochemicals 
Perkin-Elmer Life and Analytical Sciences, Beaconsfield, Buckinghamshire, UK 
[35S]GTPγS  
2.1.4 Antisera 
Amersham Pharmacia Biotech UK Ltd., Little Chalfont, Buckinghamshire, UK 
Donkey anti-mouse IgG-HRP conjugate, donkey anti-rabbit IgG-HRP conjugate 
Cell Signaling Technologies, Danvers, MA, USA 
Polyclonal anti-c-Myc antibody 
Perkin-Elmer Life and Analytical Sciences, Beaconsfield, Buckinghamshire, UK 
Anti-Flag-APC antibody, anti-c-Myc-Eu3+ antibody 
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Sigma-Aldrich Company Ltd., Poole, Dorset, UK 
Anti-Flag M2 antibody 
All G protein antibodies were produced in-house 
2.2 Buffers 
2.2.1 General buffers 
Phosphate buffered saline (PBS) (10x) 
137mM NaCl, 2.7mM KCl, 1.5mM KH2PO4, 10.2mM Na2HPO4, pH 7.4 
Diluted 1 in 10 prior to use and stored at 4oC. 
Tris-EDTA (TE) buffer 
10mM Tris, 0.1mM EDTA, pH 7.4, stored at 4oC. 
RIPA buffer (2x) 
100mM HEPES (pH7.4), 300mM NaCl, 2% (v/v) Triton X-100, 1% (w/v) Na-
deoxycholate, 0.2% (w/v) SDS, stored at 4oC. 
Physiological saline solution 
130mM NaCl, 5mM KCl, 1mM CaCl2, 1mM MgCl2, 20mM HEPES, 10mM D-glucose, 
pH 7.4.  
Laemelli buffer (2x) 
0.4M DTT, 0.17M SDS, 50mM Tris, 5M urea, 0.01% (w/v) bromophenol blue.  Stored in 
aliquots at -20oC. 
2.2.2 Molecular biology solutions 
TAE buffer (50x) 
40mM Tris, 1mM EDTA, 5.71% (v/v) glacial acetic acid.  Diluted 1 in 50 prior to use. 
DNA loading buffer (5x) 
0.25% (w/v) bromophenol blue, 40% sucrose (w/v) in H2O.  
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LB media (Luria-Bertani medium) 
1% (w/v) bactotryptone, 0.5% (w/v) yeast extract, 1% NaCl (w/v), pH 7.4.  Sterilised by 
autoclaving at 126oC. 
Competent bacteria buffers 
Competent bacteria buffer 1: 
0.03M C2H3O2K, 0.1M RbCl2, 0.01M CaCl2, 0.05M MnCl2, 15% (v/v) glycerol, pH 5.8 
with acetic acid.  Filter sterilised through a 0.2µm filter and stored at 4oC. 
Competent bacteria buffer 2: 
10mM MOPS pH 6.5, 0.075M CaCl2, 0.01M RbCl2, 15% glycerol (v/v), pH 6.5 with 
concentrated HCl.  Filter sterilised through a 0.2µm filter and stored at 4oC. 
2.3 Molecular biology protocols 
2.3.1 Preparation of LB plates 
LB was prepared as detailed in section 2.2.2 and to this 1.5% (w/v) bacto-agar was added.  
This was autoclaved and allowed to cool to 50oC prior to the addition of ampicillin 
(50µg/ml).  The medium was mixed to ensure equal distribution of antibiotic and 
approximately 25ml poured per 10cm2 petri dish.  The plates were left to set at room 
temperature before being stored at 4oC. 
2.3.2 Preparation of competent bacterial cells 
DH5α cells were streaked onto an agar plate in the absence of antibiotics and incubated 
overnight at 37oC.  A single colony was inoculated into a 5ml culture of LB broth and 
grown in a shaking incubator for 16 hours.  This culture was used to inoculate 100 ml of 
LB broth that was grown with aeration at 37oC until the optical density at 550nm reached 
0.48.  The culture was chilled on ice for 10 minutes then centrifuged at 3220 x g for 10 
minutes at 4oC.  All traces of LB broth were removed and the pellet resuspended in 20ml 
of competent bacteria buffer 1.  The suspension was incubated on ice for 5 minutes prior to 
centrifugation at 3220 x g for 10 minutes at 4oC.  Following removal of supernatant, cell 
pellets were resuspended in 2ml of competent bacteria buffer 2.  After incubation on ice for 
15 minutes the competent bacteria were aliquoted and stored at -80oC until required. 
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2.3.3 Transformation of competent bacterial cells 
An aliquot of competent bacteria was allowed to thaw on ice.  To 50µl of competent 
bacteria between 1 and 10ng of DNA was added and incubated on ice for 15 minutes.  The 
cells were subjected to a heat shock at 42oC for 90 seconds and returned to ice for 2 
minutes.  To the cells, 450µl of LB broth was added and incubated at 37oC for 45 minutes 
in a shaking incubator.  100µl of the reaction was spread onto a LB plate containing the 
appropriate antibiotic and incubated inverted overnight at 37oC.  
2.3.4 Preparation of plasmid DNA 
2.3.4.1 Mini-preps 
Miniprep purification was carried out using Promega miniprep kits as per manufactures 
instructions.  Briefly, cells were pelleted by centrifugation at 16,000 x g for 5 minutes and 
re-suspended by pipetting in 100µl of re-suspension buffer (50mM Tris-HCl, 10mM 
EDTA, pH 8.0 containing 100µg/ml RNase A).  Cells were treated with 100µl of lysis 
buffer (200mM NaOH, 1% (w/v) SDS), mixed and incubated for 5 minutes.  Lysis was 
terminated by the addition of 100µl of neutralisation buffer (3mM potassium acetate, pH 
5.5).  The cell lysates were centrifuged for 10 minutes at 16,000 x g and the supernatant 
loaded onto miniprep columns.  The columns were centrifuged for 1 minute at 16,000 x g 
and washed twice with 750µl wash buffer (1.0mM NaCl, 50mM Tris-HCl, pH 7.0, 15% 
(v/v) isopropanol).  After washing, bound DNA was eluted into a clean 1.5ml eppendorf 
tubes with 100µl sterile H2O 
2.3.4.2 Maxi-preps 
The Qiagen Qiafilter kit was used to produce larger scale DNA samples.  Purification of 
DNA was carried out as per manufactures instructions.  Briefly, a 100ml culture of 
transformed bacteria was pelleted by centrifugation for 30 minutes at 3220 x g at 4oC.  All 
traces of media were removed and the pellet resuspended in 10ml of chilled buffer P1 
(50mM Tris-HCL pH 8.0, 10mM EDTA, 100µg/µl Rnase A).  Cell lysis was achieved by 
the addition of 10ml buffer P2 (200mM NaOH, 1% (w/v) SDS) and incubated for 10 
minutes at room temperature.  10ml of buffer P3 (3.0M potassium acetate pH 5.5) was 
added to neutralise the reaction and the solution was immediately applied to a QIAfilter 
cartridge and left for 10 minutes at room temperature to settle.  Meanwhile, a Qiagen tip 
500 was equilibrated by the addition of buffer QBT (750mM NaCl, 50mM MOPS pH 7.0, 
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15% (v/v) isopropanol).  After 10 minutes, the lysed cells were added onto the equilibrated 
tip and allowed to filter through.  The column was washed with 60ml of buffer QC (1.0M 
NaCl, 50mM MOPS pH 7.0, 15% (v/v) isopropanol).  The DNA was eluted by the addition 
of 15ml of buffer QF (1.25M NaCl, 50mM Tris-HCl pH 8.5, 15% (v/v) isopropanol) to the 
tip.  The DNA was precipitated by the addition of 10.5ml isopropanol and pelleted by 
centrifugation at 12,000 x g for 30 minutes at 4oC.  The DNA pellet was washed with 5ml 
of room temperature 70% (v/v) ethanol and then centrifuged for 15 minutes at 12,000 x g 
at 4oC.  The supernatant was carefully removed and the pellet allowed to air dry prior to 
resuspension in 1ml of sterile water. 
2.3.5 Quantification of DNA 
Quantification of DNA samples was performed by examining the absorbance of a 1:100 
dilution of the sample at 260nm.  An A260 value of 1 unit was taken to correspond to 
50µg/ml of double stranded DNA.  The A280 value of sample was also measured to assess 
the purity of the DNA solution.  A DNA solution with A260/A280 ratio of between 1.7 and 
2.0 was considered pure enough for use.   
2.3.6 Digestion of DNA with restriction endonucleases 
Digests were prepared using the appropriate restriction enzyme (1-2 units), buffer as 
specified by the manufacturer, and 1µg of DNA, in a final volume of 20µl.  Reactions were 
incubated at 37oC for a minimum of 2 hours.   
2.3.7 DNA gel electrophoresis 
Digested DNA samples or PCR reactions were examined using gel electrophoresis.  
Samples were diluted in 5x DNA loading buffer.  A 1% (w/v) agarose gel was prepared by 
mixing agarose with 1 x TAE and 2.5mg/ml ethidium bromide.  The gels were set in a 
horizontal gel tank and once set immersed in 1 x TAE.  Samples were loaded and the gels 
ran at 75mA for 20-30 minutes.  The DNA fragments were visualised using ultraviolet 
light.  The size of each fragment was assessed by comparison with DNA molecular 
markers X. 
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2.3.8 DNA purification from agarose gels 
The required DNA fragments were excised from the gel and purified using the QiaQuick 
gel extraction kit as per the manufacturer’s instructions.  DNA was eluted from the 
purification column using 30µl sterile water. 
2.3.9 Alkaline phosphatase treatment of plasmid vectors 
The 5´ phosphate group of digested plasmid vector was removed to minimise re-ligation of 
the vector to itself.  200ng of digested vector was incubated with 2 units of shrimp alkaline 
phosphatase for 30 minutes at 37oC.  The treated plasmid was isolated first by resolving on 
an agarose gel by electrophoresis and then extracted as previously described in section 
2.3.8. 
2.3.10 Ligation of DNA 
Digested PCR fragments were ligated into plasmid vector using T4 DNA ligase.  A ratio of 
1:3 and 1:6 vector:PCR product was used in a volume of 10µl containing 1 unit of ligase 
and the supplied buffer.  The reaction was incubated at room temperature for 4 hours.  The 
ligation reactions were transformed as detailed in section 2.3.3. 
2.3.11 Polymerase chain reaction 
2.3.11.1 Standard PCR 
PCR reactions were carried out to amplify specific sections of DNA.  Pfu DNA 
polymerase was used due to its high fidelity and its ability to withstand higher 
temperatures.  This PCR method was used to introduce tags and to introduce new 
restriction sites to construct fusion proteins.  All reactions were performed using sterile 
materials. The PCR reactions contained;  
Pfu polymerase buffer (10x)    5µl 
DMSO (optional)     5µl 
Deoxynucleotide tri-phosphates (dNTPs)  5µl 
(0.2mM of each dATP, dCTP, dGTP, dTTP) 
Primer sense: 25pmol/µl     1µl 
Primers antisense: 25pmol/µl    1µl 
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DNA template: 50ng/µl    1µl 
Pfu enzyme: 1 unit     1µl 
dH2O to a final volume of     50µl 
Reactions were carried out on an Eppendorf gradient Thermocycler.  PCR cycles used 
were as follows and the annealing temperatures were dependent on the Tm of primers 
used; 
1. Preheating   95oC  5min 
2. Denaturation   95oC  1min 
3. Annealing   50-60oC  1min 
4. Extension   72oC  3min 
5.  Repeat from step 2.    29x 
6. End    72oC  10min 
7. Hold    4oC 
2.3.11.2 QuikChange mutagenesis PCR 
The QuikChange site-directed mutagenesis method was used to make point mutations 
(either single or multiple residues).  Manufactures instructions were followed when 
designing primers and carrying out the PCR reactions. 
PCR reactions were compiled with the following components: 50ng DNA template, 15pM 
of both forward and reverse primers, 1µl of dNTP mix (0.2µM of each dATP, dCTP, dGTP 
and dTTP) and 1µl (2.5U) Pfu DNA polymerase, total volume of 50µl with reaction buffer.  
Samples were cycled 30 times in an Eppendorf Thermocycler system under the following 
conditions  
 Cycle 1:  95oC for 30 seconds 
 Cycles 2-30:  95oC for 30 seconds,  
50oC for 1 minute  
68oC for 1 minute per kbp of plasmid length 
The product was treated with 1µl (10U) DpnI restriction enzyme and incubated for 60 
minutes at 37oC.  Control reactions contained 50ng DNA, 1µl of dNTP mix and 1µl Pfu, 
total volume of 30µl with reaction buffer. This allows the digestion of parental methylated 
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dsDNA.  The digested mutated DNA and control were then transformed into DH5α cells 
following the protocol described in section 2.3.3. 
2.3.12 DNA sequencing 
DNA sequencing was performed by The Sequencing Service (School of Life Sciences, 
University of Dundee, Scotland) using Applied Biosystems Big-Dye Ver 3.1 chemistry on 
an Applied Biosystems model 3730 automated capillary DNA sequencer. 
2.4 Generation of GPR40 constructs 
2.4.1 C-terminally epitope tagged constructs 
GPR40-Flag 
Primers to remove the stop codon of GPR40 and to introduce the Flag epitope sequence 
were used to generate C-terminally tagged GPR40-Flag;                                                
sense 5’ – CCGGGTACCATGGACCTGCCCCCGCAGCTCTCCTTC – 3’,                  
anti-sense 5’ – 
CTAGTCTAGACTAAGACTTATCATCGTCGTCCTTGTAGTCCTTCTGGGACTTGCC
CCCTTGCGT – 3’.  The region encoding the Flag epitope tag is shown in bold italics.  
The KpnI and XbaI sites present in the sense and anti-sense primers respectively are 
underlined and the amplified fragment was digested and ligated into pcDNA3. 
GPR40-c-Myc 
Primers to remove the stop codon of GPR40 and to introduce the c-Myc epitope sequence 
were used to generate C-terminally tagged GPR40-c-Myc;                                                
sense 5’ – CCGGGTACCATGGACCTGCCCCCGCAGCTCTCCTTC – 3’,                    
anti-sense 5’ – 
CTAGTCTAGACTACAGATCTTCTTCAGAAATAAGTTTTTGTTCCTTCTGGGACTT
GCCCCCTTGCGT – 3’.  The region encoding the c-Myc epitope tag is shown in bold 
italics.  The KpnI and XbaI sites present in the sense and anti-sense primers respectively 
are underlined and the amplified fragment was digested and ligated into pcDNA3. 
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2.4.2 Fluorescent fusions 
GPR40–eCFP 
Primers were designed to amplify GPR40 and to remove the stop codon;                       
sense 5’ – CCCCCAAGCTTCCACCATGGACCTGCCCCCGCAGCTC – 3’,                 
anti-sense 5’ – AAAAGATATCCTTCTGGGACTTGCCCCCTTGC – 3’.  The HindIII 
and EcoRV sites present in the sense and anti-sense primers respectively are underlined.  
The amplified fragment was digested and ligated into pcDNA3 in frame with eCFP ligated 
between NotI and XhoI. 
GPR40-eYFP 
Primers were designed to amplify GPR40 and to remove the stop codon;                       
sense 5’ – CCCCCAAGCTTCCACCATGGACCTGCCCCCGCAGCTC – 3’,                 
anti-sense 5’ – AAAAGATATCCTTCTGGGACTTGCCCCCTTGC – 3’.  The HindIII 
and EcoRV sites present in the sense and anti-sense primers respectively are underlined.  
The amplified fragment was digested and ligated into pcDNA3, in frame, with eYFP 
ligated between NotI and XhoI.  
GPR40-eYFP was subcloned by digestion with HindIII and XhoI and ligation into the 
pcDNA5/FRT/TO vector.   
2.4.3 Receptor-G protein fusion 
GPR40-Gαq  
Primers were designed to amplify GPR40 and to remove the stop codon;                       
sense 5’ – CCCCCAAGCTTCCACCATGGACCTGCCCCCGCAGCTC – 3’,                 
anti-sense 5’ – AAAAGATATCCTTCTGGGACTTGCCCCCTTGC – 3’.  The HindIII 
and EcoRV sites present in the sense and anti-sense primers respectively are underlined.  
Primers to amplify Gαq were also designed;                                                                                 
sense 5’ – AAAAGATATCACTCTGGAGTCCATCATGGCGTGC – 3’,                     
anti-sense 5’ – TTTTTTCCTTGCGGCCGCTTAGACCAGATTGTACTCCTTCAG – 3’.  
The EcoRV and NotI sites present in the sense and anti-sense primers respectively are 
underlined.  The amplified fragments of GPR40 and Gαq were digested with the 
appropriate enzymes and ligated, in frame, into pcDNA3. 
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2.4.4 Single point basic mutations 
GPR40 Lys
62
Ala 
Using the Stratagene QuikChange method, primers were designed to mutate Lys62 in 
GPR40 to Ala, with the mutated bases shown in bold italics;                                                                                                                  
Sense 5’ – CTCTGCCCCTGGCGGCGGTGGAGGCG – 3’                                          
Anti-sense 5’ – CGCCTCCACCGCCGCCAGGGGCAGAG– 3’.                                    
The primers were used to introduce the mutation into GPR40-eYFP or GPR40-Gαq in 
pcDNA3 and the template was digested with DpnI to leave mutated plasmid.  Sequencing 
was carried out to confirm the introduction of the mutation. 
GPR40 His
137
Ala 
Using the Stratagene QuikChange method, primers were designed to mutate His137 in 
GPR40 to Ala, with the mutated bases shown in bold italics;                                                                                                                  
Sense 5’ – GCCCTCGTCCTGTGTGCCCTGGGTCTGGTCTTTGGG – 3’                 
Anti-sense 5 – CCCAAAGACCAGACCCAGGGCACACAGGACGAGGCC – 3’.           
The primers were used to introduce the mutation into GPR40-eYFP in pcDNA3 and the 
template was digested with DpnI to leave mutated plasmid.  Sequencing was carried out to 
confirm the introduction of the mutation. 
GPR40 Arg
183
Ala 
Using the Stratagene QuikChange method, primers were designed to mutate Arg183 in 
GPR40 to Ala, with the mutated bases shown in bold italics;                                                                                                                 
Sense 5’ – GCCGGCCCGGCCGCCTTCAGCCTCTCTCTCC – 3’                              
Anti-sense 5’ – GGAGAGAGAGGCTGAAGGCGGCCGGGCCGGC – 3’.                   
The primers were used to introduce the mutation into GPR40-eYFP or GPR40-Gαq in 
pcDNA3 and the template digested with DpnI to leave mutated plasmid.  Sequencing was 
carried out to confirm the introduction of the mutation. 
2.4.5 Double basic mutations 
GPR40 Lys
62
Ala, His
137
Ala 
Using the Stratagene QuikChange method, primers were designed to mutate His137 to Ala 
in GPR40 already containing a Lys62Ala mutation, with the mutated bases shown in bold 
italics;                                                                                                                               
Sense 5’ – GCCCTCGTCCTGTGTGCCCTGGGTCTGGTCTTTGGG – 3’                 
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Anti-sense 5 – CCCAAAGACCAGACCCAGGGCACACAGGACGAGGCC – 3’.           
The primers were used to introduce the mutation into GPR40 Lys62Ala-eYFP in pcDNA3 
and the template was digested with DpnI to leave mutated plasmid.  Sequencing was 
carried out to confirm the introduction of the mutation. 
GPR40 Lys
62
Ala, Arg
183
Ala 
Using the Stratagene QuikChange method, primers were designed to mutate Arg183 to Ala 
in GPR40 already containing a Lys62Ala mutation, with the mutated bases shown in bold 
italics;    Sense 5’ – GCCGGCCCGGCCGCCTTCAGCCTCTCTCTCC – 3’                              
Anti-sense 5’ – GGAGAGAGAGGCTGAAGGCGGCCGGGCCGGC – 3’.                   
The primers were used to introduce the mutation into GPR40 Lys62Ala-eYFP in pcDNA3 
and the template was digested with DpnI to leave mutated plasmid.  Sequencing was 
carried out to confirm the introduction of the mutation. 
GPR40 His
137
Ala, Arg
183
Ala 
Using the Stratagene QuikChange method, primers were designed to mutate Arg183 to Ala 
in GPR40 already containing a His137Ala mutation, with the mutated bases shown in 
italics;    Sense 5’ – GCCGGCCCGGCCGCCTTCAGCCTCTCTCTCC – 3’                              
Anti-sense 5’ – GGAGAGAGAGGCTGAAGGCGGCCGGGCCGGC – 3’.                   
The primers were used to introduce the mutation into GPR40 His137Ala-eYFP in pcDNA3 
and the template was digested with DpnI to leave mutated plasmid.  Sequencing was 
carried out to confirm the introduction of the mutation. 
2.4.6 TM3 mutations 
GPR40 GGG
93-95
STW 
Using the Stratagene QuikChange method, primers were designed to mutate GGG93-95 in 
GPR40 to STW, with the mutated bases shown in bold italics;                                                 
Sense 5’ – CTTCCCACTCTATGCCAGCACGTGGTTCCTGGCCGCCC – 3’            
Anti-sense 5’ – GGGCGGCCAGGAACCACGTGCTGGCATAGAGTGGGAAG – 3’. 
The primers were used to introduce the mutation into GPR40-eYFP in pcDNA3 and the 
template was digested with DpnI to leave mutated plasmid.  Sequencing was carried out to 
confirm the introduction of the mutation. 
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2.5 Generation of GPR41 constructs 
2.5.1 C-terminally epitope tagged constructs 
GPR41-Flag 
Primers to remove the stop codon of GPR41 and to introduce the Flag epitope sequence 
were used to generate C-terminally tagged GPR41-Flag;                                                 
sense 5’ – CCGGGTACCATGGATACAGGCCCCGACCAGTCCTACTTC – 3’,        
anti-sense 5’ – 
CTAGTCTAGACTAAGACTTATCATCGTCGTCCTTGTAGTCGCTTTCAGCACAGG
CCACCTGGCCACCAGTTCC – 3’.  The region encoding the Flag epitope tag is shown 
in bold italics.  The KpnI and XbaI sites present in the sense and anti-sense primers 
respectively are underlined and the amplified fragment was digested and ligated into 
pcDNA3. 
GPR41-c-Myc 
Primers to remove the stop codon of GPR41 and to introduce the c-Myc epitope sequence 
were used to generate C-terminally tagged GPR41-c-Myc;                                                 
sense 5’ – CCGGGTACCATGGATACAGGCCCCGACCAGTCCTACTTC – 3’,         
anti-sense 5’ – 
CTAGTCTAGACTACAGATCTTCTTCAGAAATAAGTTTTTGTTCGCTTTCAGCACA
GGCCACCTGGCC – 3’.  The region encoding the c-Myc epitope tag is shown in bold 
italics.  The KpnI and XbaI sites present in the sense and anti-sense primers respectively 
are underlined and the amplified fragment was digested and ligated into pcDNA3. 
2.5.2 Fluorescent fusions 
GPR41–eCFP 
Primers were designed to amplify GPR41 and to remove the stop codon;                       
sense 5’ – TACGGGGTACCCCACCATGGATACAGGCCCCGACCAG – 3’, anti-sense 
5’ – TTTTCCTTTTGCGGCCGCTGCTTTCAGCACAGGCCACCTG – 3’.  The KpnI and 
NotI sites present in the sense and anti-sense primers respectively are underlined.  The 
amplified fragment was digested and ligated into pcDNA3 in frame with eCFP ligated 
between NotI and XhoI. 
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GPR41-eYFP 
Primers were designed to amplify GPR41 and to remove the stop codon;                       
sense 5’ – TACGGGGTACCCCACCATGGATACAGGCCCCGACCAG – 3’, anti-sense 
5’ – TTTTCCTTTTGCGGCCGCTGCTTTCAGCACAGGCCACCTG – 3’.  The KpnI and 
NotI sites present in the sense and anti-sense primers respectively are underlined.  The 
amplified fragment was digested and ligated into pcDNA3 in frame with eYFP ligated 
between NotI and XhoI. 
2.5.3 Receptor-G protein fusion 
GPR41-Gαi3 Cys
351
Ile  
Primers were designed to amplify GPR41 and to remove the stop codon;                       
sense 5’ – TACGGGGTACCCCACCATGGATACAGGCCCCGACCAG – 3’, anti-sense 
5’ – TTTTCCTTTTGCGGCCGCTGCTTTCAGCACAGGCCACCTG – 3’.  The KpnI and 
NotI sites present in the sense and anti-sense primers respectively are underlined.  Primers 
to amplify Gαi3 were also designed;                                                                                 
sense 5’ – AAAAGGAAAAGCGGCCGCGGCTGCACGTTGAGCGCCGAGGAC – 3’, 
anti-sense 5’ – CCCCGCTCGAGTCAGTAAAGCCCGATTTCCTTTAAGTTG – 3’.  The 
NotI and XhoI sites present in the sense and anti-sense primers respectively are underlined.  
The amplified fragments of GPR41 and Gαi3 were digested with the appropriate enzymes 
and ligated, in frame, into pcDNA3. 
2.5.4 Basic mutants 
GPR41 Arg
71
Ala 
Using the Stratagene QuikChange method, primers were designed to mutate Arg71 in 
GPR41 to Ala, with the mutated bases shown in bold italics;                                                 
Sense 5’ – GCTGTTCCTGCCTTTCGCCATGGTGGAGGCAGCC – 3’                      
Anti-sense 5’ – GGCTGCCTCCACCATGGCGAAAGGCAGGAACAGC -3’.              
The primers were used to introduce the mutation into GPR41-eYFP or GPR41-Gαi3 
Cys351Ile in pcDNA3 and the template digested with DpnI to leave mutated plasmid.  
Sequencing was carried out to confirm the introduction of the mutation. 
GPR41 His
146
Ala 
Using the Stratagene QuikChange method, primers were designed to mutate His146 in 
GPR41 to Ala, with the mutated bases shown in bold italics;                                                 
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Sense 5’ – GCTGTTGGCCTCTGCTGCCTGCAGCGTGGTCTACG – 3’                   
Anti-sense 5’ – CGTAGACCACGCTGCAGGCAGCAGAGGCCAACAGC – 3’.          
The primers were used to introduce the mutation into GPR41-eYFP or GPR41-Gαi3 
Cys351Ile in pcDNA3 and the template was digested with DpnI to leave mutated plasmid.  
Sequencing was carried out to confirm the introduction of the mutation. 
GPR41 Arg
185
Ala 
Using the Stratagene QuikChange method, primers were designed to mutate Arg185 in 
GPR41 to Ala, with the mutated bases shown in bold italics;                                                  
Sense 5’ – CCTCCTGCCCGTGGCGCTGGAGATGGC – 3’                                        
Anti-sense 5’ – GCCATCTCCAGCGCCACGGGCAGGAGG – 3’.                                 
The primers were used to introduce the mutation into GPR41-eYFP or GPR41-Gαi3 
Cys351Ile in pcDNA3 and the template digested with DpnI to leave mutated plasmid.  
Sequencing was carried out to confirm the introduction of the mutation. 
2.6 Generation of GPR43 constructs 
2.6.1 N-terminally epitope tagged  
Flag-GPR43 
Primers encoding the Flag epitope sequence were used to generate N-terminally tagged 
Flag-GPR43; 
Sense 5’ – 
CCCAAGCTTATGGACTACAAGGACGACGATGATAAGTGTCTGCCCGACTTGAAG
AGCTCCTTGATC - 3’, anti-sense 5’- 
CTAGTCTAGACTACTCTGTAGTGAAGTCCGAACTTGG – 3.  The region encoding 
the Flag epitope tag is shown in bold italics.  The HindIII and XbaI sites present is the 
sense and anti-sense primers respectively are underlined and the amplified fragment was 
digested and ligated into pcDNA3. 
c-Myc-GPR43 
Primers encoding the c-Myc epitope sequence were used to generate N-terminally tagged 
c-Myc-GPR43; 
sense 5’ – 
CCCAAGCTTATGGAACAAAAACTTATTTCTGAAGAAGATCTGCTGCCGGACTGG
AAGAGCTCCTTGATC – 3’, anti-sense 5’ – 
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CTAGTCTAGACTACTCTGTAGTGAAGTCCGAACTTGG – 3’.  The region encoding 
the c-Myc epitope tag is shown in bold italics.  The HindIII and XbaI sites presents is the 
sense and anti-sense primers respectively are underlined and the amplified fragment was 
digested and ligated into pcDNA3.   
2.6.2 C-terminally epitope tagged  
GPR43-Flag 
Primers to remove the stop codon of GPR43 and to introduce the Flag epitope sequence 
were used to generate C-terminally tagged GPR43-Flag;                                                 
sense 5’ – CCCAAGCTTATGCTGCCGGACTGGAAGAGCTCCTTGATC – 3’,        
anti-sense 5’ – 
CTAGTCTAGACTAAGACTTATCATCGTCGTCCTTGTAGTCCTCTGTAGTGAAGT
CCGAACTTGGCATCCCTTC – 3’.  The region encoding the Flag epitope tag is shown in 
bold italics.  The HindIII and XbaI sites present in the sense and anti-sense primers 
respectively are underlined and the amplified fragment was digested and ligated into 
pcDNA3. 
GPR43-c-Myc 
Primers to remove the stop codon of GPR43 and to introduce the c-Myc epitope sequence 
were used to generate C-terminally tagged GPR43-c-Myc;                                                 
sense 5’ – CCGGGTACCATGGATACAGGCCCCGACCAGTCCTACTTC – 3’,         
anti-sense 5’ – 
CTAGTCTAGACTACAGATCTTCTTCAGAAATAAGTTTTTGTTCCTCTGTAGTGAA
GTCCGAACTTGG – 3’.  The region encoding the c-Myc epitope tag is shown in bold 
italics.  The HindIII and XbaI sites present in the sense and anti-sense primers respectively 
are underlined and the amplified fragment was digested and ligated into pcDNA3 
2.6.3 Fluorescent fusions 
GPR43-eCFP 
Primers were designed to amplify GPR43 and to remove the stop codon;                       
sense 5’ – CCCCCAAGCTTCCACCATGCTGCCGGACTGGAAGAGC – 3’,                 
anti-sense 5’ – AAAAGATATCCTCTGTAGTGAAGTCCGAACTTGG – 3’.  The 
HindIII and EcoRV sites present in the sense and anti-sense primers respectively are 
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underlined.  The amplified fragment was digested and ligated into pcDNA3, in frame, with 
eCFP ligated between NotI and XhoI. 
GPR43-eYFP 
Primers were designed to amplify GPR43 and to remove the stop codon;                       
sense 5’ – CCCCCAAGCTTCCACCATGCTGCCGGACTGGAAGAGC – 3’,                 
anti-sense 5’ – AAAAGATATCCTCTGTAGTGAAGTCCGAACTTGG – 3’.                     
The HindIII and EcoRV sites present in the sense and anti-sense primers respectively are 
underlined.  The amplified fragment was digested and ligated into pcDNA3, in frame, with 
eCFP ligated between NotI and XhoI. 
2.6.4 Basic mutations 
GPR43 Lys
65
Ala 
Using the Stratagene QuikChange method, primers were designed to mutate Lys65 in 
GPR43 to Ala, with the mutated bases shown in bold italics;                                                  
Sense 5’ – GCTGCTGCTGCCCTTCGCGATCATCGAGGCTGCG – 3’                     
Anti-sense 5’ – CGCAGCCTCGATGATCGCGAAGGGCAGCAGCAGC – 3’.            
The primers were used to introduce the mutation into GPR43-eYFP in pcDNA3 and the 
template was digested with DpnI to leave mutated plasmid.  Sequencing was carried out to 
confirm the introduction of the mutation. 
GPR43 His
140
Ala 
Using the Stratagene QuikChange method, primers were designed to mutate His140 in 
GPR43 to Ala, with the mutated bases shown in bold italics;                                                 
Sense 5’ - GGTTATGTCCTTTGGTGCCTGCACCATCGTGATCATC – 3’               
Anti-sense 5’ – GATGATCACGATGGTGCAGGCACCAAAGGACATAACC – 3’      
The primers were used to introduce the mutation into GPR43-eYFP in pcDNA3 and the 
template digested with DpnI to leave mutated plasmid.  Sequencing was carried out to 
confirm the introduction of the mutation. 
GPR43 Arg
180
Ala 
Using the Stratagene QuikChange method, primers were designed to mutate Arg175 in 
GPR43 to Ala, with the mutated bases shown in bold italics;                                                 
Sense 5’ – GGTGCTGCCCGTGGCGCTGGAGCTGTGC – 3’                                     
Anti-sense 5’ – GCACAGCTCCAGCGCCACGGGCAGCACC – 3’.                             
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The primers were used to introduce the mutation into GPR43-eYFP in pcDNA3 and the 
template was digested with DpnI to leave mutated plasmid.  Sequencing was carried out to 
confirm the introduction of the mutation. 
GPR43 Arg
180
Leu 
Using the Stratagene QuikChange method, primers were designed to mutate Arg175 in 
GPR43 to Leu, with the mutated bases shown in bold italics;                                                 
Sense 5’ – GGTGCTGCCCGTGCTGCTGGAGCTGTGC – 3’                                     
Anti-sense 5’ – GCACAGCTCCAGCAGCACGGGCAGCACC – 3’.                              
The primers were used to introduce the mutation into GPR43-eYFP in pcDNA3 and the 
template digested with DpnI to leave mutated plasmid.  Sequencing was carried out to 
confirm the introduction of the mutation. 
GPR43 Arg
180
Lys 
Using the Stratagene QuikChange method, primers were designed to mutate Arg175 in 
GPR43 to Lys, with the mutated bases shown in bold italics;                                                    
Sense 5’ – GGTGCTGCCCGTGAAGCTGGAGCTGTGC – 3’                                     
Anti-sense 5’ – GCACAGCTCCAGCTTCACGGGCAGCACC – 3’.                              
The primers were used to introduce the mutation into GPR43-eYFP in pcDNA3 and the 
template digested with DpnI to leave mutated plasmid.  Sequencing was carried out to 
confirm the introduction of the mutation. 
GPR43 Arg
180
Ser 
Using the Stratagene QuikChange method, primers were designed to mutate Arg175 in 
GPR43 to Ser, with the mutated bases shown in bold italics;                                                    
Sense 5’ – GGTGCTGCCCGTGTCGCTGCTGTGC – 3’                                              
Anti-sense 5’ – GCACAGCTCCAGCGACACGGGCAGCACC – 3’.                                   
The primers were used to introduce the mutation into GPR43-eYFP in pcDNA3 and the 
template was digested with DpnI to leave mutated plasmid.  Sequencing was carried out to 
confirm the introduction of the mutation. 
2.6.5 TM3 mutations 
GPR43 Trp
98
Gly 
Using the Stratagene QuikChange method, primers were designed to mutate Trp98 in 
GPR43 to Gly, with the mutated bases shown in bold italics;                                                   
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Sense 5’ – CTACTGCAGCACGGGGCTCCTGGCGGGC – 3’                                     
Anti-sense 5’ – GCCCGCCAGGAGCCCCGTGCTGCAGTAG – 3’.                                
The primers were used to introduce the mutation into GPR43-eYFP in pcDNA3 and the 
template was digested with DpnI to leave mutated plasmid.  Sequencing was carried out to 
confirm the introduction of the mutation. 
GPR43 Thr
97
Gly, Trp
98
Gly 
Using the Stratagene QuikChange method, primers were designed to mutate Thr97 to Gly in 
GPR43 already containing a Trp98Gly mutation, with the mutated bases shown in bold 
italics;                                                  
Sense 5’ – CTACTGCAGCGGGGGGCTCCTGGCGGGC – 3’                                     
Anti-sense 5’ – GCCCGCCAGGAGCCCCCCGCTGCAGTAG – 3’.                              
The primers were used to introduce the mutation into GPR43 Trp98Gly-eYFP in pcDNA3 
and the template was digested with DpnI to leave mutated plasmid.  Sequencing was 
carried out to confirm the introduction of the mutation. 
GPR43 Ser, Thr, Trp
96-98
Gly, Gly, Gly 
Using the Stratagene QuikChange method, primers were designed to mutate Ser96 to Gly in 
GPR43 already containing Thr87Gly and Trp98Gly mutations, with the mutated bases 
shown in bold italics;                                                  
Sense 5’ – GCATCTACTGCGGCGGGGGGCTCCTGG – 3’                                       
Anti-sense 5’ – CCAGGAGCCCCCCGCCGCAGTAGATGC – 3’.                                
The primers were used to introduce the mutation into GPR43 Thr97Gly, Trp98Gly-eYFP in 
pcDNA3 and the template was digested with DpnI to leave mutated plasmid.  Sequencing 
was carried out to confirm the introduction of the mutation. 
2.7 Cell culture 
2.7.1 Cell maintenance 
2.7.1.1 HEK293T 
Human embryonic kidney cells stably expressing the SV40 large T-antigen (HEK293T) 
were grown in Dulbecco’s modified Eagle’s medium supplemented with 10% newborn 
calf serum and 2mM L-glutamine.  Cells were grown in a humidified incubator of 95% 
air/5% CO2 at 37
oC. 
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2.7.1.2 HEK293 MSRII 
Human embryonic kidney cells (HEK293 MSRII) transformed with the macrophage 
scavenger receptor (Class A, type1; GenBank Accession no. D90187) were maintained in 
minimal essential medium containing 2mM L-glutamine supplemented with 10% foetal 
calf serum, 1% non-essential amino acids and 0.8% G418. Cells were grown in a 
humidified incubator of 95% air/5% CO2 at 37
oC.  The expression of this receptor by the 
HEK293 cells enhances their ability to stick to tissue culture treated plasticware.   
2.7.1.3 Flp-In T-REx HEK293 
Cell were maintained in Dulbecco's modified Eagle's medium without sodium pyruvate, 
4500mg/litre glucose, and L-glutamine supplemented with 10% (v/v) foetal calf serum, 1% 
antibiotic mixture, and 10µg/ml blasticidin at 37°C in a humidified atmosphere of air/CO2 
(19:1).  
2.7.1.4 INS-1E 
The transformed rat pancreatic β-cell line INS-1E was maintained in RPMI 1640 medium 
with L-glutamine supplemented with 10% foetal calf serum, 10mM HEPES, 1mM sodium 
pyruvate, 50µM 2-mercaptoethanol and 1% antibiotic mixture at 37oC in a humidified 
atmosphere of air/CO2 (19:1).  Cells were grown in Falcon flasks and passaged once a 
week. 
2.7.2 Passage of cells 
Confluent HEK293T, Flp-In T-Rex HEK293 and INS-1E cells were passaged by the 
addition of sterile 0.25% trypsin-EDTA after removal of growth media.  HEK293 MSRII 
cells were washed once with sterile PBS before the addition of versene to detach the cells.  
Flasks were gently rotated to cover the monolayer and placed in the incubator for 5 
minutes.  Once detached, 7ml of fresh media was added and the cells centrifuged at 288 x 
g for 5 minutes.  The resulting pellet was resuspended in fresh media.  The suspension was 
split into flasks, dishes, plates or coverslips as required. 
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2.7.3 Transient transfection 
Transfection of cells was performed when the cells had reached 60-70% confluency.  
Plasmid DNA was transfected using Lipofectamine in accordance with the manufacturer’s 
instructions.  
2.7.4 Generation of Flp-In T-Rex HEK293 inducible cell line  
Flp-In T-Rex HEK293 cells were transfected with a mixture of GPR40-eYFP in the 
pcDNA5/FRT/TO vector and the pOG44 vector in a 1:9 ratio with Lipofectamine as 
described in section 2.7.3.  After 48 hours, the medium was changed to medium as 
described in section 2.7.1.3 supplemented with 200µg/ml hygromycin to initiate selection 
of stably transfected selected cells.  To initiate expression of GPR40-eYFP, cells were 
treated with 1µg/ml doxycycline for 24 hours. 
2.7.5 Cell harvesting 
Transfected cells were harvested 24-48 hours post-transfection.  The media was discarded 
and cells washed 3 times in ice cold 1 x PBS.  Cells were scraped from the flask using a 
disposable cell scraper and transferred to a 15ml centrifuge tube.  The detached cells were 
centrifuged for 5 minutes at 288 x g at 4oC.  After discarding the supernatant, the cell pellet 
was frozen at -80oC until required. 
2.8 Biochemical assays and other methods of analysis 
2.8.1 Preparation of cell membranes 
Harvested pellets were thawed and resuspended in Tris/EDTA buffer.  The cells were 
homogenised by 50 passes of a glass-on-Teflon homogeniser.  The resulting suspension 
was centrifuged at 288 x g for 10 minutes to remove unbroken cells and nuclei.  The 
supernatant was subsequently ultracentrifuged at 50,000 x g for 30 minutes in a Beckman 
Optima TLX Ultracentrifuge (Palo Alto, CA).  The resulting pellet was resuspended in 
Tris/EDTA buffer and passed 10 times through a 25 gauge needle.  The protein 
concentration was determined as detailed in section 2.8.2 and the membranes diluted to 
1µg/µl and stored at -80oC until required. 
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2.8.2 BCA protein quantification 
The protein concentration in samples was quantified using the BCA assay.  This assay 
utilises bincinhoninic acid (BCA) and copper sulphate solutions, in which proteins reduce 
the Cu(II) ions to Cu(I) ion in a concentration dependent manner and the reduced Cu(I) can 
be bound by BCA.  When BCA binds Cu(I) a colour change occurs which has an 
absorption maximum of 562nm.  Using solutions of known protein concentrations a 
standard curve was constructed, which allows the concentrations of unknown samples to 
be established.  Solutions used in this assay consisted of: Reagent A – 1% (w/v) BCA, 2% 
(w/c) Na2C03, 0.16% (w/v) sodium tartrate, 0.4% NaOH, 0.95% NaHCO3, pH 11.25 and 
Reagent B – 4% CuSO4.  1 part reagent B was mixed with 49 parts reagent A and 200µl of 
this solution added to 10µl of protein standard or unknown sample in a 96 well ELISA 
plate.  The assay was incubated at 37oC before the absorbance was read.    
2.8.3 Co-immunoprecipitation 
Cells were harvested as described in section 2.7.4 and the resulting pellets resuspended in 
1ml of 1 x RIPA buffer supplemented with 10mM NaF, 5mM EDTA pH 8, 10mM 
NaH2PO4, 5% ethylene glycol and a complete EDTA-free protease inhibitor tablet.  The 
resuspended pellet was rotated for 1 hour at 4oC on a rotating wheel.  After 1 hour, the 
samples were centrifuged at 100,000 x g for 30 minutes.  To the supernatant, 200µl of 1 x 
RIPA and 50µl of protein G were added and rotated for 1 hour at 4oC to pre-clear the 
samples.  The samples were centrifuged at 16,000 x g for 10 minutes at 4oC and the protein 
concentration of the samples determined as detailed in section 2.8.2.  The protein 
concentration of the samples was equalised to 1µg/µl using 1 x RIPA.  To 600µl of each 
sample 40µl of protein G and 5µl M2 anti-Flag antibody was added and incubated 
overnight at 4oC on a rotating wheel.  To investigate protein expression 100µl of the 
equalised supernatant was reserved and to this 20µl of 5 x Laemmli buffer was added.  
After approximately 16 hours of rotation, the samples were centrifuged at 16,000 x g for 1 
minute at 4oC and the supernatant removed and the protein G beads washed in 1 x RIPA 
buffer.  This was repeated twice before addition of 40µl Laemmli buffer.  Both 
immunoprecipitated samples and cell lysates were then subjected to SDS-PAGE and 
western blotting. 
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2.8.4 Sodium dodecylsulphate polyacrylamide gel 
electrophoresis 
Protein samples were resolved using sodium dodecylsulphate polyacrylamide gel 
electrophoresis (SDS-PAGE).  After the addition of Lamemelli buffer samples were heated 
at 65oC for 10 mins then left overnight at room temperature before loading.   Samples were 
loaded onto precast NuPage Novex Bis-Tris gels with 4-12% acrylamide concentration 
alongside full range Rainbow molecular weight markers.  NuPage MOPS SDS buffer was 
used for electrophoresis at 200V using the XCell Surelock mini-cell gel tank until the dye 
front reached the foot of the gel.   
2.8.5 Western blotting 
Following separation of samples by SDS-PAGE as detailed in section 2.8.4, proteins were 
electrophoretically transferred onto nitrocellulose using the XCell II blot module.  Proteins 
were transferred at 30V for at least 1 hour in transfer buffer (0.2M glycine, 25mM Tris and 
20% (v/v) methanol).  Efficient transfer was monitored using Ponceau stain (0.1% (w/v) 
Ponceau S, 3% (w/v) trichloroacetic acid).  To block non-specific binding sites, the 
nitrocellulose was incubated in 5% (w/v) low fat milk, PBS/0.1% (v/v) Tween 20 at room 
temperature on a rotating shaker for two hours.  The membrane was incubated with 
primary antibody overnight in 5% (w/v) low fat milk, PBS/0.1% (v/v) Tween 20 
containing the required antibody (Table 2.1) at 4oC.  After overnight incubation, the 
membrane was washed 4 times in PBS/0.1% (v/v) Tween 20 over a 30 minute period.  The 
horseradish peroxidase linked secondary antibody (Table 2.1) in 5% (w/v) low fat milk, 
PBS/0/1% (v/v) Tween 20 was incubated at room temperature for 20 minutes.  Again the 
membrane was washed 4 times in PBS/0.1% (v/v) Tween 20 over a 30 minute period.  The 
nitrocellulose was then incubated for 5 minutes with ECL solution and then exposed to 
blue Kodak film and developed.  For co-immunoprecipitation experiments the blot was 
stripped and re-probed using different antibodies.  To strip the antibodies from the 
nitrocellulose the membrane was incubated for 15 minutes in 10% (v/v) ReBlot Plus 
solution and then the non-specific sites blocked as described above. 
  
Primary Antibody Dilution Factor Secondary Antibody Dilution Factor
Anti-c-Myc 1:1000 Anti-rabbit 1:10000
Anti-Flag M2 1:2000 Anti-mouse 1:10000  
Table 2.1 Primary and secondary antibody dilutions for western blotting 
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2.8.6 Time resolved FRET 
HEK293T cells were singly transfected to express c-Myc or Flag epitope tagged versions 
of GPR40 or GPR43, or co-transfected with c-Myc tagged GPR40 or GPR43 and Flag 
tagged GPR40 or GPR43.  Cells were harvested 48 hours post-transfection and samples 
containing singly tagged receptors mixed to form a negative control.  Membranes were 
prepared as detailed in section 2.8.1 but the membrane pellet was resuspended in PBS. 
Protein concentrations were equilibrated to 1µg/µl. To investigate energy transfer 
antibodies directed against the c-Myc and Flag epitope tagged versions conjugated to the 
donor, europium3+ (Eu3+) and acceptor, allophycocyanin (APC) fluorophores respectively.  
The antibodies were diluted in 50% newborn calf serum:50% PBS to a final concentration 
of 5nM anti-c-Myc Eu3+ and 15nM anti-Flag.  A dilution containing only the anti-c-Myc 
Eu3+ antibody at a concentration of 5nM was also prepared.  To 250µl of the antibody 
dilutions 50µl of membranes were added resulting in antibody incubations containing only 
anti-c-Myc Eu3+ or containing both anti-c-Myc Eu3+ and anti-Flag APC antibodies for each 
sample.  The samples were incubated on a rotating wheel at room temperature for 2 hours.  
The samples were covered in aluminium foil to minimise exposure of the fluorophores to 
light.  After incubation the sample were centrifuged at 16,000 x g for 15 minutes and the 
antibody mix removed from the membrane pellet.  The pellet was washed in ice-cold PBS 
and centrifuged again at 16,000 x g for 15 minutes. The samples were resuspended in 
250µl of PBS and passed through a 25 gauge needle.  In order to measure the energy 
transfer, 40µl of each sample was dispensed in triplicate into a black 384-well plate.  
Background readings were performed on wells containing PBS. 
Tr-FRET was determined using a Victor2 plate reader (PackardBioscience).  Excitation 
was at 340nm and emission filters generated data representing donor (615nm) and acceptor 
(665nm) emission.  Normalized FRET was calculated using the following equation; 
Normalized FRET = ((A665-BLK)/D615)-C 
Where A665 is the fluorescent emission from the acceptor, D615 is the fluorescent emission 
from the donor and BLK represents the background reading at 665nm from the wells 
containing PBS.  C represents the crosstalk between the donor and acceptor windows for 
the samples incubated with only anti-c-Myc Eu3+ and is equal to A665-BLK/D615. 
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2.8.7 FRET imaging in single living cells 
HEK293T cells were gown on coverslips treated with poly-D-lysine and transiently 
transfected to express the receptor or receptors of interest.  Coverslip fragments were 
placed into a microscope chamber containing physiological saline solution.  Cells were 
visualised using a Nikon Eclipse TE2000-E fluorescence inverted microscope and images 
obtained individually for eYFP, eCFP and FRET filter channels using a Optoscan 
monochromator (Cairn Research, Faversham, Kent, UK) and a dichroic mirror 86002v2bs 
(Chroma Inc., Rockingham, VT).  The filter sets used were; eYFP (excitation – 500/5 nm; 
emission – 535/30 nm), eCFP (excitation 430/12 nm; emission – 470/30 nm) and FRET 
(excitation 430/12 nm; emission 535/30 nm).  The illumination time was 250 ms and 
binning modes 2x2.  MetaMorph imaging software (Universal Imaging Corp., West 
Chester, PA) was used to quantify FRET images using the donor only specified bleed 
through FRET method.   
Bleed through coefficients were calculated using cells singly transfected with either the 
eCFP (donor in FRET) or eYFP (donor in acceptor) fused receptors.  The values obtained 
for the constructs used in this study are shown in table 2.2. 
Construct Coefficient
GPR40-eYFP 0.653
GPR40-eCFP 0.0092
GPR43-eYFP 0.6253
GPR43-eCFP 0.0078
H1-eYFP 0.0155  
Table 2.2 FRET bleedthrough coefficients  
To correct the FRET levels for the varying amounts of donor (CFP) and acceptor (eYFP), 
normalised FRET was calculated using the following equation; 
FRETn = FRETc/CFP x eYFP 
Where FRETc, CFP and eYFP are equal to the fluorescence values measured for each 
individual cell.  FRET was measured for 30-50 cells. 
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2.8.8 [35S]GTPγS binding assays 
[35S]GTPγS  binding experiments were initiated by the addition a given amount of 
membranes expressing the required construct (2.5µg for GPR40 constructs and 5µg  for 
GPR41 constructs) to an assay buffer (20mM HEPES (pH 7.4), 3mM MgCl2, 100mM 
NaCl, 1µM GDP, 0.2mM ascorbic acid, and 50nCi [35S]GTPγS) containing the given 
concentration of agonist or antagonist.  Non-specific binding was determined in the above 
condition with the addition of 100µM GTPγS.  Reactions were incubated for 30 minutes at 
30oC and were terminated by the addition of 500µl of ice-cold buffer containing 20mM 
HEPES (pH 7.4), 3mM MgCl2, 100mM NaCl and 0.2mM ascorbic acid.  The samples 
were centrifuged at 16,000 x g for 10 minutes at 4oC.  The resulting pellets were 
resuspended in 50µl solubilisation buffer (100mM Tris, 200mM NaCl, 1mM EDTA, and 
1.25% Nonidet P-40) plus 0.2% SDS.  Samples were pre-cleared with pansorbin followed 
by immunoprecipitation with the required anti-serum against the C-terminus of the given G 
protein.  Finally, the immunocomplexes were washed once with solubilisation buffer, and 
bound [35S]GTPγS was estimated by liquid-scintillation spectrometry.   
2.8.9 Single cell calcium assay 
HEK293T cells grown on poly-D-lysine coated coverslips were transiently transfected to 
express the receptor of interest.  24 h after transfection cells were loaded with the calcium 
sensitive dye fura-2. 1.5µM fura-2 was added to normal growth media and the cells 
incubated at 37oC for 30 minutes.  After loading of the dye, fragments of coverslips were 
placed into a microscope chamber containing physiological saline solution and illuminated 
with an ultra high point intensity 75-watt xenon arc lamp (Optosource, Cairn Research, 
Faversham, Kent, UK) and imaged using a Nikon Diaphot inverted microscope equipped 
with a Nikon 40× oil immersion Fluor objective lens (NA = 1.3) and a monochromator 
(Optoscan, Cairn Research), which was used to alternate the excitation wavelength 
between 340/380nm and to control the excitation band pass (340nm band pass = 10nm; 
380nm band pass = 8nm).  Fura-2 fluorescence emission at 510nm was monitored using a 
high resolution interline-transfer cooled digital CCD camera (Cool Snap-HQ, Roper 
Scientific/Photometrics, Tucson, AZ).  MetaFluor imaging software (Universal Imaging 
Corp., Downing, PA) was used for control of the monochromator, CCD camera, and for 
processing of the cell image data. Sequential images (2 × 2 binning) were collected every 
2s, exposure to excitation light was 100 ms/image.  Agonist was added after 60s (after 30 
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images) for 60s using a perfusion system.  Experiments were ran for 5 minutes in total.  
MetaFluor software was used to analyse the images 
2.8.10 FLIPR based calcium assay 
HEK293 MSRII cells were transiently transfected to express the receptor of interest.  24 h 
after transfection cells were detached from flasks and counted on a Cedex AS20 cell 
counter (Innovatis Inc, Malvern, PA) using the tryptan blue exclusion method.  Cells were 
seeded at 15,000 cells/well into poly-D-lysine coated 384-well black-wall, clear-bottom 
microtiter plates (Greiner Bio-One, Kremsmünster, Austria) using a Multidrop dispenser.  
The following day the media was aspirated from the cells and 40µl of assay buffer (Hanks' 
balanced salts solution, 10mM HEPES, 200µM Ca2+, 2.5mM probenicid, 0.5M brilliant 
black, 1µM fluo-4 AM) was added to each well, this was repeated once and the cells 
incubated at 37oC for 1 hour to allow loading of the fluorescent dye.  After 1 hour the 
assay was ran on a fluorometric imaging plate reader (FLIPR, Molecular Devices, 
Sunnyvale, CA).  Images were collected every 2s and agonist was added after 10s, a total 
of 60 images were collected.  The data was analysed using the following equation and 
plotted using XLfit curve fitting software (IDBS, Guildford, Surrey) 
2.8.11 RT-PCR 
Total RNA was extracted from INS-1E cells using the RNeasy miniprep procedure as per 
manufacturer’s instructions.  Prior to reverse transcription, RNA was treated with 
deoxyribonuclease to ensure that there was no contamination with genomic DNA.  First 
strand cDNA was produced using the 1st Strand cDNA synthesis kit.  Detection of specific 
mRNA transcripts was carried out by PCR using 50ng cDNA and 200nM oligonucleotides 
corresponding to rat GPR40, rat GPR41, rat GPR43 or rat cyclophilin.  The primers used 
for PCR are as follows;  
rat GPR40  5’ – CCCTGCCCGACTCAGTTTC – 3’,  
5’ – GGCAGCCCACATAGCAGAA – 3’,  
rat GPR41  5’ – GTGCGACTGGAAATGGCTG – 3’,  
5’ – CACACCAGGCGACTGTAGC – 3’, 
rat GPR43  5’ – GAGCTGTGCCTGGCCTC – 3’,  
5’ – GCATGATCCATACAAAGC – 3’,  
rat cyclophilin 5’ – TCACCATCTCCGACTGTGGA – 3’,  
5’ – AAATGCCCGCAAGTCAAAGA – 3’. 
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cDNA was amplified using the following cycling conditions: 10 minutes at 95oC, then 40 
cycles of 1 minute at 95oC, 1 minute at 52oC, 2 minutes at 72oC, which was followed by 5 
minutes at 72oC.  Samples were resolved on a 1% agarose gel as described in section 2.3.7. 
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3 Development of functional assays to monitor 
activation of GPR40, GPR41 and GPR43 
3.1 Introduction 
Fatty acids have recently been described as the likely endogenous ligands for GPR40 
(Briscoe et al., 2003; Itoh et al., 2003; Kotarsky et al., 2003), GPR41 and GPR43 (Brown 
et al., 2003; Le Poul et al., 2003; Nilsson et al., 2003).  The recent de-orphanisation of the 
receptors means that there are many areas of their pharmacology and function that are 
poorly understood.  In order to investigate the pharmacology of the receptors and to 
determine the function of mutants generated to identify areas important in fatty acid 
binding, assays that monitor the activation of each of the three receptors had to be 
optimised.  Also, to investigate the possible oligomerisation of the receptors, a variety of 
modified versions of the receptors were generated to allow assays to determine protein-
protein interactions to be carried out.  Therefore, in this chapter, a variety of modified 
versions of each of the receptors were generated and their usefulness and function 
assessed. 
Epitope tags are a useful tool in studying GPCRs as they facilitate detection of the protein 
by immunocytochemistry or by immunoblotting without the need for receptor specific 
antibodies.  Epitope tags consist of a short sequence of amino acids that may be added at 
the N- or C-terminus of a receptor.  Addition of the epitope tag at the N-terminus enables 
visualisation of the receptor at the cell surface using commercially available antibodies 
generated to recognise the specific sequence.  In this study c-Myc and Flag epitopes have 
been used.  The c-Myc epitope consists of a 10 amino acid sequence of the human proto-
oncogene myc (Evan et al., 1985), whereas the Flag epitope is a synthetic octapeptide 
(Chubet and Brizzard, 1996). 
A number of proteins have been fused onto the C-terminus of GPCRs without disrupting 
their ligand binding and signal transduction.  Fusion of a G protein α subunit onto the C-
terminus of a GPCR provides a way by which [35S]GTPγS binding studies can be 
performed with receptors that couple to Gαq/11 or Gαs, as historically it has proved difficult 
to use any receptor that does not couple to the Gαi/o family of G proteins due to the low 
levels of [35S]GTPγS binding observed.  Using the combination of a receptor-G protein 
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fusion and an immunocapture step with antibodies generated towards the G protein helps 
to overcome this problem (Milligan, 2003). 
It is becoming increasingly common to fuse a fluorescent protein to the C-terminus of a 
GPCR.  There is a wide range of fluorescent proteins, with many of them based on GFP 
from the jellyfish Aequoria victoria as it folds into a fully functioning fluorescent protein 
without the need for a substrate or accessory protein (Giepmans et al., 2006).  There are 
many variants of GFP, each possessing distinct spectral properties and these have been 
exploited in several resonance energy transfer techniques.  The two variants used in this 
study are enhanced cyan fluorescent protein (eCFP) and enhanced yellow fluorescent 
protein (eYFP).  eCFP has a blue-green colour with an excitation maximum of 430nm and 
emission maximum of 470nm (Cubitt et al., 1999; Heim and Tsien, 1996).  eYFP is a red-
shifted GFP variant which presents an excitation maximum of 500nm and an emission 
maximum of 535nm.  The spectral properties of eCFP and eYFP have been extensively 
exploited as donor and acceptor moieties in FRET to demonstrate molecular interactions 
between proteins (Tsien, 1998; Zhou et al., 2003; Dinger et al., 2003). 
The limited number of previous studies into the pharmacology of GPR40 have taken 
advantage of its selective coupling to the Gαq/11 family of G proteins, as activation of these 
G proteins results in the elevation of intracellular calcium ([Ca2+]i ).  Changes in [Ca
2+]i  
levels are relatively easy to measure due to the wide range of Ca2+ sensitive dyes on the 
market and the availability of high throughput systems based on this technology.  In this 
study two assays have been used that monitor mobilisation of [Ca2+]i as an end point; a 
single cell based approach using the ratiometric dual wavelength dye Fura-2 (Roe et al., 
1990) and a fluorescent microscope, and a high throughput method using a Fluorometric 
Imaging Plate Reader (FLIPR) and a single wavelength dye, Fluo-4 (Gee et al., 2000).  
Both systems have advantages and disadvantages which will be discussed later.  To 
monitor activation of GPR41, which is predominately Gαi/o coupled, by measuring changes 
in [Ca2+]i, a G protein that allows a switch to the activation of this cascade had to be co-
expressed with the receptor.  This can be a promiscuous G proteins α subunit, such as Gα15 
or Gα16 which couple to many GPCRs, or a G protein chimera in which the last five amino 
acids of Gαq have been replaced by the corresponding sequence from Gαi1 or Gαs 
(Kostenis et al., 2005).  The G protein chimera used in this study is a recently described 
Gαqi5 mutant that has a glycine to aspartic acid mutation introduced at position 66 that 
allows it to more effectively couple to a panel of Gαi/o coupled receptors (Kostenis et al., 
2004).  However, [Ca2+]i mobilization assays are not ideally suited to monitoring activation 
of these receptors due to the relatively low potency of the fatty acids at the receptors.   
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3.2 Functional assays to monitor activation of GPR41 
As GPR41 is a predominately Gi/o coupled receptor, a [
35S]GTPγS binding assay using this 
receptor was developed.  GPR41 was co-transfected with a panel of Gi/o α subunits (Gαi1, 
Gαi2, Gαi3 or Gαo) and a [
35S]GTPγS binding assay carried out on the membranes prepared 
from these cells. The increase in [35S]GTPγS binding obtained on the addition of a high 
concentration of propionate (10mM) was small although it appeared that GPR41 showed 
some selectivity towards Gαi3 over any of the other α subunits tested (data not shown).  
When using membranes co-expressing GPR41 and Gαi3, concentration-response curves 
were generated to propionate (Figure 3.1).  [35S]GTPγS binding at maximally effective 
concentrations was only 58±3% higher than basal binding and due to this small activation 
window a fusion protein between GPR41 and Gαi3 was generated, with the aim to improve 
the activation window.  When this fusion protein was transfected into HEK293T cells and 
[35S]GTPγS binding studies carried out on membranes prepared from these cells in the 
presence of increasing concentrations of propionate, a maximal increase in [35S]GTPγS 
binding of 661±26% was observed.  The pEC50 value for propionate at the GPR41-Gαi3 
Cys351Ile fusion protein was 3.6±0.1 and at GPR41 when co-transfected with Gαi3 the 
pEC50 was 3.7±0.2.  The increase in binding was much more robust when using the 
receptor-G protein fusion protein and allowed potencies of other short chain fatty acids to 
be determined with greater accuracy (Figure 3.2 and Table 3.1).  Using this method the 
rank order of potencies for short chain fatty acids at GPR41 was valerate > butyrate = 
propionate > acetate.   
Most of the work on GPR41 has concluded that it is a predominately Gαi/o coupled 
receptor (Brown et al., 2003, Le Poul et al., 2003, Xiong et al., 2004).  To confirm this, 
GPR41-eYFP was transiently expressed in HEK293T grown on coverslips.  24h post 
transfection cells were loaded with the Ca2+ sensitive dye Fura-2 for 30mins.  Cells were 
mounted into a chamber containing live cell buffer and the changes in Fura-2 fluorescence 
monitored.  Cells were exposed to 10mM propionate, added using a perfusion system, after 
60s of basal readings and data collected for a further 240s.  The cells were exposed to 
propionate for 60s.  In the absence of a co-expressed promiscuous or chimeric G protein α 
subunit, only a negligible change in [Ca2+]i was observed in cells positively transfected 
with GPR41 selected on the basis of eYFP fluorescence (Figure 3.3).  Upon co-expression 
with the chimeric G protein α subunit, GαqG66Di5, challenge with 10mM propionate resulted 
in a rapid, transient rise in [Ca2+]i only in cells expressing GPR41-eYFP.  When GPR41-
eYFP was co-expressed with the promiscuous G protein α subunit, Gα16, a rise in [Ca
2+]i 
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was also observed, although the kinetics of the increase in [Ca2+]i were different from those 
in cells co-expressing GPR41-eYFP and GαqG66Di5 (Figure 3.3).   
3.3 Function of N- and C-terminally modified forms of 
GPR43 and C-terminally modified forms of GPR40 
To confirm that GPR43 was able to couple to Gαq, the receptor was transiently expressed 
with Gαq in mouse embryonic fibroblasts that lack expression of both Gαq and Gα11, called 
EF88 cells herein (Liu et al., 2002).  A large, transient rise in [Ca2+]i was recorded in 
response to the addition of 10mM acetate (Figure 3.4).  EF88 cells were difficult to 
transfect with high efficiency and for the purpose of developing an assay to monitor 
function of modified versions of GPR43, they were poorly suited.  To overcome this, 
HEK293T cells were used in further assays as transfection was much more efficient.   
The effect of N-terminally epitope tagging GPR43 was assessed (Figure 3.5).  Flag-GPR43 
and c-Myc-GPR43 were generated and the sequence confirmed by DNA sequencing.  The 
modified versions of GPR43 were transfected into HEK293T cells, membranes prepared 
and samples resolved using SDS-PAGE.  Proteins were transferred onto nitrocellulose 
membrane and an immunoblot performed using commercial versions of anti-Flag or anti-c-
Myc antibodies.  A band of approximately 35kDa was observed in the Flag-GPR43 sample 
lane but no band was present in the lane corresponding to c-Myc-GPR43.  c-Myc-CXCR1 
and Flag-CXCR1 (Wilson et al., 2005) were included as positive or negative controls 
depending on the antibody used.  The apparent lack of expression of c-Myc-GPR43 may 
have been due to the inability of the antibody to identify the epitope therefore to explore 
this finding, HEK293T cells were transiently transfected with wild type GPR43, Flag-
GPR43 and c-Myc-GPR43, loaded with Fura-2 and changes in [Ca2+]i monitored in 
response to 10mM acetate.  Wild type GPR43 was able to elicit a rapid, transient rise in 
[Ca2+]i similar to that seen in the EF88 cells.  The magnitude of the response from Flag-
GPR43 was slightly reduced compared to the wild type receptor whereas no signal could 
be detected in cells transfected with the c-Myc-GPR43 construct.  From these data, it 
appears that c-Myc-GPR43 does not express when transfected into HEK293T cells 
whereas Flag-GPR43 was expressed and rise in [Ca2+]i could be detected.  It was therefore 
concluded that N-terminally tagging GPR43 was detrimental to the function of the receptor 
and as a fully functioning receptor was required for future experiments they were not used 
further. 
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To address the problem of not being able to effectively epitope tag GPR43 at its N-
terminus with multiple distinct tags, constructs were generated with c-Myc and Flag fused 
to the C-terminus of GPR43.  These constructs were transfected into HEK293T cells and 
their ability to mediate a rise in [Ca2+]i compared to that of the wild type receptor assessed 
(Figure 3.6).  Both GPR43-Flag and GPR43-c-Myc were able to mediate a rapid, transient 
rise in [Ca2+]i and this Ca
2+ mobilisation was very similar to that mediated by the wild type 
receptor.  In addition, immunoblot analysis of the C-terminally tagged versions of GPR43 
confirmed their expression (data shown in Chapter 6).  Fusion proteins between GPR43 
and eCFP, eYFP or Gαq were also constructed (GPR43-eCFP, GPR43-eYFP and GPR43-
Gαq) and tested for their ability to induce a rise in [Ca
2+]i levels in response to 10mM 
acetate.  Each of these fusion proteins was able to produce a transient rise [Ca2+]i, 
comparable to that of the wild type receptor (Figure 3.6).  Using GPR43-eCFP allowed 
positively transfected cells to be identified and tested for their response to various short 
and long chain fatty acids (Figure 3.7).  Acetate, butyrate and propionate (all at 10mM) 
were able to mediate a rise in [Ca2+]i via GPR43.  Whereas, when cells expressing GPR43-
eCFP were exposed to 100µM lauric acid no change in [Ca2+]i levels was detected.   
Monitoring [Ca2+]i mobilisation in single cells is poorly suited to investigate the potency of 
fatty acids at GPR43 due to its time consuming nature, therefore a high throughput FLIPR-
based method was employed.  This method enabled a panel of short and long chain fatty 
acids to be tested for their ability to mediate a rise in [Ca2+]i via GPR43.  GPR43-eYFP 
and a G protein cocktail (consisting of Gαqo5, Gαqi5, Gαqz5, Gαqs5, Gα15 and Gα16) was 
transiently transfected into HEK293 MSRII cells and the ability of a variety of fatty acids 
to mediate a rise in [Ca2+]i monitored by a change in Fluo-4 fluorescence measured by the 
FLIPR .  Figure 3.8 shows that acetate, propionate and butyrate were all able to mediate a 
rise in [Ca2+]i in a concentration-dependent manner and relative potencies were ascribed 
(Table 3.2).  Only at high concentrations was formate able to transiently rise [Ca2+]i levels.  
None of the longer chain fatty acids tested were able to activate GPR43 and no change in 
fluorescence was seen when short chain fatty acids were added to control cells transfected 
with GPR40-eYFP or the neuromedin U receptor (NMU-R).  The rank order of potency of 
the short chain fatty acids at GPR43 using this method was 
propionate>acetate>butyrate>formate. 
When GPR40 is co-expressed with Gαq in EF88 cells that lack endogenous expression of 
Gαq or Gα11, caproic acid (C6:0) allowed rapid and transient elevation of [Ca
2+]i (Figure 
3.9).  In HEK293T cells, co-transfection with Gαq was not required for caproic acid to 
generate a Ca2+ signal as these cells express both Gαq and Gα11 endogenously.  A range of 
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C-terminal modifications were introduced onto GPR40, including c-Myc and Flag epitope 
tags, and the in-frame fusion of eCFP, eYFP or Gαq.  When the modified versions of 
GPR40 were transfected into HEK293T cells and challenged with caproic acid, no loss of 
agonist function could be detected (Figure 3.10).  Caproic acid has been described as a low 
affinity agonist for GPR40 and the shortest chain length fatty acid able to activate this 
receptor (Briscoe et al., 2003).  A range of other fatty acids were tested for their capacity to 
elevate [Ca2+]i in HEK293T cells expressing GPR40-eCFP.  Each of lauric acid (C12:0), 
palmitic acid (C16:0) and elaidic acid (C18:1) were able to mediate a rise in [Ca2+]i only in 
positively transfected cells displaying eCFP fluorescence (Figure 3.11).  It was noted that 
slower elevation of [Ca2+]i was observed with increasing fatty acid chain length and that 
the signal generated by each of the fatty acids displayed distinct kinetics.  This was 
particularly clear with elaidic acid, with a slower increase in [Ca2+]i compared to the other 
fatty acids and the Ca2+ levels within the cells did not return to baseline during the duration 
of the assay.  This difference may reflect variations in the affinity or ligand association rate 
of the fatty acids, or variations in their solubility characteristics.  As the fatty acids were 
solubilised in 100% ethanol and diluted down to the required concentration, it was 
necessary to confirm that the signal generated was specific to the addition of a fatty acid.  
Therefore, 1% ethanol was added to cells expressing GPR40-eCFP and no change in 
[Ca2+]i was detected (Figure 3.11).   
As mentioned above, single cell Ca2+ experiments are poorly suited to determine potencies 
of agonists at a specific receptor.  Therefore, to determine the potencies of a variety of 
saturated and un-saturated fatty acids at GPR40, a FLIPR-based Ca2+ release assay was 
developed.  GPR40-eYFP was transiently expressed in HEK293 MSRII cells and the 
ability of a variety of fatty acids to mediate a change in Fluo-4 fluorescence monitored.  
The resulting potencies are detailed in Table 3.3.  As expected, GPR40 was able to mediate 
a rise in [Ca2+]i in response to increasing concentrations of both saturated and un-saturated 
fatty acids.   
The majority of fatty acids circulating in the body are complexed with albumin and other 
serum proteins and it is important to take this into consideration when studying fatty acids 
and experiments were carried out to address this issue (Figure 3.12).  HEK293T cells 
transiently expressing either GPR40-eCFP or GPR43-eCFP were exposed to fatty acids 
with increasing concentrations of fatty acid free bovine serum albumin (BSA).  The 
addition of 0.1% fatty acid free BSA reduced the signal generated by 100µM lauric acid at 
GPR40-eCFP but had little effect on the magnitude of signal generated by GPR43-eCFP in 
response to 10mM acetate.  With 0.5% fatty acid free BSA added to 100µM lauric acid no 
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detectable signal was produced by GPR40-eCFP and when GPR43-eCFP was exposed to 
10mM acetate and 0.5% fatty acid free BSA a reduction in the maximal signal was 
observed.   
3.4 BSA allows the pharmacology of GPR40 to be 
uncovered 
The differing kinetics of fatty acids at GPR40 in single cell Ca2+ imaging studies 
demonstrated that this method is not well suited for examining ligand concentration-
dependence, especially for these low affinity ligands.  To overcome this and to carry out 
detailed pharmacological assessment of ligands at GPR40, the GPR40-Gαq fusion protein 
was employed and a [35S]GTPγS binding assay developed.   
Historically, it has been difficult to carry out [35S]GTPγS binding studies on GPCRs that 
couple to Gαq or Gα11.  Using a GPCR-G protein fusion in combination with a 
immunocapture step with G protein specific antibodies, enriches the levels of Gαq/11 and 
allows monitoring of activation of the receptor (Carrillo et al., 2002, Milligan et al., 2004, 
Canals et al., 2006).  GPR40-Gαq was transiently expressed in HEK293T cells and 
membranes prepared.  [35S]GTPγS binding studies were performed with subsequent 
immunoprecipitation using the anti Gαq/11 antiserum CQ (Mitchell et al., 1991).  High 
levels of [35S]GTPγS were present in the GPR40-Gαq immunoprecipitates in the absence of 
an added agonist.  When 30µM palmitic acid or elaidic acid were present in the assay, no 
increase in levels of [35S]GTPγS was detected (Figure 3.13).  This is unlike a range of 
other GPCR-Gαq or GPCR-Gα11 fusion proteins that have been studied, where loading of 
[35S]GTPγS is very low in the absence of receptor stimulation (Carrillo et al., 2002, 
Milligan et al., 2004, Canals et al., 2006). 
As the reported endogenous agonists at GPR40 are medium and long chain free fatty acids 
and fatty acid free BSA was able to inhibit the function of free fatty acids in the Ca2+ 
mobilization assay, it was therefore possible that the high level of basal loading of 
[35S]GTPγS onto GPR40-Gαq might reflect the presence of endogenous agonist in the 
assay which could activate GPR40-Gαq and give the appearance of high levels of 
[35S]GTPγS binding in basal conditions.  The most obvious means by which the 
endogenous agonist could be present is via the release of free fatty acids during cell rupture 
and membrane preparation.  To explore this possibility, fatty acid free BSA was added to 
GPR40-Gαq expressing membranes in increasing concentrations and [
35S]GTPγS 
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incorporation onto GPR40-Gαq measured.  Levels of bound [
35S]GTPγS decreased with 
increasing concentrations of fatty acid free BSA over the full concentration range tested.  
At high levels of fatty acid free BSA (300µM), the levels of bound [35S]GTPγS were very 
low (Figure 3.14).  As noted earlier, in the absence of BSA the stimulation of [35S]GTPγS 
binding induced by the addition of 30µM palmitic acid was very limited.  In the presence 
of concentrations of fatty acid free BSA up to 1µM, 30µM palmitic acid was now able to 
increase [35S]GTPγS binding up to the levels observed in the absence of fatty acid free 
BSA.   At concentrations of fatty acid free BSA between 1-10µM, basal [35S]GTPγS 
binding continued to decrease but although 30µM palmitic acid was still able to stimulate 
[35S]GTPγS binding it was unable to achieve the same maximal level.  This is likely to be 
due to substantial amounts of palmitic acid now being bound by the excess of fatty acid 
free BSA.  Also, when membranes expressing GPR40-Gαq were treated with the selective 
Gαq/11 inhibitor, YM254890, which blocks guanine nucleotide exchange on the G protein 
(Takasaki et al., 2004, Canals et al., 2006), the presence of [35S]GTPγS in the 
immunoprecipitates was virtually eliminated (Figure 3.15).  This demonstrates that the 
high levels of [35S]GTPγS bound at GPR40-Gαq in basal conditions reflects direct 
exchange of the guanine nucleotide on the G protein.  Taken together, these results suggest 
that high levels of [35S]GTPγS binding in basal conditions are a consequence of an 
endogenous agonist being present which can be stripped away by fatty acid free BSA and 
this results in a window in which detailed pharmacology of ligands at GPR40 could be 
measured in [35S]GTPγS binding studies.  
To demonstrate that concentration-response curves could be generated by reducing the 
basal activation of GPR40-Gαq, [
35S]GTPγS binding studies were performed on 
membranes expressing GPR40-Gαq in the presence of increasing concentrations of 
palmitic acid and three concentrations of fatty acid free BSA.  In the presence of a low 
concentration of fatty acid free BSA (100nM), basal [35S]GTPγS binding was high and no 
increase in binding was observed with increasing concentrations of palmitic acid.  By 
contrast, in the presence of either 10µM or 100µM fatty acid free BSA, basal [35S]GTPγS 
binding was greatly reduced, with a larger reduction seen on the addition of 100µM fatty 
acid free BSA.  When increasing concentrations of palmitic acid were added a 
concentration response curves was seen and allowed the potency of palmitic acid to be 
determined (Figure 3.16 and Table 3.4).  At the higher concentration of fatty acid free 
BSA, the concentration-response curve to palmitic acid was shifted to higher apparent 
concentrations which is consistent with the higher amounts of fatty acid free BSA binding 
a greater amount of the added palmitic acid.  The potency of palmitic acid achieved with 
Leigh Ann Stoddart, 2007   95 
the addition of 10µM fatty acid free BSA is similar to that observed using other methods 
(Briscoe et al., 2003; Itoh et al., 2003; Nilsson et al., 2003) and therefore was used in 
further experiments to examine the pharmacology of a range of fatty acids (Figure 3.17).  
The potencies of the fatty acids examined using the [35S]GTPγS binding assay are shown 
in Table 3.5.  Due to time constraints a full panel of fatty acids could not be tested against 
GPR40-Gαq.   
Compared to GPR40-Gαq, the GPR41-Gαi3 Cys
351Ile fusion protein did not display 
unusually high levels of basal [35S]GTPγS binding and a large increase in [35S]GTPγS 
binding upon addition of agonist could be observed.  [35S]GTPγS binding studies were 
performed on membranes expressing GPR41-Gαi3 Cys
351Ile , with the addition of 
increasing concentrations of fatty acid free BSA in the absence or presence of 10mM 
propionate.  Figure 3.18 shows that the addition of fatty acid free BSA had little effect on 
the basal binding of [35S]GTPγS to GPR41-Gαi3 Cys
351Ile and only at high concentrations 
of fatty acid free BSA was a reduction in the levels of stimulation observed.  This was 
likely to be due to the binding of propionate to BSA and therefore to reduce the amount 
available to activate the receptor.  To confirm this observation, membranes expressing 
GPR41-Gαi3 Cys
351Ile were used in [35S]GTPγS binding studies where increasing 
concentrations of propionate were added in the presence of three concentrations of fatty 
acid free BSA (Figure 3,19).  Only a slight shift in apparent potency of propionate was 
observed on the addition of 100µM fatty acid free BSA (Table 3.6).  It was therefore 
deemed unlikely that GPR41-Gαi3 Cys
351Ile is activated by an endogenous ligand in 
[35S]GTPγS binding studies. 
3.5 Detection of GPR40, GPR41 and GPR43 in a β-cell line 
and the function of GPR40 in these cells 
The expression of GPR40 in β-cells has been well documented in many studies using a 
range of β-cell lines and human tissue.  To confirm the expression of GPR40 in β-cells, a 
rat insulinoma cell line (INS-1E) was used, as human pancreatic cell lines are not generally 
available.  RNA from these cells was isolated and cDNA generated via reverse 
transcription.  The cDNA was probed using primers specific for rat GPR40 and a protein 
accepted to be expressed in β-cells, cyclophilin (Figure 3.20(a-b)).  This confirmed the 
expression of GPR40 in these cells.  In the absence of reverse transciptase no band was 
observed (data not shown).  To date the only evidence of GPR41 and GPR43 being 
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expressed in pancreatic β cells comes from a patent applications by Arena 
Pharmaceuticals, to investigate if these receptors were also expressed in the INS-1E cells 
cDNA from these cells was probed using primers specific for rat GPR41 and rat GPR43, 
and bands corresponding to each of these receptors were present (Figure 3.20 c-d). 
The proceeding studies on GPR40 were performed on cells and cell membranes into which 
forms of GPR40 has been introduced and it was of interest to assess if similar results 
would be obtained in INS-1E cells endogenously expressing GPR40.  It was confirmed that 
100µM lauric acid could activate GPR40 in these cells by generation of a robust and 
transient elevation of [Ca2+]i (Figure 3.21).  Membranes from INS-1E cells were prepared 
and used in [35S]GTPγS binding studies.  With end of assay immunoprecipitation of Gαq/11, 
levels of bound [35S]GTPγS in the basal state were again very high and little stimulation 
was produced by the addition of 100µM palmitic acid (Figure 3.22).  As with HEK293T 
membranes transiently expressing GPR40-Gαq, addition of fatty acid free BSA resulted in 
a large reduction in the apparent basal [35S]GTPγS binding in Gαq immunoprecipitates and 
these levels were now markedly increased by the addition of palmitic acid.   
3.6 Discussion 
There are many difficulties in studying newly deorphanised GPCRs.  In the case of 
GPR40, GPR41 and GPR43 the recent description of their activating ligands means that 
there is a vast amount to be discovered about them but the availability of tool compounds 
and well developed assay systems makes this difficult.  To be able to investigate their 
function and pharmacology, robust methods of monitoring their activation and expression 
were developed.  
GPR41 mainly couples to the Gαi/o family of Gα subunit and this allowed [
35S]GTPγS 
binding studies to be carried out by Brown et al., (2003) and Le Poul et al., (2003) with 
GPR41 co-transfected with Gαi1 or in membranes prepared from CHO cells stably 
expressing GPR41 respectively.  In this present study, when GPR41 was co-transfected 
with Gαi3 and [
35S]GTPγS binding studies performed on the resulting membranes using 
immuno-capture of Gαi3 only a small rise in [
35S]GTPγS binding (60% increase over basal 
binding) was observed at high concentrations of propionate (Figure 3.1).  This level of 
activation was not robust enough to allow good pharmacological assessment to be carried 
out.  To overcome this, a GPR41-Gαi3 Cys
351Ile fusion protein was constructed and this 
fusion protein showed a 661±26% increase in [35S]GTPγS binding over basal in response 
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to propionate.  This provided an effective means to measure ligand-stimulated binding of 
[35S]GTPγS.  Using this fusion protein, potencies of four short chain fatty acids were 
determined (Table 3.1).  The potencies observed using this assay system were similar to 
those seen by Brown et al., (2003) in a [35S]GTPγS binding assay.  The rank order of 
potency differs slightly but this is likely to be due to the similar potencies observed for 
propionate, valerate and butyrate.   
The use of promiscuous and chimeric G proteins allows receptors that do not naturally 
couple to G protein α subunits that activate PLC-β to be used in assays that monitor the 
mobilization of [Ca2+]i.  The Gα subunit Gα16 is viewed as being promiscuous, although it 
has been shown to be unable to couple to a subset of GPCRs and the majority of these 
receptors are Gαi/o selective (Kostenis, 2001).  When GPR41 was co-transfected with Gα16 
the kinetics of [Ca2+]i release in response to propionate was slower than observed upon co-
transfection with GαqG66Di5.  GαqG66Di5 has been shown to be more effective in coupling to a 
set of Gαi/o coupled receptors than Gαqi5 (Kostenis et al., 2005).  Although Gαqi5 was not 
tested in this study, it does appear that GPR41 coupled better to GαqG66Di5 than Gα16, 
although this could also be due to expression levels and the scope of this study did not look 
into this.  Therefore, in further experiments with GPR41 where [Ca2+]i mobilization was 
measured, GαqG66Di5 was co-expressed.   
To investigate cell surface expression of GPR43, N-terminally modified forms of the 
receptor were generated.  Unusually, the addition of the c-Myc epitope tag resulted in the 
loss of expression of the receptor monitored by immunoblotting and no rise in [Ca2+]i 
could be initiated in cells transfected with c-Myc-GPR43 upon the addition of acetate.  The 
inability to detect c-Myc-GPR43 by immunoblotting may be due to low levels of 
expression of the receptor rather than the receptor not expressing at all.  The single cell 
Ca2+ assay is a sensitive assay system and no rise in [Ca2+]i could be detected in any cell 
transfected with c-Myc-GPR43 cDNA, which supports a loss of expression rather than low 
levels of expression that may fall below expression levels required to be detected by 
immunblotting.   The addition of the Flag epitope tag to GPR43 allowed detection of the 
receptor by immunoblotting and the signal generated in response to acetate was similar to 
that generated by the wild type receptor.  For many GPCRs, the addition of N-terminally 
epitope tags has been shown to have no or limited effects on expression or ligand binding.  
These include the α1A adrenoceptor (Stanasila et al., 2002), β2 adrenoceptor (Hebert et al., 
1996), CXCR1 and CXCR2 chemokine receptors (Wilson et al., 2005), D1 dopamine 
receptor (George et al., 1998), and MT1 and MT2 melatonin receptors (Ayoub et al., 2002).  
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The large effect seen when N-terminally tagging GPR43 may be due to its relatively short 
N-terminal extracellular domain.  The addition of an epitope tag onto this short N-terminal 
may affect the receptor synthesis and maturation.  It was shown in single cell [Ca2+]i 
experiments that the addition of a variety of C-terminal tags did not have an effect on the 
function of GPR43.  The addition of the fluorescent proteins, eCFP and eYFP to the C-
terminus of GPR43 provided an ideal way to monitor the expression of the receptor and 
allowed only positively transfected cells to be selected when analysing the single cell Ca2+ 
experiments.  
Using the GPR43-eYFP fusion, potencies of short chain fatty acids at the receptor were 
determined using a FLIPR-based [Ca2+]i mobilization assay.  The potencies determined 
were very close to those reported by Brown et al., (2003) and Le Poul et al., (2003) when 
using a Ca2+-based assay with propionate being the most potent in all three studies.  The 
data generated by Nilsson et al., (2003) on the potency of short chain fatty acids at GPR43 
found that they were less potent using both a reporter gene assay and a Ca2+ mobilisation 
based assay.  In HEK293T cells, it was not necessary to co-transfect GPR43 with 
additional G protein, as a robust signal could be generated upon the expression of GPR43 
alone.  Whereas, in the FLIPR-based assay system, expression of GPR43-eYFP in 
HEK293 MSRII cells was not sufficient to generate a change in fluorescence upon the 
addition of an activating ligand that could be detected by the FLIPR.  Only upon the co-
transfection of a G protein cocktail could a signal be detected.  This highlights the differing 
sensitivities of the two assay systems used in this study to monitor agonist induced Ca2+ 
release.  The single cell Ca2+ mobilization assay allowed single cells to be measured for 
their response to agonist.  In the FLIPR based assay, the change in fluorescence is 
measured over a field of cells.  Comparing the change in Fura-2 ratio generated by GPR43 
and GPR40, GPR43 does not produce as large an increase in [Ca2+]i compared to GPR40.  
It may also be due to the transient expression of the receptor in these cells or due to low 
levels of receptor expression. This signal, although robust enough to be measured in single 
cells, is likely to have been too small an average change over a field of cells to be 
measured by the FLIPR.    
Agonist ligands act to stabilize and enrich populations of active states of GPCRs (Milligan, 
2003).  In the case of opsins, 11-cis retinal is bound by the receptor as an endogenous 
inverse agonist to virtually eliminate active states in the absence of light, however, other 
GPCRs display varying levels of agonist-independent or constitutive activity (Milligan, 
2003, Bond and IJzerman, 2006).  When studying GPCRs in transfected cell systems this 
constitutive activity can be extensive and may virtually occlude detection of effects of 
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agonists above such high basal activity.  The importance of constitutive activity in native 
tissue is not fully understood but there is significant evidence that for some receptors it 
may be relevant to their physiological effect and the effects of therapeutic medicines (Bond 
and IJzerman, 2006).  The role of constitutive activity, the ability of inverse agonists to 
reduce this activity and the advantages this may have as a therapeutic strategy has been 
difficult to interpret due the possibility that ‘basal’ activity may reflect the presence of an 
endogenous agonist that is difficult to eliminate or remove.   
It is now well appreciated that a substantial number of GPCRs respond to hydrophobic, 
lipid or lipid-like endogenous mediators and these have the potential to be difficult to 
remove from cell preparations if they are long lived.  Taking this into consideration when 
developing the [35S]GTPγS binding assay using GPR40-Gαq the detection of very high 
levels of apparent constitutive activity were of considerable interest not only because of the 
hydrophobic nature of the proposed endogenous agonist but also because high levels of 
constitutive activity has been reported for other GPCRs that are of therapeutic interest in 
the areas of feeding, obesity and the metabolic syndrome, such as the ghrelin receptor 
(Holst and Schwartz, 2004, Holst et al., 2004).   
It may be argued that the apparent high constitutive activity of GPR40 in these assays 
could relate to the close proximity enforced between the GPCR and G protein in the use of 
the GPR40-Gαq fusion protein.  This is unlikely as in other GPCR-Gαq or Gα11 fusions 
studied only low levels of [35S]GTPγS were bound in the absence of ligand (Carrillo et al., 
2002, Milligan et al., 2004, Canals et al., 2006) and when using membranes prepared from 
INS-1E high levels of basal binding of [35S]GTPγS were also seen.  A common feature of 
constitutively active GPCRs is constitutive internalisation of the receptor seen using 
GPCR-fluorescent protein fusions.  When GPR40-eYFP is transiently expressed in 
HEK293T cells or inducibly expressed in Flp-In TRex cells it is membrane delineated and 
only low levels of the receptor are internalised (seen in Figure 4.1).  Thus, although not 
providing definitive evidence these observations would be consistent with GPR40 having 
low levels of constitutive activity.  
Ca2+ mobilization assays are inherently unsuited to the detection of receptor constitutive 
activity because the capacity and requirement of intact cells to dynamically re-equilibrate 
alterations in Ca2+ levels.  A key issue in these studies is that the high basal activity of 
GPR40 was only detected using the [35S]GTPγS binding assays and not in either of the 
[Ca2+]i mobilization assays.  The potential key difference in the two assays is that the 
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[35S]GTPγS binding assay employed membrane preparation.  Although not addressed in 
this study, it may be that fatty acids released upon cell breakage during membrane 
preparation can remain in the membranes, rather than in the supernatant fraction, and 
therefore potentially bind and activate GPR40 during the assay.  This is supported by the 
ability of fatty acid free BSA to reduce the basal loading of [35S]GTPγS as it could bind 
and prevent the unappreciated fatty acids from activating the receptor.  The addition of 
palmitic or lauric acid was unable to significantly increase binding of [35S]GTPγS.  With 
the addition of fatty acid free BSA, the effect of these fatty acids in combination the BSA 
was to elevate [35S]GTPγS binding back to the basal level.  If there is an endogenous 
ligand binding and activating this receptor then it is activating the receptor to it maximum 
which cannot be increased by the presence of additional fatty acid.   
The addition of increasing concentrations of fatty acid free BSA and the recovery of 
maximal stimulation by additional fatty acid only occurred over a limited range of BSA 
and the effects of the added fatty acids were eventually decreased, presumably as the added 
fatty acid also became bound to BSA.  To confirm this effect of fatty acid free BSA 
binding to the added fatty acid, the observed concentration response curve for palmitic acid 
moved to higher concentrations as greater concentrations of BSA were added to further 
reduce basal [35S]GTPγS binding but the additional BSA in turn bound the added fatty acid 
and prevented it from activating the receptor.  Using membranes prepared from INS-1E 
cells that endogenously express GPR40 it was found that they also showed high levels of 
basal [35S]GTPγS binding and as with the membranes transiently expressing GPR40, no 
increase in [35S]GTPγS binding was detected with addition of fatty acid.  Fatty acid free 
BSA was again able to reduce the basal loading of [35S]GTPγS and levels of incorporated 
[35S]GTPγS could be returned to that seen in the basal state when fatty acids were added in 
combination with BSA.  Therefore, the observations using transiently expressed GPR40 
are unlikely to be due to an artefact of over-expression of the receptor or from the use of 
the receptor-G protein fusion.   
If the endogenous ligand is a medium or long chain fatty acid, due to their hydrophobic 
nature, it might partition into the membranes rather than into the supernatant wash buffer.  
By contrast, for GPR41 there was no high basal levels of [35S]GTPγS binding and 
stimulation was be seen in the presence of added fatty acid.  There was little effect of 
increasing concentrations of fatty acid free BSA on the basal [35S]GTPγS loading of 
GPR41-Gαi3 Cys
351Ile or on the increase in binding of [35S]GTPγS stimulated by 
propionate.  In addition, there was no significant change in the concentration-response 
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curves to propionate on addition of varying concentrations of fatty acid free BSA.  During 
membrane preparation, any short chain fatty acid are likely to be found in the wash buffer, 
as they are more water soluble, and therefore be removed and unable to activate GPR41.  
These findings support the hypothesis that the high levels of basal loading of GPR40-Gαq 
are due to an endogenous ligand, which is likely to be a fatty acid or lipid, being present in 
membrane preparations.   
Two further GPCRs, GPR120 and GPR84 (Katsuma et al., 2005, Wang et al., 2006) have 
been described whose endogenous ligands appear to be medium to long chain fatty acids.  
Wang et al., (2006) performed [35S]GTPγS binding studies using GPR84.  Rather than 
using an immunocapture step at the end of assay, they terminated the assay by filtration.  
They were able to show fatty acid-mediated increases in [35S]GTPγS binding in a 
concentration-dependent manner, which could be completely abolished by the addition of 
PTX.  In their study GPR84 was shown to respond to fatty acids of between 9 and 14 
carbons in length whereas GPR40 can be activated by longer chain fatty acids.  If GPR40 
is being activated by an endogenous ligand released upon cell rupture then this ligand does 
not appear to activate GPR84.   
The expression of GPR40 in pancreatic β-cell lines (Briscoe et al., 2003, Itoh el al., 2003, 
Itoh and Hinuma, 2006, Shapiro et al., 2005) and in human pancreatic tissue (Tomita et al., 
2006) has been well documented.  In this study I have confirmed the expression of GPR40 
in INS-1E cells but I have also shown that mRNA corresponding to rat GPR41 and GPR43 
could also be detected.  Although, Brown et al., (2003) were able to identify low levels of 
expression of human GPR41 in the pancreas they did not determine if expression was 
localised to the β-cells.  None of the other studies looking into the tissue distribution of 
GPR41 and GPR43 have reported expression of either of these receptors in the pancreas 
(Le Poul et al., 2003, Kotarsky et al., 2003, Hong et al., 2005).  Recent patents by Arena 
Pharmaceuticals also reported expression of all three receptors in pancreatic islet cells.  
This is the first time that all three receptors have been shown to be expressed in the same 
cell line and leads to the possibility that they may form hetero-dimers, which in turn may 
affect their function.   
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Figure 3.1 Comparison of levels of [
35
S]GTPγS binding using a GPR41-Gαi3 Cys
351
Ile  
fusion protein to that when GPR41 is co-transfected with Gαi3 
HEK293T cells were co-transfected with GPR41 and Gαi3 Cys
351Ile (triangles) or 
transfected with a GPR41-Gαi3 Cys
351Ile fusion (squares) and membranes prepared.  
Membranes were exposed to increasing concentrations of propionate and levels of 
[35S]GTPγS bound in Gαi3 immunoprecipitates determined.  Graph shown is representative 
of three individual experiments performed in triplicate.  Data points represent 
means±SEM. 
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Figure 3.2 Potency of various short chain fatty acids at GPR41-Gαi3 Cys
351
Ile 
measured by [
35
S]GTPγS binding 
HEK293T cells were transfected with GPR41-Gαi3 Cys
351Ile and membranes prepared.  
[35S]GTPγS binding studies were performed in the presence of increasing concentrations of 
(a) acetate, (b) propionate, (c) butyrate and (d) valerate.  Assay samples were 
immunoprecipitated with the Gαi3 antiserum I3 before scintillation counting.  Graphs 
shown are representative of results obtained for three individual experiments performed in 
triplicate.  Data points represent means±SEM.   
Leigh Ann Stoddart, 2007   104 
SCFA pEC50
Acetate (C2) 1.83±0.69
Propionate (C3) 3.61±0.11
Butyrate (C4) 3.63±0.16
Valerate (C5) 3.94±0.22  
Table 3.1 Potency of short chain fatty acids at GPR41 measured in the [
35
S]GTPγS 
binding assay 
[35S]GTPγS binding studies were performed on membranes expressing GPR41-Gαi3 
Cys351Ile in the presence of the specified short chain fatty acid.  Data represent mean±SEM 
from three individual experiments. 
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Figure 3.3 Co-transfection of GPR41 with either Gα16 or a Gαq/Gαi1 chimera 
(GαqG66Di5) allows the response to agonist to be observed by monitoring [Ca
2+
]i.  
HEK293T grown on coverslips were transfected to express GPR41-eYFP (black line), 
GPR41-eYFP and Gα16 (red line), or GPR41-eYFP and GαqG66Di5 (green line).  Cells were 
loaded with Fura-2.  Images were collected every 2s and10mM propionate was added at 
the 60s time point.  Alterations in Fura-2 fluorescence was monitored for a further 240s.  
Data represent means±SEM from 20 positively transfected cells selected on the basis of 
eYFP fluorescence. 
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Figure 3.4 GPR43 can mediate mobilisation of [Ca
2+
]i in Gαq/11 knock out cells when 
co-transfected with Gαq. 
EF88 mouse embryonic fibroblasts lacking expression of both Gαq and Gα11 were 
transiently transfected using the Amaxa nucleofection system to express both GPR43 and 
Gαq.  Cells were loaded with Fura-2.  10mM acetate was added at the 60s time point and 
alterations in Fura-2 fluorescence measured over the following 240s.  Images were 
collected every 2s.  Data shown represent means±SEM from 20 individual cells.   
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Figure 3.5 Detrimental effect of N-terminally tagging GPR43 
(a) HEK293T cells were transiently transfected with cDNA encoding the required tagged 
receptor.  Cells were harvested 24h after transfection and membranes prepared.  10µg of 
protein was loaded per well and resolved by SDS-PAGE and immunoblotted with (i) anti-
Flag antibody and (ii) anti c-myc antibody.  (b) HEK293T cells were grown on coverslips 
and transiently transfected with cDNA encoding GPR43 (black line), c-Myc-GPR43 (green 
line) or Flag-GPR43 (red line).  After loading with the Ca2+ sensitive dye Fura-2, 10mM 
acetate was added at the 60s time point and alterations in [Ca2+]i measured by monitoring 
changes in Fura-2 fluorescence over a further 240s.  Data shown represent means±SEM 
from 20 individual cells.   
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Figure 3.6 A variety of C-terminal tags do not affect the ability of GPR43 to mediate 
a rise in [Ca
2+
]i in response to acetate 
HEK293T cells grown on coverslips were transfected with GPR43 (black line), GPR43-c-
Myc (red line), GPR43-Flag (green line), GPR43-eCFP (blue line), GPR43-eYFP (purple 
line) or GPR43-Gαq (grey line).  Cells were loaded with Fura-2 and 10mM acetate added 
after 60s of basal readings.  Alterations in Fura-2 fluorescence were monitored for a further 
240s.  Images were collected every 2s.  Data shown represent means±SEM from at least 15 
individual cells.   
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Figure 3.7 Stimulation of GPR43 specifically with various short chain fatty acids 
causes a transient rise in [Ca
2+
]i in HEK293T cells 
HEK293T cells were transiently transfected to express GPR43-eCFP.  Cells were loaded 
with Fura-2.  Cells were exposed to 10mM acetate (black line), 10mM butyrate (red line), 
10mM propionate (green line) or 100µM lauric acid (blue line) at the 60s time point.  
Alterations in Fura-2 ratio were monitored over a further 240s.  Images were collected 
every 2s.  Data represent means±SEM from 20 positively transfected cells selected on the 
basis of eCFP fluorescence.   
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Figure 3.8 Short chain fatty acids can activate GPR43 in a concentration-dependent 
manner in a FLIPR based [Ca
2+
]i mobilization assay 
HEK293 MSRII cells were transiently transfected to express GPR43-eYFP and a G protein 
cocktail consisting of Gαqo5, Gαqi5, Gαqz5, Gαqs5, Gα15 and Gα16.  24h post transfection cells 
were seeded at 15,000 cells per well into 384 well microtitre plates.  Changes in [Ca2+]i 
levels were measured using the FLIPR apparatus following challenge with increasing 
concentrations of (a) acetate, (b) propionate or (c) butyrate added at the 10s time point and 
data collected for a further 110s.  Graph shown are representative of data obtained from 
three individual experiments performed in duplicate.  Data points represent means±SEM.   
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SCFA pEC50
Formate (C1) 2.8±1.0
Acetate (C2) 4.6±0.2
Propionate (C3) 4.9±0.2
Butyrate (C4) 4.4±0.5  
Table 3.2 Potency of various short chain fatty acids at GPR43 measured by a FLIPR 
based [Ca
2+
]i mobilization assay 
HEK293 MSRII cells were transiently transfected to express GPR43-eYFP.  24h post 
transfection, cells were seeded at 15,000 cells per well into 384 well microtitre plates.  
Changes in [Ca2+]i 
 levels were measured using the FLIPR apparatus following challenge 
with test ligands added at the 10s time point and data collected for a further 110s.  Data 
represent mean±SEM of three individual experiments.  
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Figure 3.9 GPR40 can mediate mobilisation of [Ca
2+
]i in response to caproic acid in 
Gαq/11 knock out cells when co-transfected with Gαq 
EF88 mouse embryo fibroblasts lacking expression of both Gαq and Gα11 were transiently 
transfected using the Amaxa nucleofection system to express both GPR40 and Gαq.  
Following loading with Fura-2, 10mM caproic acid was added at the 60s time point and the 
alteration in Fura-2 fluorescence monitored over the following 240s. Images were collected 
every 2s.  Data represent means±SEM. from 15 individual cells. 
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Figure 3.10 A variety of C-terminal modifications do not affect the ability of GPR40 
to mediate a rise of [Ca
2+
]i in response to caproic acid 
HEK293T cells were transfected to transiently express GPR40 (black), GPR40-c-myc 
(red), GPR40-Flag (grey), GPR40-Gαq (purple), GPR40-eCFP (blue) or GPR40-eYFP 
(green).  Following loading of the cells with Fura-2, cells were exposed to 10mM caproic 
acid at the 60s time point.  Changes in Fura-2 fluorescence were monitored over a further 
240s.  Images were collected every 2s.  Data shown represent means±SEM from at least 20 
individual cells.   
Leigh Ann Stoddart, 2007   114 
0 60 120 180 240 300
0.9
1.0
1.1
1.2
1.3
1.4
1.5
1.6
1.7
1.8
1.9
2.0
10mM caproic ccid
100µM elaidic acid
100µM lauric acid
100µM palmitic acid
1% ethanol
agonist
Time (s)
F
u
ra
-2
 r
a
ti
o
 
Figure 3.11 GPR40-eCFP responds to different fatty acids but kinetics of Ca
2+
 
mobilisation depends on the identity of the fatty acid used 
GPR40-eCFP was transiently transfected into HEK293T cells.  Cells were loaded with 
Fura-2 and were exposed to 100µM lauric acid (blue), 100µM palmitic acid (green), 
100µM elaidic acid (red), 10mM caproic acid (black) or 1% ethanol (grey) at the 60 sec 
time point and the alteration in Fura-2 fluorescence monitored over time.  Images were 
collected every 2s.  Data shown represent means±SEM from at least 20 individual 
positively transfected cells selected on the basis of eCFP fluorescence.   
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Fatty Acid pEC50
Caproic Acid (C6:0) 4.0±0.1
Caprylic Acid (C8:0) 4.3±0.3
Capric Acid (C10:0) 5.5±0.6
Lauric Acid (C12:0) 5.3±0.4
Myristic Acid (C14:0) 5.4±0.5
Palmitic Acid (C16:0) 5.5±0.8
Stearic Acid (C18:0) 4.9±0.7
Palmitoleic Acid (C16:1) 5.3±0.3
Linolenic Acid  (C18:3) 5.6±0.3
γ-Linolenic Acid (C18:3) 5.5±0.2
Linoleic Acid (C18:2) 5.6±0.2
Elaidic Acid (C18:1) 5.2±0.2
Retinoic Acid   (C20:1) 5.3±0.4
Arachidonic Acid 
(C20:4) 5.4±0.3
Docosapentaenoic Acid 
(C22:5) 5.3±0.2
 
 
Table 3.3 Potency of various fatty acids at GPR40 measured by a FLIPR-based 
[Ca
2+
]i mobilisation assay 
HEK293 MSRII cells were transiently transfected to express GPR40-eYFP.  24h post 
transfection, cells were seeded at 15,000 cells per well into 384 well microtitre plates.  
Changes in [Ca2+]i levels were measured using the FLIPR apparatus following challenge 
with the test ligands added at the 10s time point and data collected for a further 110s.  Data 
represent mean±SEM of three individual experiments.   
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Figure 3.12 Increasing concentrations of fatty acid free BSA reduces the magnitude of 
[Ca
2+
]i release generated by GPR40 and GPR43 in response to fatty acids 
HEK293T cells were transfected to transiently express (a) GPR40-eCFP or (b) GPR43-
eCFP.  Cells were loaded with Fura-2.  At the 60s time point cells were exposed to (a) 
100µM lauric acid or (b) 10mM acetate in the absence (black line) or presence of 0.1% 
fatty acid free BSA (blue line) or 0.5% fatty acid free BSA (red line) and changes in Fura-2 
fluorescence monitored for a further 240s.  Images were collected every 2s.  Data represent 
means±SEM from at least 20 positively transfected cells selected on the basis of eCFP 
fluorescence.  
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Figure 3.13 GPR40 appears to display high constitutive activity in [
35
S]GTPγS  
binding studies  
HEK293 cells were transfected to express GPR40-Gαq and membranes prepared.  
[35S]GTPγS binding studies were performed.  Assay samples were immunoprecipitaed with 
the Gαq/11 antiserum, CQ.  Basal (black bar) [
35S]GTPγS binding in Gαq/11 
immunoprecipitates was determined and the effect of 30µM palmitic acid (grey bar) and 
30µM elaidic acid (white bar) assessed.  Graph shown is representative of three individual 
experiments and data points represent means±SEM. 
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Figure 3.14 Increasing concentrations of fatty acid free BSA reduces the ‘basal’ 
[
35
S]GTPγS binding of GPR40-Gαq  
HEK293T cells were transfected to transiently express GPR40-Gαq and membranes 
prepared.  [35S]GTPγS binding studies were performed with the addition of varying 
concentrations of fatty acid free BSA in the absence (triangles) or presence (squares) of 
30µM palmitic acid.  At the end of assay GPR40-Gαq was recovered by 
immunoprecipitation with the anti Gαq/11 antiserum CQ and bound [
35S]GTPγS estimated 
using scintillation counting.  Graph shown is representative of results obtained from three 
individual experiments performed in triplicate.  Data points represent means±SEM. 
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Figure 3.15 The Gαq/11 specific inhibitor YM254890 reduces the basal [
35
S]GTPγS 
loading of GPR40-Gαq 
HEK293T cells were transiently transfected with GPR40-Gαq and membranes prepared.  
[35S]GTPγS binding studies were performed in the absence (black bar) or presence (red 
bar) of 10µM fatty acid free BSA.  The effect of the Gαq/11 inhibitor YM254890 (100nM) 
was assessed.  All assay samples were immunoprecipitated with the Gαq/11 antiserum CQ 
before scintillation counting.  Data shown are representative of results obtained for three 
individual experiments performed in triplicate.  Data points represent means±SEM. 
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Figure 3.16 Varying concentrations of fatty acid free BSA alter the potency of 
palmitic acid at GPR40-Gαq  
HEK293T cells were transiently transfected to express GPR40-Gαq and membranes were 
prepared.  [35S]GTPγS binding studies were performed in the presence of varying 
concentrations of palmitic acid and differing concentrations of fatty acid free BSA, 100nM 
(triangles), 10µM (squares) or 100µM (circles).  All assay samples were 
immunoprecipitated with the Gαq/11 antiserum CQ before scintillation counting.  Graph 
shown is representative of three individual experiments.  Data points represent 
means±SEM. 
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[Fatty acid free 
BSA] added
pEC50           
(palmitic acid)
100nM inactive
10µM 4.4±0.5
100µM 3.8±0.5  
Table 3.4 Potency of palmitic acid in the presence of varying concentrations of fatty 
acid free BSA 
[35S]GTPγS binding studies were performed on membranes expressing GPR40-Gαq in the 
presence of increasing concentrations of palmitic acid and 100nM, 10µM or 100µM fatty 
acid free BSA.  Data represent means±SEM from three individual experiments. 
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Figure 3.17 The addition of fatty acid free BSA allows the potency of fatty acids at 
GPR40-Gαq to be determined 
Membranes were prepared from HEK293T cells transiently transfected to express GPR40-
Gαq.  [
35S]GTPγS binding studies were performed the presence of 10µM fatty acid free 
BSA and increasing concentrations of (a) palmitic acid, (b) elaidic acid, (c) linoleic acid or 
(d) oleic acid.  Bound [35S]GTPγS  in Gαq immunoprecipitates was estimated by 
scintillation counting.  The graphs shown are representative of three individual 
experiments performed in triplicate.  Data points represent means±SEM.   
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Fatty Acid pEC50
Palmitic Acid (C16:0) 4.94±0.13
Elaidic Acid (C18:1) 5.76±0.12
Linoleic Acid (C18:2) 5.41±0.10
Oleic Acid (C18:1) 5.24±0.26
 
Table 3.5 Potency of various fatty acids at GPR40-Gαq measured by a [
35
S]GTPγS 
binding assay in the presence of 10µM fatty acid free BSA 
[35S]GTPγS binding studies were performed on HEK293T cell membranes expressing 
GPR40-Gαq in the presence of 10µM fatty acid free BSA and the specified fatty acid.  Data 
represent means±SEM from three individual experiments  
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Figure 3.18 Fatty acid free BSA has no effect on the basal [
35
S]GTPγS loading of 
GPR41-Gαi3 Cys
351
Ile and only reduces stimulated levels at high concentrations 
HEK293T cells were transfected to transiently express GPR41-Gαi3 Cys
351Ile and 
membranes prepared.  [35S]GTPγS binding studies were performed with the addition of 
varying concentrations of fatty acid free BSA in the absence (triangles) or presence 
(squares) of 10mM propionate.  At the end of assay GPR41-Gαi3 Cys
351Ile was recovered 
by immunoprecipitation with the anti Gαi3 antiserum I3 and bound [
35S]GTPγS estimated 
using scintillation counting.  Graph shown is representative of results obtained from three 
individual experiments performed in triplicate.  Data points represent means±SEM. 
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Figure 3.19 Varying concentrations of fatty acid free BSA have little effect on the 
potency of propionate at GPR41-Gαi3 Cys
e
Ile 
HEK293T cells were transiently transfected to express GPR41-Gαi3 Cys
351Ile and 
membranes were prepared.  [35S]GTPγS binding studies were performed in the presence of 
varying concentrations of propionate and differing concentrations of fatty acid free BSA, 
100nM (triangles), 10µM (circles) or 100µM (squares).  All assay samples were 
immunoprecipitated with the Gαi3 antiserum I3 before scintillation counting.  Graph shown 
is representative of results obtained from three individual experiments performed in 
triplicate.  Data points represent means±SEM.   
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[Fatty acid free 
BSA] added
pEC50     (propionate)
100µM 3.37±0.11
10µM 3.74±0.08
100nM 3.79±0.10  
Table 3.6 Potency of propionate at GPR41-Gαi3 Cys
351
Ile in the presence of varying 
concentrations of fatty acid free BSA 
[35S]GTPγS binding studies were performed on membranes expressing GPR41-Gαi3 
Cys351Ile in the presence of increasing concentrations of propionate and 100nM, 10µM or 
100µM fatty acid free BSA.  Data represent mean±SEM of three individual experiments.   
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Figure 3.20 Expression of GPR40, GPR41 and GPR43 in INS-1E cells 
mRNA was isolated from INS-1E cells using the Qiagen RNeasy Mini Kit.  First strand 
cDNA was synthesised using the First Strand cDNA synthesis kit. Detection of (a) 
rGPR40, (b) rGPR41, (c) rGPR43 and (d) rCyclophilin specific mRNA transcripts was 
carried out by PCR and samples resolved on a 1% agarose gel.  Lane 1, DNA markers, 
Lane 2, plus cDNA.   In each case the expected size of the amplified fragment was 75 bp.   
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Figure 3.21 Elevation of [Ca
2+
]i by lauric acid in INS-1E cells 
INS-1E cells were grown on coated coverslips and loaded with Fura-2.  Cells were 
exposed to 100µM lauric acid at the 60s time point and data collected for a further 240 sec.  
Images were collected every 2s.  Data represents means±SEM from 50 cells. 
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Figure 3.22 Endogenously expressed GPR40 also displays high levels of basal 
[
35
S]GTPγS 
Membranes were prepared from INS-1E cells.  Basal (white bar) levels of [35S]GTPγS 
binding in Gαq/11 immunoprecipitates was determined and the effects of 10µM fatty acid 
free BSA (black bar), 100µM palmitic acid (light blue bar) and a combination of 10µM 
fatty acid free BSA and 100µM palmitic acid (dark blue bar) on levels of [35S]GTPγS 
binding were assessed.  Graph shown is representative of three individual experiments 
performed in triplicate.  Data points represent means±SEM.  
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4 Characterisation of GPR40 synthetic agonists 
and antagonist 
4.1 Introduction 
Of the three receptors within the GPR40 family, it is GPR40 that has attracted the most 
interest since fatty acids were shown to be the likely endogenous agonists for this family of 
receptors (Covington et al., 2006; Milligan et al., 2006).  The expression profile of GPR40 
has shown GPR40 mRNA to be present in high levels in the insulin secreting β-cells of the 
pancreas, both in a large range of pancreatic β-cell lines (Briscoe et al., 2003, Itoh et al., 
2003, Itoh and Hinuma, 2006, Shapiro et al., 2005) as well as in human pancreatic tissue 
(Tomita et al., 2006).  The chronic detrimental effects of fatty acids on pancreatic islets 
have been well documented and the role of GPR40 in this is still under debate.  At present, 
GPR40 is a potential therapeutic target in the regulation of insulin secretion and diabetes. 
Interestingly, a report by Kotarsky et al. (2003) identified that rosiglitazone, a compound 
that has antidiabetic effects, was able to act as an agonist at GPR40 in a reporter gene 
assay.  Rosiglitazone belongs to a class of drugs termed thiazolidinediones that have been 
shown to reduce plasma glucose levels and improve insulin sensitivity in adipose tissue, 
liver and muscle (Lehmann et al., 1995).  The thiazolidinediones are accepted as agonists 
at peroxisome proliferator activated receptor gamma (PPARγ).  There are three major 
isoforms of the PPAR family;α, β/δ and γ although most is known about PPARγ due to its 
therapeutic potential for treatment of diabetes (Rangwala et al., 2004).  There are four main 
thiazolidinediones, rosiglitazone, troglitazone, pioglitazone and ciglitazone, that have been 
employed clinically.  Ciglitazone was the first thiazolidinedione identified but it was never 
marketed.  Troglitazone was the first of the thiazolidinediones to be licensed for use but 
was withdrawn from all markets due to its association with acute liver failure (Graham et 
al., 2002).  At present both rosiglitazone and pioglitazone are being used for the treatment 
of type 2 diabetes.  There is also a growing body of evidence that indicates that there are 
PPARγ-independent effects of thiazolidinediones (Feinstein et al., 2005). The 
interpretation of the observation that rosiglitazone is an agonist at GPR40 is hampered by 
the possible expression of PPARγ in the pancreatic cell lines used (Kotarsky et al., 2003).  
They did not attempt to determine the structure-activity relationship of various 
thiazolidinediones at GPR40 and this is required to dissect out the role of GPR40 agonism 
by these compounds in vivo.   
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The interest in GPR40 as a therapeutic target has led to the synthesis of a number of small 
molecule agonists of GPR40 (Garrido et al., 2006).  These have been shown to be more 
potent than any fatty acid at GPR40 in an assay based on the measurement of [Ca2+]i.  One 
of these compounds, GW9508 (called GW839508 herein) was further characterised, along 
with a GPR40 specific antagonist, GW1100, in a follow up study (Briscoe et al., 2006).  
They showed that the agonist was able to potentiate glucose-stimulated insulin release in 
the pancreatic β cell line, MIN6 and that these effects could be reversed by the inclusion of 
the antagonist GW1100. 
4.2 Agonist activity of thiazolidinediones at GPR40 
To demonstrate that troglitazone has agonistic activity at human GPR40 as shown by 
Kotarsky et al (2003) for rat GPR40, HEK293T cells grown on coverslips were transiently 
transfected with GPR40-eYFP, challenged with 10µM troglitazone and the effect on 
[Ca2+]i monitored (Figure 4.1a).  Troglitazone caused a rapid and transient elevation of 
[Ca2+]i only in cells positively transfected with GPR40-eYFP as monitored by eYFP 
fluorescence.  To confirm that expression of GPR40 was required to allow elevation of 
[Ca2+]i in response to troglitazone, Flp-In T-Rex-HEK293 cells with GPR40-eYFP located 
at the Flp-In locus were generated and employed as in this system GPR40-eYFP 
expression is controlled by the addition of doxycycline.  In the absence of antibiotic 
treatment no auto-fluorescence corresponding to eYFP could be detected and when 
exposed to troglitazone no change in [Ca2+]i was observed (Figure 4.1b(i)).  By contrast, 
following doxycyline treatment (1µg/ml, 24 h) GPR40-eYFP was apparently present at the 
cell surface, and when challenged with troglitazone produced a robust and rapid elevation 
of [Ca2+]i (Figure 4.1b(ii)) similar to that seen in transiently transfected cells.   
The ability of troglitazone to mediate a rise in [Ca2+]i in cells expressing GPR40 led to the 
question of whether other thiazolidinediones could also act as agonists at this receptor.  In 
cells expressing GPR40-eYFP, rosiglitazone and pioglitazone were also able to mediate a 
rise in [Ca2+]i only in positively transfected cells (Figure 4.2).   
As mentioned previously, single cell [Ca2+]i mobilization experiments are poorly suited to 
measure potency of agonists therefore to investigate the potency of the thiazolidinediones 
at human GPR40 [35S]GTPγS binding experiments had to be performed.  In chapter 3, it 
was shown that an increase in [35S]GTPγS binding in response to a fatty acid agonist could 
only be observed in the presence of 10µM fatty acid free BSA and Figure 4.3a shows that 
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this is also true for troglitazone.  The basal loading of [35S]GTPγS onto GPR40-Gαq was 
high and with the addition of 10µM troglitazone, which is able to elicit a large increase in 
[Ca2+]i, the levels of [
35S]GTPγS binding were similar to those observed in basal 
conditions.  The basal loading of GPR40-Gαq was reduced by the addition of 10µM fatty 
acid free BSA and when 10µM troglitazone was also included there was an increase in 
[35S]GTPγS binding.  To determine the potency of four thiazolidinediones, troglitazone, 
rosiglitazone, ciglitazone and pioglitazone, their ability to increase [35S]GTPγS binding in 
a concentration dependent manner was assessed (Figure 4.3b(i-iv)).  Each of these 
thiazolidindiones was able to increase [35S]GTPγS binding, although ciglitazone and 
pioglitazone did not give sigmoidal concentration response curves with Hill slopes 
approaching a value of 1 (Table 4.1).  The potency of these compounds varied, with the 
rank order of potency being troglitazone >rosiglitazone=pioglitazone>ciglitazone (Table 
4.1).  In order to confirm the potencies seen in the [35S]GTPγS binding experiments, 
HEK293 MSRII cells were transiently transfected with GPR40-eYFP and loaded with the 
calcium sensitive dye Fluo-4 and changes in Fluo-4 fluorescence measured using the 
FLIPR, which corresponds to a change in [Ca2+]i.  Using this method both troglitazone and 
rosiglitazone were able to produce a measurable signal and the observed potencies are 
shown in Table 4.2.  Again, troglitazone was shown to be more potent at GPR40-eYFP 
than rosiglitazone.  Neither ciglitazone nor pioglitazone produced a change in [Ca2+]i and 
were consequently concluded to be inactive at GPR40-eYFP using this technique.  In 
addition, control cells transiently transfected with GPR43-eYFP or the neuromedin U 
receptor (NMU-R) showed no change in [Ca2+]i in response to any of the 
thiazolidinediones. 
4.3 Potency of small molecule agonists of GPR40 
A variety of synthetic small molecule agonists of GPR40 have recently been described.  I 
was able to test five (a-e in Figure 1.3) of these compounds in a [Ca2+]i based FLIPR assay 
and six (a-f in Figure 1.3) in [35S]GTPγS binding experiments.  I was unable to test 
GSK248257A in the FLIPR based assay due to problems in obtaining the compound.  In 
order to determine the ability of these compounds to mediate a rise in [Ca2+]i in a 
concentration dependent manner HEK293 MSRII cells were transiently transfected with 
GPR40-eYFP, loaded with Fluo-4 and the changes in [Ca2+]i in response to test compound 
were measured using the FLIPR.  With this assay method three of the five compounds; 
GW839508X, GSK250089A and GSK223112A, were able to generate robust, transient 
rises in [Ca2+]i in cells transfected with GPR40-eYFP and relative potencies could be 
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ascribed (Table 4.3).  GW839508X was shown to be the most potent, followed by 
GSK250089A and then GSK223112A.  Neither GSK272235A nor GSK269778A were 
able to mediate a rise in [Ca2+]i in cells transfected with GPR40-YFP and were therefore 
deemed inactive using this method.  In addition, control cells transiently transfected with 
GPR43-eYFP or NMU-R showed no change in [Ca2+]i in response to any of these 
compounds.  To confirm these observed potencies [35S]GTPγS binding experiments were 
performed on membranes prepared from cells transiently transfected to express GPR40-
Gαq.  As with fatty acids and thiazolidinediones, GSK250089A only showed agonistic 
effects in the presence of fatty acid free BSA (Figure 4.4).  Of the six compounds tested in 
the [35S]GTPγS  binding experiments, GW839508X, GSK258257A and GSK250089A 
were able to produce sigmodial concentration response curves that reached saturation 
(Figure 4.5 a-c).  Two further compounds, GSK223112A and GSK269778A (Figure 4.5 d-
e), showed some agonist activity by increasing [35S]GTPγS  binding at the highest 
concentrations tested (10µM).  The assays were never performed at higher concentrations 
to determine if saturation could be reached.  As in the FLIPR assay, GSK272235A was 
unable to increase [35S]GTPγS  binding at any concentrations and therefore was inactive at 
GPR40-Gαq (Figure 4.5f).  The rank order of potency differed from that obtained in the 
FLIPR assay, with GSK250089A being the most potent giving a pEC50 of 8.5±0.02, 
followed by GSK248257A, then GW839508X, GSK269778A and finally GSK223112A 
(Table 4.4).   
4.4 Characterisation of GW1100 as an antagonist at 
GPR40 
GW1100 has recently been described as an antagonist at GPR40 (Briscoe et al., 2006) 
mainly using [Ca2+]i mobilization based assays.  As I have developed a robust [
35S]GTPγS 
binding assay it provided an ideal way to further characterise GW1100 as an antagonist of 
GPR40.  Firstly, HEK293T membranes expressing GPR40-Gαq were exposed to 10µM 
GW1100 and the effect on basal loading of [35S]GTPγS in the presence or absence of fatty 
acid free BSA determined (Figure 4.6).  GW1100 reduced the basal binding of [35S]GTPγS 
at GPR40-Gαq in the absence of fatty acid free BSA.  The combination of 10µM GW1100 
and 10µM fatty acid free BSA had an additive effect and reduced [35S]GTPγS binding to 
minimal levels.  As shown earlier, the agonist effect of GSK250089A could only be seen 
in the presence of fatty acid free BSA but this agonist effect could be reduced by the 
addition of 10µM GW1100, both in the absence and presence of fatty acid free BSA.  This 
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also showed that GSK250089A can increase the low levels [35S]GTPγS bound in the 
presence of GW1100 and fatty acid free BSA, potentially indicative of the competitive 
nature of these ligands.   
HEK293T membranes expressing GPR40-Gαq were used to investigate the ability of 
GW1100 to reduce the basal [35S]GTPγS binding of GPR40-Gαq in a concentration 
dependent manner.  In the absence of fatty acid free BSA, the curves did not level off and 
concentrations higher than shown were not tested (Figure 4.7).  In the presence of 10µM 
fatty acid free BSA, the maximum decrease in [35S]GTPγS binding was observed at 10µM 
GW1100 and higher concentrations did not result in a further decrease of [35S]GTPγS 
binding.  Even in the presence of 10µM fatty acid free BSA, [35S]GTPγS binding was 
substantially reduced by GW1100 in a concentration-dependent manner.  This suggest that 
GW1100 is either an inverse agonist at GPR40 or that GW1100 is able to compete with 
remaining endogenous agonist not removed by treatment with fatty acid free BSA.   
As shown above, agonist activity of GSK250089A could only be detected in the presence 
of fatty acid free BSA.  However, in the absence of BSA, the agonist activity of 
GSK250089A could also be detected when 10µM GW1100 was also present (Figure 4.6).  
Figure 4.8 demonstrates that this effect was concentration dependent.  When GSK250089A 
was added to membranes expressing GPR40-Gαq in increasing concentrations in the 
absence of GW1100 no increase in [35S]GTPγS binding was observed but an increase in 
[35S]GTPγS binding, and consequently a concentration response curve, could be observed 
when 10µM GW1100 was added (Figure 4.8).  Interestingly, even very high concentrations 
of GSK250089A were unable to stimulate [35S]GTPγS binding to the levels observed in the 
absence of GW1100.  The apparent pEC50 of GSK250089A when 10µM GW1100 was 
present was 7.1±0.2.  In a similar fashion, the presence of either fatty acid free BSA or 
GW1100 allowed 1µM troglitazone to elevate [35S]GTPγS binding to GPR40-Gαq (Figure 
4.9a).  GW1100 was able to inhibit the rise in [35S]GTPγ binding mediated by 1µM 
troglitazone in a concentration-dependent fashion and at 10µM appeared to be the 
concentration where maximum reduction was observed (Figure 4.9b). 
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4.5 Ability of synthetic agonists to activate endogenously 
expressed GPR40 
As shown in Chapter 3, GPR40 is endogenously expressed in the rat β cell line, INS-1E 
and shows the same high levels of basal [35S]GTPγS binding as transfected human GPR40.  
To assess whether the effects of troglitazone and GSK250089A could be reproduced in 
these cells, the effects of these compounds were first evaluated by investigating their 
ability to mediate a rise in [Ca2+]i in this cell line.  INS-1E cells were grown on coated 
coverslips and their response to 10µM troglitazone or 1µM GSK250089A measured by the 
change in Fura-2 ratio (Figure 10a).  Troglitazone was able to induce a transient, large rise 
in [Ca2+]i.  GSK250089A was unable to mediate a rise in [Ca
2+]i.  To confirm the 
observations seen in the [Ca2+]i mobilization assay, cell membranes prepared from INS-1E 
cells were used in [35S]GTPγS binding assays.  As observed in Chapter 3, in basal 
conditions a high level of [35S]GTPγS was bound and this could be reduced by the addition 
of 10µM fatty acid free BSA (Figure 10b).  There was no increase in [35S]GTPγS binding 
upon the addition of saturating concentration of troglitazone (1µM) or GSK250089A 
(100nM) in the absence of fatty acid free BSA.  The combination of 1µM troglitazone and 
10µM fatty acid free BSA resulted in an increase of [35S]GTPγS binding compared to that 
with the BSA alone. Whereas the combination of 100nM GSK230089A and 10µM fatty 
acid free BSA gave [35S]GTPγS binding levels similar to BSA alone. 
4.6 Discussion 
The interest in GPR40 as a potential therapeutic target for the treatment of type 2 diabetes 
demands full understanding of the pharmacology and activation of the receptor.  The 
endogenous fatty acid ligands for the receptor display relatively low potency which 
hampers their use as pharmacological tools.  The recent description of small molecule 
agonists of GPR40 which are significantly more potent than any of the fatty acids (Garrido 
et al., 2006) and the observation that rosiglitazone appeared to display agonist activity at 
rat GPR40 (Kotarsky et al., 2003) provided tools to uncover some of the pharmacology of 
this receptor which cannot easily be investigated using fatty acids.   
To date, only Kotarsky et al., (2003) have shown that rosiglitazone is able to act as an 
agonist at GPR40.  This was confirmed for human GPR40 in two [Ca2+]i mobilization 
based assays (Figure 4.2 and Table 4.2) and in the [35S]GTPγS binding assay (Figure 4.3).  
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In addition to rosiglitazone, three further members of the thiazolidinedione family 
(troglitazone, ciglitazone and pioglitazone) were tested.  Troglitazone was shown to be the 
most potent of the thiazolidinediones tested here with a pEC50 of 6.5±0.1 measured in a 
[35S]GTPγS binding assay and 5.9±0.1 measured by the FLIPR-based Ca2+ release assay.  
Taking the [35S]GTPγS binding and Ca2+ mobilization data together, the rank order of 
potency of these compounds at GPR40 is troglitazone > rosiglitazone > pioglitazone > 
ciglitazone.  The observation that the thiazolidinediones are able to act as agonists at 
GPR40 with varying degrees of potency according to their structure poses interesting 
questions as to possible contributions of GPR40 to their in vivo actions rather than PPARγ.  
Interpretation of the results from Kotasky et al., (2003) is hampered by the accompanying 
PPAR activity of the tool compounds.  By using an inducible cell line I demonstrated that 
only in the presence of GPR40-eYFP could troglitazone mediate a rise in [Ca2+]i (Figure 
4.1).  This confirmed that the rise in [Ca2+]i in response to troglitazone must be mediated 
by GPR40. 
The thiazolidinediones were first described as agonists for PPARγ by Lehmann et al., 
(1995) and since then much work has been undertaken to understand the mode of action of 
these compounds.  Activated PPARγ binds and activates peroxisome proliferator 
responsive elements (PPREs) in the promoter region of target genes and increases gene 
transcription.  Genes with PPREs include those in glucose and lipid metabolism pathways, 
which reduce adipocyte lipolysis, reduce plasma free fatty acids and improve insulin-
stimulated glucose disposal (Kliewer et al., 1992).  Although much of the research into 
thiazolidindiones has focused on their insulin-sensitizing properties (Rangwala et al., 
2004), they have also been shown to have anti-inflammatory properties (Genolet et al., 
2004; Youssef et al., 2004) and display antiproliferative activity against a variety of cancer 
cell lines (Grommes et al., 2004; Theocharis et al., 2004; Rume et al., 2004).  Although 
there is good correlation between the EC50 of various thiazolidinediones at PPARγ and the 
in vivo minimum effective antihyperglycemic dose (Willson et al., 1996) developments in 
the field have uncovered a series of rapid, apparently PPARγ independent effects, of these 
compounds (Feinstein et al., 2005; Gardner et al., 2005).  The activation of GPR40 by 
various thiazolidinediones may help to explain some of these effects.  Palakurthi et al., 
(2001) showed that troglitazone and ciglitazone were able to mediate a rise in [Ca2+]i in 
both PPARγ+/+ and PPARγ-/- mouse embryonic stem cells.  The kinetic of this [Ca2+]i 
release was similar to that observed in GPR40-eYFP transfected HEK293T cells (Figure 
4.1a) and in INS-1E cells endogenously expressing GPR40 (Figure 4.10b).   
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There are marked differences in the potency of the thiazolidinediones at GPR40 and 
PPARγ and these are shown in Table 4.5.  It has been noted that the anti-inflammatory 
effects of thiazolidinediones are often observed at concentrations much higher than their 
EC50 values for binding to (Willson et al., 1996) or activating PPARγ (Pershadsingh et al., 
2004).  In activated macrophage, 30µM troglitazone has been shown to inhibit induction of 
the inducible form of nitric oxide synthase (Ricote et al., 1998), which is significantly 
higher than the EC50 at PPARγ.  The concentrations of troglitazone required to reduce 
cytokine release from activated human monocytes was 100µM (Jiang et al., 1998) which is 
again significantly higher than the EC50 value at PPARγ.  The expression of GPR40 in 
monocytes was shown by Briscoe et al., (2003) and these levels of troglitazone may be 
activating GPR40.  To separate the contribution of GPR40 from that of PPARγ to the mode 
of action of the thiazolidinediones requires much more work.  The knowledge of the 
structure-activity relationship of these compounds at GPR40 and PPARγ, along with 
analysis of the effects of these compounds in GPR40 knock-out animals and selective 
knock-down of GPR40 in model systems will help answer this question.  The recent 
development of PPARγ inactive thiazolidinedione analogues which retain the ability to 
cause apoptosis of cancer cell lines but have no PPARγ activity (Huang et al., 2005) may 
provide interesting tools in this field if they can be shown to have activity at GPR40.  
It is also important to consider whether levels of thiazolidinediones reached in vivo would 
be sufficient to activate GPR40.  In humans, maximum serum concentrations of 
troglitazone can reach about 7-8µM (Plosker et al., 1999) and for pioglitazone levels reach 
about 2.2µM (Gillies et al., 2000).  With the data generated in this study on the potency of 
these compounds, the serum levels of pioglitazone would not be expected to have any 
effect on GPR40 but with troglitazone this concentration should be able to activate GPR40 
extensively.  Figure 4.10 shows that 10µM troglitazone can activate a large and rapid 
increase in [Ca2+]i in cells that endogenously express GPR40 and only 1µM troglitazone is 
required to increase [35S]GTPγS in membranes prepared from these cells.   
The recently described small molecule agonists for GPR40 may also provide tools for 
investigating the role of GPR40 in vivo.  The six compounds tested in this study were 
shown to be GPR40 agonists in a reporter gene assay (Garrido et al., 2006), it was 
therefore necessary to test these compounds in assays that measure signals produced 
further upstream.  Only GW839508X had previously been tested in a [Ca2+]i release assay 
(Briscoe et al., 2006).  Table 4.6 shows the comparison between the potencies seen for 
each of the compounds in the three difference assay systems in which they have been 
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tested.  GW839508X, GSK248257A and GSK250089A all show similar potency in the 
reporter gene assay and the [35S]GTPγS binding assay.  By contrast, of the other three 
compounds GSK272235A was shown to be inactive in both the FLIPR based [Ca2+]i 
release assay and the [35S]GTPγS binding assay, GSK269778A inactive in the [Ca2+]i 
based assay and much less potent in the [35S]GTPγS binding than reported in the published 
data.  GSK223112A was less potent in the [Ca2+]i release assay than in the reporter gene 
assay but was basically inactive in the [35S]GTPγS binding assay.  The six compounds 
tested here fall into two broad categories, those with a carboxylate group (GW839508X, 
GSK250089A and GSK248257A) and those with an amide group in place of the 
carboxylic acid headgroup (GSK223112A, GSK272235A and GSK269778A).  Garrido et 
al., (2006) found little difference when replacing the carboxylic acid with an amide but the 
data in this study argues against this.  The three compounds that showed little or no activity 
in the two assay systems tested were the ones with the amide group, whereas the 
compounds containing the carboxylic acid proved to be potent agonists of GPR40.  The 
importance of the carboxylic group for activation of the receptor by fatty acids has not 
been fully assessed in the literature and time constraints prevented this been investigated in 
this study.   
These small molecule ligands may help in dissecting the role GPR40 plays in fatty acid-
potentiated, glucose-stimulated insulin release.  Briscoe et al., (2006) were able to show in 
a mouse β-cell line a concentration-dependent stimulation of insulin secretion in the 
presence of glucose by GW839508X but they were unable to reproduce these results in 
isolated rat or mouse islets.  This is consistent with the observation in this study where 
GSK250089A was unable to mediate a rise in [Ca2+]i in single INS-1E cells or increase 
[35S]GTPγS binding in membranes prepared from these cells.  This may reflect a difference 
in the binding of these compounds to rat or mouse GPR40 compared to human GPR40.  If 
this is shown to be true, it would reduce their potential as compounds to unravel the 
pharmacology and function of GPR40 in vivo as many of the model systems for insulin 
release are rodent based.  Although this may have an impact on the usefulness of these 
compounds, they still are at least 100 times more potent than any of the fatty acids at 
GPR40 and will definitely play a part in uncovering the true role of GPR40 in vivo and 
detailed comparisons of the activation of human and rat GPR40 by these compounds will 
provide insights into the mechanisms of ligand binding. 
Briscoe et al., (2006) also described GW1100 as an antagonist of GPR40.  This was shown 
by its ability to reduce GW839598X-stimulated increases in [Ca2+]i and glucose-stimulated 
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insulin secretion in a concentration-dependent manner.  The observation that the GPR40-
Gαq fusion protein displayed apparent high levels of constitutive activity that could be 
reduced by treatment with fatty acid free BSA provided an assay system to define both the 
role of GW1100 as an antagonist of GPR40 and the basis for the high levels of basal 
[35S]GTPγS binding.  In this study it was confirmed that GW1100 is an antagonist of 
GPR40-Gαq by using the [
35S]GTPγS binding assay.  GW1100 can reduce the basal 
[35S]GTPγS binding to this protein in a concentration-dependent manner in the absence of 
fatty acid free BSA.  In the presence of fatty acid free BSA, GW1100 was able to reduce 
basal loading further, which was comparable to the levels of [35S]GTPγS binding seen 
when GPR40-Gαq was treated with the Gαq/11 inhibitor YM254890 (Figure 3.15).  In the 
presence of BSA, GW1100 appeared to be a more potent antagonist, with saturation of 
reduction of binding being reached (Figure 4.7).  The conventional interpretation of 
GW1100’s ability to reduce basal [35S]GTPγS loading of GPR40 would be to describe 
GW1100 as an inverse agonist at GPR40.  Consideration of the data obtained using fatty 
acid free BSA prevents GW1100 to be defined in this way as it is not possible to assess 
clearly whether this effect reflects competition with an endogenous agonist which binds to 
the receptor or if it is suppression of a high level of constitutive activity.  The only way 
that this could be resolved would be if both inverse agonists and neutral antagonist are 
available for GPR40 but as it is a recently characterised GPCR the availability of small 
molecule modulators is limited and to date the only antagonist of GPR40 described is 
GW1100.  The lack of inverse agonists and neutral antagonists has been the most limiting 
issue in defining the contribution of constitutive activity to the physiological function of 
GPCRs (Gardner and Mallet., 2006; Negus, 2006).  It is therefore only possible to refer to 
GW1100 as a GPR40 antagonist until this issue can be clearly defined.   
The detrimental effect of chronic exposure of β-cells to fatty acids is well documented 
(Lee et al., 1994; El Assaad et al., 2003; Prentki et al., 2003).  The use of a GPR40 
antagonist may be of use to help in the understanding of this effect and establish the role 
GPR40.  It has recently been shown that mice expressing GPR40 under the control of the 
PDX-1 (pancreatic duodenal homobox-1) promoter had impaired beta-cell function and 
developed diabetes (Steneberg et al., 2005).  Hence development of a GPR40 antagonist 
may be an attractive approach for the treatment of diabetes.  
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Figure 4.1 Troglitazone can produce a rise in [Ca
2+
]i via GPR40 
(a) HEK293T cells were transfected to transiently express GPR40-eYFP.  Following 
loading with Fura-2, 10µM troglitazone was added at the 60 second time point and the 
alteration in Fura-2 fluorescence monitored over the following 240 seconds with images 
collected every 2 seconds.  Data represent means±SEM from 20 positively transfected cells 
selected on the basis of eYFP fluorescence.  (b) (i) Cells of a clone of Flp-In T-REx-
HEK293 cells with GPR40-eYFP located at the Flp-In locus were grown on poly-D lysine 
coated coverslips and treated with (+ DOX) (right panel) or without (- DOX) (left panel) 
1µg/ml doxycycline for 24h.  Cells were visualized to detect expression of GPR40-eYFP.  
(ii) Cells were loaded with Fura-2 and 10µM troglitazone added at the 60s time point.  
Alterations in Fura-2 fluorescence were monitored for a further 240s in at least 20 + DOX 
(black) and – DOX (red) cells. 
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Figure 4.2 Other thiazolidinediones can act as agonists at GPR40 in a single cell 
calcium assay 
HEK293T cells were transfected to transiently express GPR40-eYFP.  Following loading 
with Fura-2, 10µM troglitazone (red), 10µM pioglitazone (green) or 20µM rosiglitazone 
(black) were added at the 60 second time point and the alteration in Fura-2 fluorescence 
monitored over the following 240 seconds with images collected every 2 seconds.  Data 
represent means±SEM from at least 20 positively transfected cells selected on the basis of 
eYFP fluorescence  
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Figure 4.3 Thiazolidinediones activate GPR40 in a concentration-dependent manner 
in a [
35
S]GTPγS binding assay with varying degrees of potency but only in the 
presence of fatty acid free BSA 
HEK293T cells were transfected to express GPR40-Gαq and membranes prepared.  (a) 
Basal (black bar) [35S]GTPγS binding in Gαq immunoprecipitates was determined and the 
effects of 10µM troglitazone (white), 10µM fatty acid free BSA (red), and 10µM fatty acid 
free BSA plus 10µM troglitazone (blue) on levels of [35S]GTPγS bound were determined.  
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(b) [35S]GTPγS binding studies were performed in the presence of 10µM fatty acid free 
BSA and increasing concentrations of (i) troglitazone, (ii) rosiglitazone, (iii) ciglitazone 
and (iv) pioglitazone.  Graphs shown are representative of results obtained for three 
individual experiments performed in triplicate.  Data points represent means±SEM. 
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Compound pEC50 Hill Slope
Troglitazone 6.5±0.1 0.96±0.2
Rosiglitazone 5.5±0.2 0.90±0.1
Ciglitazone >4 0.34±0.1
Pioglitazone 5.5±.0.1 4.53±1.1  
Table 4.1 Potency of thiazolidinediones at GPR40-Gαq measured by in the[
35
S]GTPγS 
binding assay 
[35S]GTPγS binding studies were performed on membranes expressing GPR40-Gαq in the 
presence of 10µM fatty acid free and the specified thiazolidinedione.  Data represent 
means±SEM of three individual experiments. 
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Compound pEC50
Troglitazone 5.9±0.1
Rosiglitazone 5.7±0.3
Ciglitazone inactive
Pioglitazone inactive  
Table 4.2 Potency of thiazolidinediones at GPR40 measured in a FLIPR based [Ca
2+
]i 
mobilisation assay 
HEK293 MSRII cells were transiently transfected to express GPR40-eYFP.  24h post 
transfection cells were seeded at 15,000 cells per well into 384 well microtitre plates.  
Changes in [Ca2+]i levels were measured using the FLIPR apparatus following challenge 
with test ligands added at the 10s time point and data collected for a further 110s.  Data 
represent mean±SEM of three individual experiments. 
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Compound pEC50
GW839508X 7.6±0.3
GSK248257A ND
GSK250089A 7.0±0.2
GSK223112A 5.7±0.7
GSK272235A inactive
GSK269778A inactive  
Table 4.3 Potency of synthetic small molecules at GPR40 measured in a FLIPR based 
[Ca
2+
]i assay 
HEK293 MSRII cells were transiently transfected to express GPR40-eYFP.  24h post 
transfection cells were seeded at 15,000 cells per well into 384 well microtitre plates.  
Changes in [Ca2+]i levels were measured using the FLIPR apparatus following challenge 
with test ligands added at the 10s time point and data collected for a further 110s.  Data 
represent mean±SEM of three individual experiments. ND = not determined.   
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Figure 4.4 GSK250089A can apparently only act as an agonist of GPR40-Gαq in the 
presence of fatty acid free BSA 
HEK293T cells were transfected to express GPR40-Gαq and membranes prepared.  Basal 
(black bar) [35S]GTPγS binding in Gαq immunoprecipitates was determined and the effects 
of 1µM GSK250089A (white), 10µM fatty acid free BSA (red), and 10µM fatty acid free 
BSA plus 1µM GSK250089A (blue) on levels of [35S]GTPγS bound were determined.  
Graph shown is representative of three experiments performed in triplicate and data points 
shown are means±SEM. 
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Figure 4.5 Potency of synthetic small molecules agonists at GPR40 measured in the 
[
35
S]GTPγS binding assay 
HEK293T cell membranes expressing GPR40-Gαq were used to measure the ability of 
increasing concentrations of (a) GW839508X, (b) GSK248257A, (c) GSK250089A, (d) 
GSK223112A, (e) GSK272335A and (f) GSK269778A to mediate alterations in 
[35S]GTPγS binding.  All assay samples were immunoprecipitated with the Gαq/11 
antiserum CQ before scintillation counting.  Graph shown is representative of results 
obtained for three individual experiments performed in triplicate.  Data points represent 
means±SEM.  
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Compound pEC50
GW839508X 6.9±0.2
GSK248257A 7.2±0.1
GSK250089A 8.5±0.1
GSK223112A >5
GSK272235A inactive
GSK269778A >5  
Table 4.4 Potency of synthetic small molecules at GPR40 measured in a [
35
S]GTPγS 
binding assay 
 [35S]GTPγS binding studies were performed on HEK293T cell membranes expressing 
GPR40-Gαq in the presence of 10µM fatty acid free and the specified synthetic agonist.  
Data represent mean±SEM from three individual experiments 
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Figure 4.6 GW1100 is an antagonist of GPR40-Gαq  
HEK293T cells were transiently transfected to express GPR40-Gαq and membranes were 
prepared.  Basal [35S]GTPγS binding in Gαq immunoprecipitates was determined in the 
presence (white bar) and absence (black bar) of 10µM fatty acid free BSA.  The effect of 
1µM GSK250089A, 10µM GW1100 and the combination of 1µM GSK250089A and 
10µM GW1100 in the presence (black bars) and absence (white bars) of 10µM fatty acid 
free BSA was determined.  The graph shown is representative of three individual 
experiments performed in triplicate.  Data shown are means±SEM. 
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Figure 4.7 ‘Basal’ [
35
S]GTPγS binding at GPR40-Gαq is substantially reduced by 
GW1100 in the presence and absence of fatty acid free BSA in a concentration 
dependent manner 
HEK293T cells were transiently transfected with GPR40-Gαq and membranes were 
prepared.  [35S]GTPγS  binding assays were performed in the presence of varying 
concentrations of GW1100 and the absence (squares) or presence (triangles) of 10µM fatty 
acid free BSA.  [35S]GTPγS  binding in Gαq immunoprecipitates was estimated by 
scintillation counting.  The graph show is representative of three individual experiments 
performed in triplicate.  Data points represent means±SEM. 
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Figure 4.8 Agonist activity of GSK250089A can be detected in the presence of 
GW1100 
HEK293T cells were transiently transfected to express GPR40-Gαq and membranes were 
prepared.  [35S]GTPγS binding in Gαq immunopreciptates was determined and the effect of 
increasing concentrations of GSK250089A in the presence (triangles) or absence (squares) 
of 10µM GW1100.  The graph shown is representative of three individual experiments 
performed in triplicate.  Data points represent means±SEM.   
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Figure 4.9 GW1100 can inhibit troglitazone-mediated activation of GPR40 
HEK293T cells transiently transfected with GPR40-Gαq were used to prepare membranes.  
(a) Basal [35S]GTPγS binding was assessed in Gαq immunoprecipitates in the presence 
10µM of fatty acid free BSA.  The effects of 1µM troglitazone (white bar), 10µM 
GW1100 (green bar) or the combination of 1µM troglitazone and 10µM GW1100 (blue 
bar) were assessed. (b) The effect of increasing concentrations of GW1100 on the ability of 
1µM troglitazone to increase [35S]GTPγS binding.  Graphs shown are representative of 
three individual experiments performed in triplicate.  Data points represent mean±SEM. 
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Figure 4.10 Ability of troglitazone and GSK250089A to elicit mobilization of [Ca
2+
]i in 
INS-1E cells and increase [
35
S]GTPγS binding in INS-1E cell membranes 
(a) INS-1E cells were grown on coverslips .  Following loading with Fura-2, 10µM 
troglitazone (red line) or 1µM GSK250089A (green line) was added at the 60s time point 
and the alteration in Fura-2 fluorescence monitored over the following 240s with images 
collected every 2s.  Data represents means±SEM from 50 cells. (b) Cell membranes were 
prepared from INS-1E cells.  Basal (black bar) binding of [35S]GTPγS in Gαq 
immunoprecipitates and the effects of 10µM fatty acid-free BSA alone (white bar), 1µM 
troglitazone (pink bar), 100nM GSK250089A (light green bar) and combination of 10µM 
fatty acid free BSA and 1µM troglitazone (red bar) or 100nM GSK250089A (green bar) on 
levels of [35S]GTPγS bound were assessed. 
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GPR40 PPARγ
Troglitazone 0.32 0.78
Rosiglitazone 3.16 0.076
Pioglitazone 3.26 0.55
Ciglitazone 3162 3
EC50 (µM) atAgonist
 
Table 4.5 Comparison of potency of various thiazolidinediones at GPR40 and PPARγ 
EC50 values for GPR40 determined using [
35S]GTPγS binding assay as shown in Table 4.1.  
EC50 values for PPARγ were determined using reporter gene chimera genes at mouse 
PPARγ (Pershadsingh, 2004). 
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Agonist
[
35
S]GTPγS 
binding
[Ca
2+
]i release
Reporter gene 
activation
GW839508X 6.9 7.6 7.2
GSK248257A 7.2 ND 7.9
GSK250089A 8.5 7.0 8.3
GSK223112A >5 5.7 7.3
GSK272235A inactive inactive 7.4
GSK269778A >5 inactive 7.0
pEC50 determined by
 
Table 4.6 Potency of various small molecule ligands determined in three different 
assay systems 
pEC50 values for six small molecule ligands was determined in [
35S]GTPγS binding assays 
(taken from Table 4.4), FLIPR based [Ca2+]i release assays (taken from Table 4.3) and in a 
reporter gene assay (taken from Garrido et al., 2006) 
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5 Mutagenesis to identify residues important in 
fatty acid binding and fatty acid chain length 
selectivity 
5.1 Introduction 
There is no mutational data available on the regions and residues that play a role in fatty 
acid binding to GPR40, GPR41 and GPR43.  Studies on other receptors whose ligands 
contain carboxyl groups indicate that a positively charged amino acid is very important in 
ligand binding.  Tunaru et al. (2005) demonstrated that an arginine residue in TM3 of the 
high affinity nicotinic acid receptor, HM74A provides a positive charge by which the 
carboxylate group of nicotinic acid can bind.  Studies on GPR91 have shown that four 
arginine residues are required for binding the dicarboxylate groups of succinate (He et al., 
2004).  Basic residues have also been implicated in the binding of prostanoids to 
prostanoid receptors (Stitham et al., 2003) and of leukotriene B4 to its receptor (Sabirsh et 
al., 2006).  Sequence alignment of GPR40, GPR41 and GPR43 shows that there are three 
conserved basic residues in transmembrane regions; an arginine or lysine in TM2, histidine 
in TM4 and arginine in TM5 (Figure 5.1).   
Homology models of GPR40, GPR41 and GPR43 were generated by GlaxoSmithKline 
based on the crystal structure of rhodopsin.  They were generated using the automated 
GPCR_Builder programme and the process of developing the model is described in detail 
by Berkhout et al., (2003).  The intracellular loops of the receptors were not modelled, due 
to their poor definition in the crystal structures of rhodopsin.  The receptors were aligned 
based on key conserved residues in family A GPCRs, these include an Asn in TM1, a Cys 
residue in extracellular loop 1, the D(E)RY motif at the bottom TM3, a Cys in extracellular 
loop 2, a Pro residue in TM5 and in TM6.  GPR43 contains an ERY motif in TM3 whereas 
in GPR40 a GRY triplet is found and in GPR41 it is an ERF motif.  Figure 5.2 shows one 
of the small molecule agonists of GPR40 docked into the homology model of the receptor.  
This demonstrates the ability of the Arg in TM5 to interact with the carboxylate head 
group of the compound.  The His in TM4 is found near the proposed binding site whereas 
the Lys in TM2 is quite far away.  The size of the short chain fatty acids prevents them 
from being modelled with any degree of accuracy into the models of GPR41 and GPR43 
and as there have been no small molecule ligands described at either receptor, the models 
shown in Figure 5.3 do not contain any ligand bound.  The models of both receptors show 
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the Arg in TM5 pointing into the core of the receptor, again with the His in close 
proximity.  The Arg/Lys in TM2 points away from the proposed binding site, which would 
make it unavailable for interaction with the carboxylate group of the fatty acid.   
Another important issue is the differing fatty acid chain length specificity of GPR40, 
GPR41 and GPR43.  Sequence alignment and homology modeling indicates a region in 
TM3 that may play a role in chain length specificity.  Within TM3 of GPR40 a glycine 
triplet is found whereas in GPR43 the triplet comprises serine-threonine-tryptophan.  
Figure 5.4 illustrates the role of these residues in the homology models of GPR40 and 
GPR43.  In GPR40, the triplet of glycine allows the synthetic small molecule agonist to 
bind down into the core formed by the TM helices.  In GPR43, the Ser-Thr-Trp triplet 
protrudes into the proposed binding pocket of the receptor and makes the binding pocket 
smaller.  This would prevent any compound binding down into the core of the receptor.   
To facilitate comparison between GPR40, GPR41, GPR43 and other family A GPCRs the 
Ballesteros-Weinstein numbering scheme will be used (Ballesteros and Weinstein, 1995).  
This numbering scheme asigns the most conserved residue in each TM helix the number 50 
and each residue is numbered according to its position relative to the most conserved 
residue in the helix.  In GPR40, GPR41 and GPR43 the conserved Arg/Lys in TM2 is 
numbered 2.60, the His in TM4 is numbered 4.56 and the Arg in TM5 is numbered 5.39.  
The triplet in TM3 of GPR40 and GPR43 are numbered 3.39, 3.40 and 3.41.  Within the 
discussion section of this chapter the Ballesteros-Weinstein numbering will be included to 
allow comparison between receptors.   
To investigate the roles of each of the basic transmembrane residues a point mutagenesis 
approach was used.  Using the Stratagene QuikChange mutagenesis protocol, initially each 
of the sequences corresponding to the basic residues were mutated to code for alanine.  The 
mutations were introduced into the receptor-eYFP fusion protein.  The receptor-eYFP 
fusions are a valuable tool for this study as they allowed monitoring of the expression of 
each of the mutants and selection of positively transfected cells during single cell Ca2+ 
experiments to assess the function of the mutant.  For mutation of the triplet in TM3 of 
GPR40 all three residues were mutated together to the corresponding residues in GPR43 
using the QuikChange method.  With GPR43, each of the residues was mutated in turn to 
glycine, starting with the tryptophan, as it is the most bulky of the three residues.   
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5.2 Mutation of conserved transmembrane basic residues 
in GPR43 
Three GPR43 mutants were generated in which the conserved transmembrane basic amino 
acids that are implicated in the coordination of the carboxyl group of the fatty acid were 
mutated to alanine in the GPR43-eYFP fusion protein.  Each of the mutants was tested for 
its ability to mediate a rise in [Ca2+]i in single cells in response to 10mM acetate, butyrate 
or propionate (Figure 5.5).  To each of the short chain fatty acids tested, wild type GPR43 
produced a rapid, transient increase in [Ca2+]i.  The mutant with the TM2 lysine mutated to 
alanine, GPR43 Lys65Ala-eYFP, was able to produce a transient rise in [Ca2+]i when 
challenged with acetate or propionate but when exposed to butyrate no change in [Ca2+]i  
was observed.  Mutation of the histidine in TM4 to alanine to produce GPR43 His140Ala-
eYFP, was found to have no significant effect on the function of the receptor, with a 
similar rise in [Ca2+]i as observed with the wild type receptor to all three fatty acids tested.  
The mutation of the TM5 arginine to generate, GPR43 Arg180Ala-eYFP, resulted in a 
complete loss of function of the receptor to any of the short chain fatty acids tested.  
However, expression of the receptor was confirmed by eYFP fluorescence (see Figure 5.9).   
To further investigate the role of the TM5 arginine, three additional mutants were 
generated with lysine (GPR43 Arg180Lys), leucine (GPR43 Arg180Leu) or serine (GPR43 
Arg180Ser) in place of arginine at position 180 in GPR43-eYFP  When transiently 
expressed in HEK293T cells, expression of each of the mutants was confirmed by eYFP 
fluorescence (Figure 5.9).  Challenge of cells expressing the mutant receptors with acetate 
or propionate resulted in no change in [Ca2+]i (Figure 5.6).  Replacement of the arginine 
with another positively charged amino acid does not restore function to the receptor as 
GPR43 Arg180Lys-eYFP was still unable to respond to either of the short chain fatty acids 
tested.  Without the availability of assays to directly monitor the binding of the fatty acid to 
the receptor it is impossible to determine if the fatty acid is actually binding the mutant 
receptor.  The data, therefore, indicates that the arginine in TM5 of GPR43 plays a key role 
in fatty acid mediated activation of GPR43. 
As shown in Figure 5.5, GPR43 Lys65Ala was unable to mediate a rise in [Ca2+]i when 
challenged with butyrate but still retained the ability to respond to acetate or propionate.  
Expression of the mutant receptor could be confirmed by visualization of receptor but to 
further investigate the function of the mutant cells were challenged sequentially with 
butyrate then acetate or propionate (Figure 5.7).  When challenged sequentially in this way, 
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GPR43 Lys65Ala was still able to respond to acetate or propionate.  The sequential addition 
of the fatty acids demonstrates GPR43 Lys65Ala has lost the ability to respond to butyrate 
but not to acetate or propionate.  It is therefore unlikely that Lys65 is a charge partner for 
the carboxylic acid head group of the fatty acid due to this specific loss of function to 
butyrate.   
In order to investigate the potency of various fatty acids at the GPR43 mutants generated, a 
FLIPR based Ca2+ mobilization assay was employed.  As detailed in Chapter 3, HEK293 
MSRII cells were transiently co-transfected to express GPR43-eYFP or one of the GPR43 
mutant-eYFP fusions and a G protein cocktail, challenged with increasing concentrations 
of various chain length fatty acids and the change in fluorescence of the Ca2+ dye Fluo-4 
monitored.  Table 5.1 shows the potencies of short chain fatty acids at the GPR43 mutants.  
As anticipated from the single cell Ca2+ experiments, none of the Arg180 mutants were able 
to respond to any of the fatty acids tested at any concentration.  Carbachol was added to 
cells expressing the mutant receptors to confirm the viability of the cells, and in all cases a 
robust rise in [Ca2+]i was seen upon the addition of this agonist.  With cells transfected to 
express GPR43 Lys65Ala, no rise in [Ca2+]i could be observed on the addition of any of the 
fatty acids.  This could be due to the reduced sensitivity of a FLIPR based assay compared 
to a single cell assay as in the single cell Ca2+ assays GPR43 Lys65Ala did display a 
reduced ability to mediate a rise in [Ca2+]i compared to the wild type receptor.   
GPR43 His140Ala displayed a loss of function towards formate but as this is a very low 
potency agonist at the wild type receptor any small change in the binding site is likely to be 
more apparent.  This mutant also showed a significantly reduced potency towards acetate.  
As each of the mutants were tested against a panel of fatty acids with variable chain length, 
it was shown that GPR43 His140Ala-eYFP was now able to mediate a rise in [Ca2+]i when 
exposed to caproic acid or caprylic acid (Figure 5.8), which have carbon chain lengths of 6 
and 7 respectively.  The pEC50 of caproic acid was 4.8±0.3 and for caprylic acid it was 
4.8±0.4.  These data suggests that GPR43 His140Ala has increased affinity for longer chain 
fatty acids compared to the wild type receptor. This gain of function was not examined in 
the single cell [Ca2+]i assay due to time constrains of the project.   
Figure 5.9 shows that compared to the wild type receptor there was no obvious difference 
between the expression levels or expression pattern of any of the mutants. The wild type 
receptor did not appear to be effectively targeted to the cell surface in such transient assays 
which makes observations on the possible effects on trafficking of the mutant receptors 
hard to determine.   
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5.3 Mutation of conserved transmembrane basic residues 
in GPR41 
GPR41 also contains three basic transmembrane residues.  To investigate their role in the 
function of GPR41, initially each of the residues in the receptor-eYFP fusion protein was 
mutated to alanine.  To assess their function, each of the mutants was transiently co-
transfected with GαqG66Di5 into HEK293T cells and their ability to mediate a rise in [Ca
2+]i 
in response to short chain fatty acids monitored (see Figure 3.3).  Figure 5.10 shows the 
response each of the GPR41 mutants generated when challenged with butyrate or 
propionate.  As with GPR43, mutation of the TM5 arginine in GPR41 to produce, GPR41 
Arg185Ala-eYFP, resulted in a receptor unable to respond to 10mM butyrate or propionate, 
again supporting the theory that the arginine in TM5 acts as a charge partner for the 
carboxyl group of the fatty acid.  GPR41 His146Ala-eYFP displayed similar ability as the 
wild type receptor to respond to both of the fatty acids tested, which indicates that it does 
not play a critical role in co-ordinating the fatty acid.  GPR41 Arg71Ala-eYFP was also 
able to respond to butyrate with similar kinetics to the response generated by the wild type 
receptor.  Whereas, when the mutant was challenged with propionate, the magnitude of the 
response was reduced compared to the wild type receptor.   
Attempts were made to develop a FLIPR-based assay with GPR41 to allow the potencies 
of fatty acids to be determined at the GPR41 mutants.  Even when co-transfecting GPR41-
eYFP with GαqG66Di5 or a G protein cocktail containing various G protein chimeras, no 
signal was generated by the wild type receptor that could be detected by the FLIPR in 
response to any of the fatty acids tested.  In the single cell Ca2+ assay the signal generated 
by GPR41 when co-transfected with GαqG66Di5 was relatively small and when using the 
FLIPR apparatus to measure the changes in [Ca2+]i, the signal may be below the threshold 
of detection.  Therefore, to investigate the potency of propionate at the GPR41 mutants, the 
mutations were incorporated into the GPR41-Gαi3 Cys
351Ile fusion protein (described in 
Figure 3.1) and concentration response curves were generated using the [35S]GTPγS 
binding assay (Figure 5.11a).  As shown in Chapter 3, the GPR41-Gαi3 Cys
351Ile fusion 
protein produced a robust concentration-response curve to propionate.  The incorporation 
of the His146Ala into the GPR41-Gαi3 Cys
351Ile fusion protein had little effect on the ability 
of the receptor to increase [35S]GTPγS binding in a concentration-dependent manner and 
the potency of propionate remained unchanged (Table 5.2).  When the Arg71Ala mutation 
was introduced into the GPR41-Gαi3 Cys
351Ile fusion protein a much larger effect was 
observed, with only a very small increase in [35S]GTPγS binding in response to increasing 
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concentrations of propionate observed and to be able to see the increase in binding a 
reduced scale had to be utilised (Figure 5.11b).  The potency of propionate at this mutant 
receptor was significantly reduced compared to that at the wild type receptor (Table 5.2).  
As predicted from the data obtained in the single cell Ca2+ experiments, the introduction of 
the Arg185Ala mutation into the fusion protein resulted in no increase in [35S]GTPγS 
binding upon the addition of increasing concentrations of propionate.   
Like GPR43, transiently expressed GPR41-eYFP was not very well plasma membrane 
delineated (Figure 5.12).  Figure 5.12 confirms that the GPR41 mutants express in a 
similar fashion to the wild type receptor although it is hard to determine if the mutant 
receptors are found at the cell surface.  
5.4 Mutation of conserved basic transmembrane residues 
in GPR40 
To investigate the importance of each of the basic transmembrane residues in the function 
of GPR40, each of the residues were mutated to alanine in a GPR40-eYFP fusion protein 
using the Stratagene QuikChange method.  The mutant receptors were transiently 
transfected into HEK293T cells and their ability to mediate a rise in [Ca2+]i in response to 
lauric acid monitored.  As shown in Figure 3.11, GPR40-eYFP is able to generate a rapid 
and transient rise in [Ca2+]i in response to the addition of 100µM lauric acid (Figure 5.13).  
The mutation of Lys62 to Ala resulted in a slight slowing of the kinetics of the mobilisation 
signal compared to the wild type receptor.  The GPR40 His137Ala-eYFP mutant was not as 
efficacious as the wild type receptor in the mediation of a release of [Ca2+]i in response to 
lauric acid, with a smaller increase in [Ca2+]i recorded.  Unlike GPR41 and GPR43, the 
mutation of the TM5 Arg in GPR40 did not result in complete loss of function of the 
receptor towards a fatty acid.  GPR40 Arg183Ala-eYFP still retained the ability to increase 
[Ca2+]i upon the addition of lauric acid, although the signal was reduced compared to the 
wild type receptor.   
As there are a large number of compounds that activate GPR40, to fully characterize the 
function of each of the mutants the high throughput FLIPR-based Ca2+ assay was utilised.  
Each of the mutants was transiently transfected into HEK293 MSRII cells, exposed to 
increasing concentrations of the test compound and changes in Fluo-4 fluorescence 
monitored.  Using this method, potencies of a range of fatty acids (Table 5.3), small 
molecule agonists and thiazolidinediones (Table 5.4) could be ascribed to each of the 
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mutants.  All of the mutants were able to respond to a range of fatty acids.  As expected 
from the single cell Ca2+ experiments, GPR40 Arg183Ala was able to respond to lauric acid 
and could also respond to the majority of fatty acids tested apart from caproic acid, 
palmitic acid and elaidic acid.  Only some of the fatty acids (linolenic acid, linoleic acid 
and retinoic acid) showed a reduced potency at GPR40 Arg183Ala.  Of the saturated fatty 
acids tested, GPR43 His140Ala was only able to respond to lauric acid and palmitic acid.  In 
addition to this, many of the unsaturated fatty acids showed reduced potency at this mutant 
receptor.  GPR40 Lys62Ala was able to respond to all of the fatty acids tested, apart from 
caproic acid (which is one of the least potent of the fatty acids at the wild type receptor) 
and capric acid.  Although, GPR40 Lys62Ala was still able to respond to the fatty acids, a 
significant reduction in potency was recorded for many of the unsaturated fatty acids.  The 
most marked difference observed with these GPR40 mutants was seen upon the addition of 
the small molecule agonists or thiazolidinediones (Table 5.4).  GPR40 His137Ala and 
GPR40 Arg183Ala were unable to mediate a rise in [Ca2+]i on the addition of any of the 
small molecule agonists or thiazolidinediones.  GPR40 Lys62Ala showed a reduced 
potency towards two of the small molecule agonists, GW839508X and GSK250089A, and 
was unable to respond to GSK223112A or either of the thiazolidinediones.  All the mutants 
were also tested against short chain fatty acids, ciglitazone, pioglitazone, GSK272235A 
and GSK269778A and no rise in [Ca2+]i was seen upon the addition of any of these 
compounds.   
To confirm the observations on the function of the GPR40 mutants, the Lys62Ala and 
Arg183Ala mutations were incorporated into the GPR40-Gαq fusion protein (see section 
3.4).  Using the receptor-G protein fusion allows monitoring of the activation event further 
upstream in the cascade than Ca2+ release.  The two GPR40-Gαq mutants and the wild type 
receptor-Gαq fusion were transiently transfected into HEK293T cells and [
35S]GTPγS 
binding studies performed on the resulting membranes.  Firstly, the effect of fatty acid free 
BSA on the basal loading of [35S]GTPγS onto the GPR40-G protein fusions was assessed 
(Figure 5.14).  As shown in Chapter 3, the basal loading of [35S]GTPγS onto GPR40-Gαq is 
very high and this can be reduced by the addition of 10µM fatty acid free BSA.  Both 
GPR40 Lys62Ala-Gαq and GPR40 Arg
183Ala-Gαq also displayed this property, indicating 
that the mutant receptors still display apparent high constitutive activity and are therefore 
functional with respect to G protein activation by GPR40.  To confirm the functionality of 
the mutant receptors, concentrations response curves were generated to three GPR40 
agonists; a fatty acid (palmitic acid), a thiazolidinedione (troglitazone) and a small 
molecule agonist (GSK250089A) (Figure 5.15).  Palmitic acid was able to increase 
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[35S]GTPγS binding in both GPR40 Lys62Ala-Gαq and GPR40 Arg
183Ala-Gαq, although a 
reduction in potency was observed at GPR40 Arg183Ala-Gαq.  This supports the previous 
data that Arg183 in GPR40 is not absolutely required for fatty acid binding and activation of 
the receptor.  As expected from the FLIPR data, GSK250089A was unable to activate 
GPR40 Arg183Ala-Gαq and GPR40 Lys
62Ala-Gαq displayed a significantly reduced 
potency towards this agonist.  Although it appears that GSK250089A is more efficacious at 
GPR40 Lys62Ala-Gαq than the wild type receptor, this may be due to the larger reduction 
in basal [35S]GTPγS binding seen upon the addition of fatty acid free BSA and the levels of 
[35S]GTPγS binding at GPR40 Lys62Ala-Gαq in the presence of GSK250089A did not 
increase above the levels seen in the absence of fatty acid free BSA.  Troglitazone was also 
able to increase [35S]GTPγS binding in a concentration-dependent manner at GPR40 
Lys62Ala-Gαq but it showed no activity at GPR40 Arg
183Ala-Gαq.  All the [
35S]GTPγS 
binding studies were performed in the presence of 10µM fatty acid free BSA to reduce the 
basal loading of [35S]GTPγS onto the receptors.  It is worth noting, that as with the wild 
type GPR40-Gαq fusion, none of the agonists were able to increase the levels of 
[35S]GTPγS binding above the levels of basal loading in the absence of fatty acid free BSA 
at  GPR40 Lys62Ala-Gαq or GPR40 Arg
183Ala-Gαq.   
To determine the expression pattern of these GPR40 mutants, cells transiently expressing 
the receptor-eYFP fusion proteins were visualised.  Compared to GPR41 and GPR43, the 
GPR40 wild type receptor was more membrane delineated (Figure 5.16).  The mutant 
receptors appeared to be expressed in a similar pattern to the wild type receptor, with no 
obvious change in cell surface expression seen.  
Unlike GPR41 and GPR43, mutation of the arginine in TM5 of GPR40 did not result in the 
loss of the ability of fatty acids to activate the receptor.  To determine if a second amino 
acid residue may compensate for the loss of the TM5 basic residues, three double mutants 
were generated in which two of the basic transmembrane residues were substituted for 
alanine; GPR40 Lys62Ala, His137Ala, GPR40 Lys62Ala, Arg183Ala and GPR40 His137Ala, 
Arg183Ala.  These mutations were introduced into the GPR40-eYFP fusion protein, 
transiently transfected into HEK293T cells and their ability to mediate a rise in [Ca2+]i in 
response to lauric acid monitored (Figure 5.17).  All three double GPR40 mutants were 
able to mediate a rise in [Ca2+]i upon the addition of 100µM lauric acid.  GPR40 Lys
62Ala, 
His137Ala-eYFP was able to mediate a large, transient rise in [Ca2+]i which was very 
similar to that generated by the wild type receptor, although a slight reduction in the 
maximal signal was observed.  GPR40 His137Ala, Arg183Ala-eYFP also displayed similar 
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properties to the wild type receptor in its ability to mediate a change in [Ca2+]i but the 
efficacy of the signal was markedly reduced compared to the wild type receptor.  The 
double mutant which showed the most difference in the response to lauric acid was GPR40 
Lys62Ala, Arg183Ala-eYFP, with a slower and reduced response to lauric acid than GPR40-
eYFP. 
To have a greater understanding of the function of these mutants, potencies of a range of 
compounds were determined as described for the initial GPR40 mutants using a FLIPR 
based Ca2+ assay.  Table 5.6 shows the potencies determined for a range of fatty acids at all 
three of the GPR40 double mutants.  Each of the mutants was able to respond to at least 
some of the fatty acids tested.  GPR40 Lys62Ala, His137Ala was able to respond to all of the 
saturated fatty acids tested, expect caproic acid.  Of the eight unsaturated fatty acids tested, 
GPR40 Lys62Ala, His137Ala retained the ability to respond to six of them apart from 
palmitoleic acid and elaidic acid.  Of the six unsaturated fatty acids that could activate this 
mutant receptor, three displayed a reduced potency in comparison to the wild type 
receptor; these being linolenic acid, linoleic acid and arachidonic acid.  For GPR40 
Lys62Ala, Arg183Ala, similar findings were recorded with the receptor displaying a degree 
of potency for the majority of fatty acids tested.  Only caproic acid, capric acid and retinoic 
acid were unable to activate this mutant receptor.  A significant shift in potency was also 
observed for three more fatty acids; caprylic acid, linolenic acid and linoleic acid.  The 
small effects on the potencies of fatty acids at GPR40 Lys62Ala, His137Ala and GPR40 
Lys62Ala, Arg183Ala were contrasted by the loss of ability of GPR40 His137Ala, Arg183Ala 
to respond to many of the fatty acid tested.  This double mutant, GPR40 His137Ala, 
Arg183Ala, was unable to mediate a rise in [Ca2+]i when challenged with any of the 
saturated fatty acid tested.  In addition to this loss of potency of saturated fatty acids, four 
of the eight unsaturated fatty acids were also unable activate this mutant.  Only linolenic 
acid, γ-linolenic acid, linoleic acid and docosapentaenoic acid were able to activate GPR40 
His137Ala, Arg183Ala and their potencies remained unchanged compared to the wild type 
receptor.   
The three double GPR40 mutants generated were also tested for their ability to mediate a 
rise in [Ca2+]i in response to thiazolidinediones and small molecule agonists.  These 
compounds were tested in a FLIPR-based Ca2+ assay on HEK293 MSRII cells transiently 
expressing the wild type or mutant receptor and potencies ascribed accordingly (Table 5.7).  
Unlike the GPR40 mutants where only one of the basic transmembrane residues was 
mutated and neither of the thiazolidinediones were able to activate them, two of the GPR40 
double mutant, GPR40 Lys62Ala, His137Ala and GPR40 Lys62Ala, Arg183Ala, retained the 
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ability to mediate a rise in [Ca2+]i when challenged with rosiglitazone.  The potencies 
recorded were not significantly different to that seen at the wild type receptor.  GPR40 
His137Ala, Arg183Ala was unable to produce a change in levels of [Ca2+]i in response to the 
addition of rosiglitazone.  Although GPR40 Lys62Ala, His137Ala and GPR40 Lys62Ala, 
Arg183Ala possessed the ability to respond to rosiglitazone, all three GPR40 double 
mutants were inactive when challenged with the related compound troglitazone.  The 
single mutant, GPR40 Lys62Ala was shown to maintain the ability to respond to two of the 
small molecule agonists, GW839508X and GSK250089A.  The introduction of the 
His137Ala mutation into GPR40 Lys62Ala did not abolish this response, although a 
reduction in potency was also observed to both of these compounds.  In addition, when 
Arg183 was mutated to Ala in GPR40 Lys62Ala the double mutant was no longer able to be 
activated by GSK250089A and a further reduction in potency of GW839508X recorded.  
Alternatively, it could be that the incorporation of the Lys62Ala to either the GPR40 
His137Ala or the GPR40 Arg183Ala mutant restored the ability to respond to GW839508X 
and in the case of GPR40 Lys62Ala, His137Ala also, GSK250089A.  None of the double 
mutants were able to mediate a rise in [Ca2+]i when exposed to GSK223112A.  In addition 
to the fatty acids, thiazolidinediones and small molecule agonists mentioned, the double 
mutants were also tested against short chain fatty acids, pioglitazone, ciglitazone, 
GSK272235A and GSK269778A but no change in [Ca2+]i was measured in cells 
transiently expressing the GPR40 double mutants.   
The expression pattern of the GPR40 double mutants was compared to the wild type 
receptor by visualisation of eYFP fluorescence in cells transiently expressing the receptor 
of interest (Figure 5.18).  GPR40 Lys62Ala, Arg183Ala-eYFP express in a similar fashion to 
the wild type receptor, with the receptor apparently expressed at the cell surface.  GPR40 
Lys62Ala, His137Ala and GPR40 His137Ala, Arg183Ala do not appear to be as well expressed 
at the plasma membrane as the wild type receptor.  
5.5 Mutation of the region implicated in fatty acid chain 
length selectivity in GPR40 and GPR43 
As detailed in section 5.1, there is a region in TM3 of GPR40 and GPR43 that may be 
important in determining the chain length of the fatty acids that can activate each of the 
receptors.  To investigate this, initially the glycine triplet in GPR40 was mutated to code 
for Ser, Thr, Trp which is the corresponding region of GPR43, in the GPR40-eYFP fusion 
protein.  To start to determine the fatty acids that could activate this receptor, the mutant, 
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GPR40 GGG93-95STW, was transiently expressed in HEK293T cells and tested for its 
ability to mediate a rise in [Ca2+]i in single cells in response to three long chain fatty acids; 
palmitic acid (C16:0), lauric acid (C12:0) and oleic acid (C18:1) (Figure 5.19 (a-c)).  As 
expected, wild type GPR40-eYFP was able to produce a large, transient rise in [Ca2+]i upon 
the addition of the specified long chain fatty acid.  The mutant, GPR40 GGG93-95STW-
eYFP, showed little difference in its response to oleic acid or lauric acid, showing that it 
can still respond to long chain fatty acids.  In contrast, the response to palmitic acid was 
greatly reduced compared to the wild type receptor, with only a very small change in 
[Ca2+]i mediated by GPR40 GGG
93-95STW-eYFP in response to the addition of 100µM 
palmitic acid.  When investigating the ability of the mutant to respond to the short chain 
fatty acid propionate, it was found that 12% of positively tranfected cells expressing 
GPR40-eYFP possessed the ability to generate a small release of [Ca2+]i upon the addition 
of 10mM propionate (Figure 5.19 (d)).  The GPR40 GGG93-95STW mutant produced a 
larger increase in [Ca2+]i compared to the wild type receptor and the number of cells 
producing a rise in [Ca2+]i greatly increased, with 38% of cells expressing GPR40 GGG
93-
95STW-eYFP responding to propionate.  A bigger separation between the wild type GPR40 
receptor and the GPR40 GGG93-95STW mutant was seen when investigating their ability to 
respond to acetate (Figure 5.20).  None of the imaged cells expressing GPR40-eYFP 
generated a signal in response the addition of 10mM acetate, whereas in 35 cells 
expressing GPR40 GGG93-95STW-eYFP a change in [Ca2+]i levels was observed.  
Expression of GPR40 GGG93-95STW was confirmed by visualisation of eYFP fluorescence 
in cells transiently expressing the receptor (Figure 5.21)  
As the residues in TM3 of GPR40 were replaced by those in the corresponding region of 
GPR43, it was necessary to generate the equivalent mutations in GPR43.  The region 
coding for the Ser, Thr, Trp triplet in GPR43 was not suitable for mutation to three Gly 
using the Stratagene mutagenesis approach.  To overcome this, each residue was mutated 
in turn to Gly, starting with the most bulky residue, Trp in the GPR43-eYFP fusion 
protein.  This gave three GPR43 mutants; GPR43 Trp98Gly, GPR43 Thr97Gly, Trp98Gly, 
and GPR43 Ser, Thr, Trp96-98Gly, Gly, Gly.  To investigate the fatty acid chain length 
selectivity of these mutants and to further investigate the fatty acids that could activate 
GPR40 GGG93-95STW, the FLIPR based Ca2+ assay was used to test a number of long and 
short chain fatty acids for their ability to mediate a rise in [Ca2+]i (Table 5.8).  Unlike in the 
single cell Ca2+ mobilization assay, short chain fatty acids were unable to activate GPR40 
GGG93-95STW-eYFP.  Of the medium and long chain fatty acids tested, caproic acid, 
palmitic acid, palmitoleic acid, elaidic acid and retinoic acid were unable to mediate a rise 
in [Ca2+]i in cells expressing GPR40 GGG
93-95STW-eYFP.  The majority of the fatty acids 
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tested were able to activate this GPR40 mutant, with linoleic acid, linolenic acid and 
docosapentaenoic acid showing a reduced potency compared to the wild type receptor.  
Docosapentaenoic acid (C22:5) was the longest chain length fatty acid tested against this 
mutant and for it to activate the receptor, albeit with a reduced potency, indicates that this 
region does not confer all the chain length specificity of GPR40.  In addition to the fatty 
acids, the thiazolidinediones and small molecule agonists were also tested against GPR40 
GGG93-95STW-eYFP and none of these compounds were able to mediate a change in 
[Ca2+]i levels via this mutant.   
The GPR43 mutants showed a bigger change in the chain length of fatty acids that could 
activate them (Table 5.8).  GPR43 Trp98Gly-eYFP still retained the ability to mediate a rise 
in [Ca2+]i in response to acetate and propionate but a change in [Ca
2+]i was also recorded 
upon the addition of linolenic acid, γ-linolenic acid, linoleic acid and docosapentaenoic 
acid.  Each of these longer chain fatty acids were of similar potency at GPR43 Trp98Gly-
eYFP than at GPR40.  Further mutation of the TM3 triplet, Thr97Gly, Trp98Gly, resulted in 
none of the short chain fatty acids being able to mediate a change in [Ca2+]i in cells 
expressing GPR43 Thr97Gly, Trp98Gly-eYFP.  But now upon the addition of three of the 
long chain fatty acids, a change in [Ca2+]i was detected and potencies could be determined 
for myristic acid, palmitoleic acid and elaidic acid.  Replacement of the Ser, Thr, Trp 
triplet of GPR43 with three Gly was very detrimental to the receptors ability to respond to 
any of the fatty acids tested.  Only elaidic acid was now able to mediate a rise in [Ca2+]i in 
cells expressing GPR43 Ser, Thr, Trp96-98Gly, Gly, Gly, with all other fatty acids seen as 
inactive.  None of GPR43 TM3 mutants were able to respond to any of the 
thiazolidinediones or GPR40 small molecule agonists.   
5.6 Discussion 
GPR40, GPR41 and GPR43 have been shown to be activated by fatty acids of varying 
chain length.  It is thought that a carboxylate group is required for activation of GPR40 as 
Itoh et al., (2003) showed that methyl linolate was unable to activate the receptor.  
Sequence alignment and homology modelling of GPR40, GPR41 and GPR43 identified 
residues within TM regions that were predicted to potentially play a role in binding the 
carboxylate group of an activating fatty acid.  The residue proposed to play an important 
role in binding of fatty acids was a conserved Arg in TM5 (5.39) of all three receptor.  
Sequence alignment identified two further conserved residues that had the potential to form 
ionic interactions with the fatty acid; an Arg or Lys in TM2 (2.60) and a His in TM4 
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(4.56).  To establish their relative importance, a series of mutations were introduced into 
all three receptors and their function assessed. 
Removing the charge in TM5 of GPR41 and GPR43 by mutating the arginine to alanine 
abolished the ability of both receptors to generate a signal in response to short chain fatty 
acids.  Conservation of the charge in GPR43 by inserting a Lys in place of the Arg also 
generated a receptor that was unable to respond to short chain fatty acids.  The loss of 
function of the GPR43 TM5 mutants was assessed in the single cell Ca2+ mobilization 
assay and in the FLIPR based Ca2+ assay.  For GPR41, the inability of the TM5 mutant to 
respond to fatty acids was confirmed in the single cell Ca2+ mobilization assay and a 
[35S]GTPγS binding assay.  This indicates that in GPR41 and GPR43, the conserved Arg in 
TM5 is absolutely necessary to allow activation of the receptor by fatty acid.   
The requirement of a positively charged residue has been observed in other GPCRs whose 
ligands contain carboxylate groups.  These include the high affinity nicotinic acid receptor, 
HM74A, in which Tunaru et al. (2005) demonstrated that an Arg in TM3 (3.35) of the 
receptor was absolutely required for binding of nicotinic acid and the human prostacyclin 
receptor in which the mutation of an Arg in TM7 (7.44) to Ala prevented binding of a 
synthetic agonist (Stitham et al., 2003).  The requirement of positively charged residues to 
bind a carboxyl containing ligand was also observed for the receptor for succinate, GPR91.  
In GPR91, four positively charged residues are required for activation of the receptor, with 
an Arg (3.29) and His (3.33) in TM3 and an Arg in both TM6 (6.55) and 7 (7.49) proposed 
to bind the dicarboxylate groups of succinate (He et al., 2004).   
Although the Arg in TM5 is conserved in GPR40, GPR41 and GPR43, unlike in GPR41 
and GPR43 it is not a requirement to allow fatty acid activation of GPR40.  Replacement 
of the Arg in TM5 of GPR40 with Ala gave a mutant receptor that was still able to respond 
to a range of fatty acids.  In the range of fatty acids that were tested against this receptor, 
differing effects were observed, with a reduction in potency observed with some fatty 
acids, no change in potency detected for others and for three fatty acids a complete loss of 
potency recorded.  In contrast to the ability of this mutant to respond to certain fatty acids, 
none of the thiazolidinediones or small molecule agonists were able to activate the mutant.  
The additional mutation of the His in TM4 of GPR40 resulted in a receptor that was unable 
to respond to the range of saturated fatty acids tested and only retained the ability to 
respond to certain unsaturated fatty acids.  However, the introduction of the Lys62  to Ala 
mutation into GPR40 Arg183Ala, appeared to restore the ability of the receptor to respond 
to some of the fatty acids and synthetic agonists.  This suggests that there are other 
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residues important in the binding of agonists to GPR40 and its subsequent activation.  This 
is similar to the finding by Sabirsh et al. (2006) on BLT1, whereby an Arg in TM5 (5.35) 
was shown to be important in binding the carboxyl group of leukotriene B4 but not 
essential.  It was found that the Arg in TM5 of BLT1 along with a Glu (5.42) were likely to 
bind the hydroxyl group in the ligand rather than the carboxyl head group.  The recent 
description of a range of small molecule agonists at GPR40 found that a carboxyl group 
was not required (Garrido et al., 2006), although this was not confirmed in this study (see 
Chapter 4).  Therefore, the results from the mutation of the TM5 Arg in GPR40 are not 
entirely unexpected when this is taken into consideration. 
Many studies have shown that for most small molecule receptors, such as those for the 
biogenic amines, the binding sites are contained in a binding crevice formed by the TM 
helices.  The TM helices that make up the binding sites are TM 3, 4, 5, 6 and 7 (Ji et al., 
1998; Gether, 2000; Shi and Javitch et al., 2002; Stenkamp et al.,2002).  Within the 
biogenic amine receptors, an aspartic acid residue in TM3 (3.32)is conserved and it has 
been proposed to interact with the positively charged head groups of the ligands for the 
adrenergic receptors (Strader et al., 1991), dopamine receptors (Mansour el al., 1992), 
histamine receptors (Gantz et al., 1992) and muscarinic acetylcholine receptors (Spalding 
et al., 1994).  It is starting to appear that receptors for ligands containing a carboxylate 
group have a similar requirement for a charged residue, but unlike the biogenic amine 
receptors it not conserved within a specific TM region.   
Without the availability of a ligand binding assay for GPR40, GPR41 or GPR43, it is 
impossible to say if the fatty acids or synthetic ligands are binding the mutant receptors.  It 
may be that they bind the mutant receptors but the receptor is no longer able to translate 
the binding of a ligand into a signal or that the mutant receptors can no longer bind the 
ligand.  Therefore, the results of the mutagenesis studies can only indicate that a residue is 
required or important for activation rather than ligand binding.   
To confirm the importance of the TM5 Arg in fatty acid mediated activation of GPR41 and 
GPR43, it was necessary to investigate the role of the other conserved TM basic residues.  
It was found that upon mutation of the TM4 His to Ala in GPR41 and GPR43, the mutant 
receptors responded to short chain fatty acids in a manner similar to the wild type receptor.  
By determining potencies of short chain fatty acids at GPR43 His140Ala using the FLIPR 
based Ca2+ mobilization assay, it was found that the potency of propionate was reduced but 
in addition, the mutant was now capable of responding to two medium chain fatty acids, 
caproic and caprylic acid.  The reduction in potency of short chain fatty acids and gain of 
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potency for medium chain fatty acids at this mutant taken together indicates that this 
residue of GPR43 may play a role in fatty acid chain length selectivity.  This alteration in 
fatty acid chain length selectivity was not investigated in the equivalent GPR41 mutant due 
to time constraints, although no reduction in potency of propionate was observed in the 
[35S]GTPγS binding assay.  The effects of mutating the TM4 His in GPR41 and GPR43, 
was not entirely mirrored by the equivalent mutation in GPR40.  When examining the 
potencies of a range of fatty acids, it was found that GPR40 His137Ala was unable to 
respond to some of the long chain fatty acids tested.  Interestingly, no response was 
observed upon challenge of the mutant receptor with the three shortest chain length fatty 
acids that were able to activate the wild type receptor, which again may suggest that this 
TM region may play a role in chain length selectivity.  It may be that upon the mutation of 
the Arg in TM5 of GPR40, His137 compensates for the loss of charge and vice versa, as in 
the model of GPR40 both His137 and Arg183 are found within the putative binding pocket 
for fatty acids as demonstrated by Figure 5.2.  In addition to the loss of potency for some 
fatty acids, GPR40 His137Ala was unable to respond to any of the synthetic agonists tested.  
This supports the observation that a series of residues are likely important in the activation 
of GPR40 by fatty acids.   
From the models of GPR43 and GPR40, the TM2 positively charged residue that is 
conserved in the family was not predicted to act as a charge partner for the carboxylate 
containing ligands.  Therefore, the function of the GPR41 and GPR43 mutants, where the 
Lys or Arg was replaced by Ala, was unexpected.  In the single cell Ca2+ assay it was 
found that both GPR41 and GPR43 TM2 mutants were not as efficacious as the wild type 
receptors in the mobilization of [Ca2+]i.  In the FLIPR based Ca
2+ mobilization assay, 
GPR43 Lys65Ala was unable to generate a large enough rise in [Ca2+]i for it to be measured 
by the FLIPR, therefore potencies against fatty acids could not be determined.  The only 
potency data for this mutation in GPR41 or GPR43 was generated using the GPR41-Gαi3 
Cys351Ile fusion protein containing the Arg71Ala mutation.  Using this fusion protein, the 
potency of propionate was shown to be reduced at this mutant and it appeared to be much 
less efficacious in its ability to increase [35S]GTPγS binding, although the relative amounts 
of each receptor were not monitored.  For GPR43 Lys65Ala, the most striking difference 
from the wild type receptor was its inability to mediate a rise in [Ca2+]i in response to 
butyrate.  In the single cell Ca2+ experiments it was shown that the mutant receptor when 
challenged with butyrate was unable to generate a rise in [Ca2+]i but the same cells still 
retained the ability to mediate a rise in [Ca2+]i when challenged with acetate or propionate.  
This demonstrates that the Lys is not providing a charge partner for the carboxylic acid.  It 
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is possible that butyrate may now act as an antagonist at GPR43 Lys65Ala but as the mutant 
was unable to generate a signal in the FLIPR based assay this was difficult to assess.  As 
shown in Figure 5.3, the Lys/Arg in TM2 was predicted on the basis of homology models 
to not be available to co-ordinate the carboxylate group of the fatty acids.  It is possible 
that mutation of this residue affects the receptors trafficking to the cell surface but this is 
hard to determine from the visualisation of eYFP fluorescence.  Further work would have 
to be carried out to determine their cell surface expression in comparison to the wild type 
receptor.  The models of GPR41 and GPR43 are homology models based on the crystal 
structure of rhodopsin.  It is possible that this is one of the regions of the receptors that 
may differ considerably between family A receptors and may be more exposed to the 
proposed binding site than predicted from the model.     
GPR42 is a non-functional pseudo-gene which shares 98% homology with GPR41, and 
only differs by six residues.  Brown et al., (2003) undertook a study to replace the residues 
in rat GPR41(rGPR41) with the corresponding residues in human GPR42.  They found that 
mutation of Arg170 in rGPR41 to Trp, which corresponds to position 174 in the human 
receptor, resulted in a receptor unable to respond to short chain fatty acids.  They 
suggested that this residue may form a salt bridge with the carboxylate group of the fatty 
acids.  This residue is found in extracellular loop 2 and is unlikely to form the binding site 
for the receptor as the majority of small molecule family A GPCRs have the binding site 
within the transmembrane regions of the receptor.  Although it is though that GPR40-43 
act similarly to the small molecule GPCRs, other receptors within family A, such as opioid 
and chemokine receptors, have been shown to bind their ligands within their extracellular 
domains.  In addition to this proposed role for residues in extracellular regions for ligand 
binding, the crystal structure of rhopdopsin revealed that extracellular loops form a 
compact lid that enclose the covalently bound retinal and some of these residues, especially 
residues in extracellular loop 2, are in close contact with the retinal molecule (Palczewski 
et al., 2000).  Further studies will need to be carried out to determine the role of this 
residue within GPR41.  Figure 5.22 shows the positions of the residues that differ between 
GPR41 and GPR42 and none of the residues are found around the proposed ligand binding 
site of GPR41.  
The mutation of the TM2 Lys in GPR40 also effected the receptor’s function but not to as 
large as an extent than in GPR41 and GPR43.  Using the FLIPR based assay the potencies 
of a range of fatty acid and synthetic ligands were determined at GPR40 Lys62Ala-YFP.  
Only two of the fatty acids were unable to activate this mutant although a reduction of 
potency was recorded for a large proportion of the fatty acids.  Unlike the two other 
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GPR40 single mutants, GPR40 Lys62Ala retained the ability to mediate a rise in [Ca2+]i in 
response to two of the small molecule agonists.  Using the [35S]GTPγS binding assay it 
was confirmed that the introduction of this mutation into the GPR40-Gαq fusion protein 
resulted in a receptor that was activated in a concentration dependent by GSK250089A 
albeit with a reduction in potency.  It was also found that troglitazone was able to activate 
this mutant.  The introduction of the Lys62Ala into the GPR40 His137Ala or GPR40 
Arg183Ala single mutants resulted in an apparent restoration of the some of the function of 
the single mutant receptors.  The large effect observed upon the mutation of both His137 
and Arg183 in GPR40 and the lesser effects seen upon the mutation of Lys62 along with 
either of these mutations supports the theory that His137 and Arg183 play a key role in the 
activation of the receptor.  In the model for GPR40 Lys62 is not shown to form part of the 
ligand binding domain and the mutagenesis studies go some way in supporting this.   
Considering all the data it appears that the residues important in activation of GPR41 and 
GPR43 by short chain fatty acids are similar, with the Arg in TM5 critical for activation of 
the receptors.  It also shows that the Arg or Lys in TM2 plays a role in activation of the 
receptor but it does not provide a charge partner for the carboxylate group of the fatty 
acids.  The data on GPR40 indicates a different model for ligand induced activation of the 
receptor.  The receptor does not required the TM5 Arg for activation by fatty acids and it is 
likely that there will be a scaffold of important residues in the ligand binding pocket that 
allow fatty acids to bind.  The His residue in TM4 appears to have a role within the binding 
pocket of the receptor and may affect the fatty acid chain length selectivity of the receptor.  
Unlike GPR41 and GPR43, the Lys in TM2 does not appear to play as large a role in 
GPR40.  The data on the GPR40 mutants also suggests that a more rigid binding pocket is 
required for activation by the small molecule agonists or thiazolidinediones, as both the 
His137Ala and Arg183Ala mutants were unable to respond to any of the synthetic agonists.   
The thiazolidinediones are established agonists of PPARγ but as shown by Kotarsky et al., 
(2003) and in this study, certain members of the family can act as agonists at GPR40.  
PPARγ can also be activated by fatty acids such as linoleic acid (Kliewer et al., 1997).  The 
structure of the ligand binding domain (LBD) of PPARγ has been extensively studied 
(Nolte et al., 1998, Uppenberg et al., 1998, Gamp et al., 2000, Lu et al., 2006).  The ligand 
binding site contained within the LBD is mainly hydrophobic.  X-ray crystallography 
studies on the LBD of PPARγ with rosiglitazone docked has shown that the ligand makes 
several specific interactions, including hydrogen bonding with two His residues (Nolte et 
al., 1998).  Tyr473 has also been shown to form hydrogen bonds with rosiglitazone (Lu et 
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al., 2006) and mutation of this residue results in the receptor being unable to respond to 
thiazolidinediones (Sarraf et al., 1999).  The His residues have been predicted to make 
interactions with the carboxylic head group of fatty acids ligand of PPARγ.  The 
hydrophobic chain of the fatty acid is likely to interact in a non-specific manner with the 
rest of the binding pocket (Nolte et al., 1998).  Tsukahara et al (2005) demonstrated that 
the residues important in binding of an analogue of lysophatidic acid (1-O-octadecenyl-2-
hydroxy-sn-glycer-3-phosphate) differed from those important in the binding of 
rosiglitazone.  The data on PPARγ demonstrates that the binding of synthetic ligands, such 
as the thiazolidinediones, is more specific than the binding of fatty acids.  This is similar to 
the finding with GPR40, as mutations that only slightly impair the receptors ability to 
respond to fatty acids (i.e. His137Ala and Arg183) render the receptor unable to respond to 
thiazolidinediones or small molecule agonists.  Figure 5.23 shows the position of two 
further residues, Tyr91 and Phe191, which are found in close proximity to the small 
molecule agonist when docked into GPR40.  They may play a role in stabilising the 
binding of an agonist into the receptor as they are close enough to interact with the small 
molecule agonist when co-ordinated by the Arg in TM5.  If the ligand binding properties of 
GPR40 and PPARγ are similar then they could act in a similar manner to Tyr473 of PPARγ 
and be critical in binding of a ligand and the activation of GPR40. 
The current study also aimed to address the possible determinants of fatty acid chain length 
selectivity of GPR40 and GPR43.  A triplet of residues in TM3 of both receptors was 
predicted from modelling to only allow long chain fatty acids to activate GPR40 and short 
chain fatty acids to activate GPR43.  Single cell Ca2+ mobilization experiment indicated 
that the GPR40 mutant in which its glycine triplet had been replaced by the equivalent 
region of GPR43 was now able to mediate a rise in [Ca2+]i in response to acetate.  It was 
found that the wild type receptor did possess some ability to mediate a rise in [Ca2+]i when 
challenged with propionate.  Stewart et al., (2006) showed that Xenopus oocytes 
expressing mouse GPR40 were able to generate a rise in [Ca2+]i measured by voltage 
clamp recordings in response to the addition of 500µM butyrate.  They also found that 
acetate or propionate were unable to generate a release of [Ca2+]i.  The increase in 
sensitivity of measuring [Ca2+]i release by voltage clamping, as with the single cell [Ca
2+]i 
assay utilised in this study, may expose the very slight ability of GPR40 to respond to short 
chain fatty acid that can not be observed using a FLIPR based Ca2+ release method or in a 
[35S]GTPγS binding study.  Butyrate was not tested in this study for its ability to mediate a 
rise in [Ca2+]i in single cells.  When attempting to confirm the change in fatty acid chain 
length selectivity in the FLIPR based Ca2+ release assay, no signal could be detected upon 
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the addition of any of the short chain fatty acids. It was therefore difficult to draw any 
conclusions about the change in fatty acid chain length selectivity of GPR40 GGG93-
95STW.  From the data on GPR40 GGG93-95STW from the single cell Ca2+ experiments, it 
is possible that acetate (or any of the other short chain fatty acids) may occupy the wild 
type receptor binding site but is unable to activate the receptor.  The Gly triplet in GPR40 
is found within the base of the proposed binding pocket so with the substitution with Ser, 
Thr, Trp allows the short chain fatty acids to now activate the receptor.  This leads to the 
suggestion that short chain fatty acids may antagonise wild type GPR40 but this has not 
been examined.  To support the theory that the synthetic ligands require a more conserved 
ligand binding pocket in GPR40, none of the synthetic agonists were able to activate 
GPR40 GGG93-95STW.  The equivalent mutation in GPR43 gave some interesting results.  
Due to difficulties in mutating all three residues, three mutants were made and all were 
tested in their ability to mediate a rise in [Ca2+]i in a FLIPR based assay system.  The data 
was not very clear but suggested that this region may confer the fatty acid chain length 
selectivity of GPR43 but it is likely that other regions of the receptor are also important.  
Further experiments need to be carried out to determine the full pharmacology of these 
receptors as it is possible that the longer chain fatty acid can activate the receptor but the 
signal generated is too small to be detected by the FLIPR.   
It is important to note that the inability of some of the fatty acids and synthetic ligands to 
activate the mutants in the FLIPR based assay system may reflect a reduction in efficacy of 
the ligands rather than a loss of potency.  This is difficult to assess as the mutant receptors 
were transiently expressed therefore expression levels may vary greatly.  This is 
demonstrated by the inability of troglitazone to mediate a rise in [Ca2+]i in the FLIPR based 
assay at GPR40 Lys62Ala but in the [35S]GTPγS assay activation of the mutant receptor 
could be detected.  As mentioned previously, the FLIPR assay system is not very sensitive 
and to fully assess the function of the mutant receptors a combination of techniques would 
have to be utilised.    
Considering all the data, I would propose that short chain fatty acids bind in a similar 
fashion to GPR41 and GPR43, but this differs from the way fatty acids bind GPR40.  The 
models of each of the receptor will have to be revised to take into account of the results of 
the mutagenesis studies.  A fuller understanding of the particular residues that constitute 
the ligand-binding pocket will be useful in determining any unusual features the receptors 
may contain and assist in the development of receptor specific ligands.   
Leigh Ann Stoddart, 2007   177 
 
Figure 5.1 Amino acid sequence alignment of GPR40, GPR41 and GPR43 
Amino acid sequences corresponding to human GPR40, GPR41 and GPR43 were aligned 
using the ClustalX algorithm.  Residues are coloured as follows; small and hydrophobic 
residues are coloured red, acidic residues coloured blue, basic residues coloured magenta, 
hydroxyl and amine containing residues are coloured green.  Transmembrane regions are 
boxed with a dashed line.  Conserved basic transmembrane residues and an area within 
TM3 proposed to confer fatty acid chain length specificity are boxed with a continuous 
line.  Accession numbers are as follows: human GPR40, NP005294; human GPR41, 
NP005295; human GPR43, NP005297.    
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Figure 5.2 GPR40 homology model with a small molecule agonist docked in the 
proposed binding site 
The homology model of GPR40 was generated by GlaxoSmithKline using the 
GPCR_Builder programme based on the crystal structure of rhodopsin.  GPR40 was 
aligned with rhodopsin on the basis of highly conserved residues found in family A 
GPCRs.  The model shows the residues that might be important in forming a salt bridge 
with fatty acid agonists; Lys62, His137 and Arg183 (coloured blue).  It also shows a synthetic 
small molecule agonist (coloured red) co-ordinated by Arg183 and a triplet of Gly residues 
in TM3.  (a) view from the side of the membrane and (b) view from above the membrane 
with TM helices numbered 1-7.   
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Figure 5.3 GPR41 and GPR43 homology models 
The homology models of GPR41 (a) and GPR43 (b) were generated by GlaxoSmithKline 
using the GPCR_Builder programme based on the crystal structure of rhodopsin.  GPR41 
and GPR43 were aligned with rhodopsin on the basis of highly conserved residues found in 
family A GPCRs.  (a) GPR41 viewed from the side of the membrane.  The model shows 
the residues implicated in forming a salt bridge with the fatty acid agonists; Arg71, His146 
and Arg185 (coloured blue).  (b) GPR43 viewed from the side of the membrane.  The model 
shows the residues implicated in forming a salt bridge with the fatty acid; Lys65, His140 and 
Arg180 
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Figure 5.4 GPR40 and GPR43 homology models showing position of TM3 triplet 
implicated in fatty acid chain length selectivity 
The homology models of GPR40 (a) and GPR43 (b) were generated by GlaxoSmithKline 
using the GPCR_Builder programme based on the crystal structure of rhodopsin.  GPR40 
and GPR43 were aligned with rhodopsin on the basis of highly conserved residues found in 
family A GPCRs.  (a) GPR40 viewed from the side of the membrane.  The model shows 
the residues implicated in forming a salt bridge with fatty acid agonists (blue sticks) as 
detailed in Figure 5.2 and Gly93, Gly94 and Gly95 (blue space-filled residues).  (b) GPR43 
viewed from the side of the membrane.  The model shows the residues implicated in 
forming a salt bridge with the fatty acid (blue sticks) as detailed in Figure 5.3 and Ser96, 
Thr97 and Trp98 (blue space-filled residues).  
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Figure 5.5 Effect of mutation of three conserved basic residues in GPR43 on the 
ability to mediate a rise in [Ca
2+
]i in response to short chain fatty acids 
Using the Stratagene Quikchange method of mutagenesis, three GPR43 mutants were 
generated.  HEK293T cells were transiently transfected to express GPR43-eYFP (black 
line), GPR43 Lys65Ala-eYFP (blue line), GPR43 His140Ala-eYFP (red line) or GPR43 
Arg180Ala-eYFP (green line).  Following loading with Fura-2, changes in fluorescence 
were measured upon the addition of 10mM (a) acetate, (b) propionate or (c) butyrate at the 
60s time point.  Images were collected every 2s for a total of 300s.  Data represents 
means±SEM for at least 20 positively transfected cells selected on the basis of eYFP 
fluorescence.   
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Figure 5.6 Arginine is required at position 180 in GPR43 to allow the receptor to 
respond to short chain fatty acids 
HEK293T cells were transiently transfected to express GPR43-eYFP (black line), GPR43 
Arg180Ala-eYFP (green line), GPR43 Arg180Lys-eYFP (red line), GPR43 Arg180Leu-eYFP 
(blue line) or GPR43 Arg180Ser-eYFP (purple line).  Cells were loaded with the Ca2+ 
sensitive dye, Fura-2 and changes in fluorescence monitored in response to 10mM (a) 
propionate or (b) acetate added at the 60s time point.  Images were collected every 2s for a 
total of 300s.  Data represents means±SEM for at least 20 positively transfected cells 
selected on the basis of eYFP fluorescence.   
Leigh Ann Stoddart, 2007   186 
0 60 120 180 240 300 360 420
0.9
1.0
1.1
1.2
1.3
Time (s)
F
u
ra
-2
 r
a
ti
o
10mM butyrate 10mM propionate
0 60 120 180 240 300 360 420
0.9
1.0
1.1
1.2
1.3
Time (s)
F
u
ra
-2
 r
a
ti
o
10mM butyrate 10mM acetate
(a)
(b)
 
Figure 5.7 GPR43 Lys
65
Ala has lost the ability to mediate a rise in [Ca
2+
]i when 
challenged with butyrate but retains the ability to respond to acetate or propionate 
GPR43 Lys65Ala-eYFP was transiently transfected into HEK293T cells grown on coated 
coverslips.  Cells were loaded with Fura-2 and changes in fluorescence measured.  Cells 
were exposed to 10mM butyrate at the 60s time point for 60s and then to 10mM (a) 
propionate or (b) acetate at the 180s time point for 60s.  Images were collected every 2s for 
a further 180s.  Data represents means±SEM from at least 20 positively transfected cells 
selected on the basis of eYFP fluorescence.   
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GPR43
GPR43 
Lys
65
Ala
GPR43 
His
140
Ala
GPR43 
Arg
180
Ala
Formate 2.8±1.0 inactive inactive inactive
Acetate 4.6±0.2 inactive   4.0±0.1 * inactive
Propionate 4.9±0.2 inactive 4.2±0.7 inactive
Butyrate 4.4±0.5 inactive 3.6±1 inactive
 
GPR43 
Arg
180
Lys
GPR43 
Arg
180
Leu
GPR43 
Arg
180
Ser
Formate inactive inactive inactive
Acetate inactive inactive inactive
Propionate inactive inactive inactive
Butyrate inactive inactive inactive
 
 
Table 5.1 Potency of various short chain fatty acids at GPR43 mutants  
HEK293 MSRII cells were transiently transfected to express the GPR43-eYFP or the 
indicated GPR43 mutant.  24h post transfection cells were seeded at 15,000 cells per well 
into 384 well microtitre plates.  Cells were loaded with the Ca2+ sensitive dye, Fluo-4.  
Changes in intracellular calcium levels were measured using the FLIPR apparatus 
following challenge with the required short chain fatty acid added at the 10 second time 
point and data was collected for a further 110 seconds.  Data represent mean±SEM of 
pEC50 values from three individual experiments performed in duplicate.  Data was analysed 
using Students paired T-test (GraphPad Prism 4).  Means were compared to wild type 
GPR43, * = p<0.05.  
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Figure 5.8 GPR43 His
140
Ala has gained the ability to generate a rise in [Ca
2+
]i in 
response to caproic acid and caprylic acid  
HEK293 MSRII cells were transiently co-transfected to express GPR43-eYFP (black 
squares), GPR43 Lys65Ala-eYFP (blue circles), GPR43 His140Ala-eYFP (red triangles) or 
GPR43 Arg180Ala-eYFP (green open squares) with a G protein cocktail.  24h post 
transfection cells were seeded at 15,000 cells per well into 384 well microtitre plates.  
Changes in intracellular calcium levels were measured using the FLIPR apparatus 
following challenge with increasing concentrations of (a) caprylic acid or (b) caproic acid 
added at the 10 second time point and data collected for a further 110 seconds.  Graph 
shown are representative of data obtained from three individual experiments performed in 
duplicate.  Data points represent means±SEM.   
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Figure 5.9 Localisation of GPR43 mutants visualised using eYFP fluorescence 
HEK293T cells were transiently transfected to express (a) GPR43-eYFP, (b) GPR43 
Lys65Ala-eYFP, (c) GPR43 His140Ala-eYFP, (d) GPR43 Arg180Ala –eYFP, (e) GPR43 
Arg180Lys-eYFP, (f) GPR43 Arg180Leu-eYFP or (g) GPR43 Arg180Ser-eYFP.  Cells were 
directly imaged using fluorescence microscopy.  Results shown are of a single experiment, 
representative of three experiments performed.   
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Figure 5.10 Ability of GPR41 basic mutants to mediate a rise in [Ca
2+
]i when 
challenged with propionate or butyrate 
HEK293T cells were transiently co-transfected to express GPR41-eYFP (black line), 
GPR41 Arg71Ala-eYFP (blue line), GPR41 His146Ala-eYFP (red line) or GPR41 
Arg185Ala-eYFP (green line) with GαqG66Di5.  Cells were loaded with the Ca
2+  sensitive 
dye, Fura-2 and challenged with 10mM (a) butyrate or (b) propionate at the 60s time point.  
Images were collected every 2s and collected for a total of 300s.  Data represents 
means±SEM from at least 20 positively transfected cells selected on the basis of eYFP 
fluorescence.   
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Figure 5.11 Ability of GPR41 mutants to mediate a concentration-dependent increase 
in [
35
S]GTPγS binding in response to propionate 
(a) HEK293T cells were transiently transfected to express GPR41-Gαi3 Cys
351Ile (black 
squares), GPR41 Arg71Ala-Gαi3 Cys
351Ile (red triangles), GPR41 His146Ala-Gαi3 Cys
351Ile 
(blue circles) or GPR41 Arg185Ala-Gαi3 Cys
351Ile (green diamonds).  [35S]GTPγS binding 
studies were performed on the resulting membranes in the presence of increasing 
concentrations of propionate.  Assay samples were immunoprecipitated with the anti-Gαi3 
antiserum I3 before scintillation counting.  (b) Data from GPR41 Arg71Ala-Gαi3 Cys
351Ile 
[35S]GTPγS binding studies shown on a reduced scale.  Graphs shown are representative of 
results obtained for three individual experiments performed in triplicate.  Data points 
represent means±SEM.   
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GPR41
GPR41 
Arg
71
Ala
GPR41 
His
146
Ala
GPR41 
Arg
185
Ala
Propionate 3.66±0.1 2.3±0.3* 3.59±0.02 inactive
 
Table 5.2 Potency of propionate at GPR41 mutants measured by [
35
S]GTPγS binding 
studies 
[35S]GTPγS binding studies were performed on membranes expressing GPR41-Gαi3 
Cys351Ile or the specified mutant in the presence of increasing concentrations of 
propionate.  Data represent mean±SEM of pEC50 from three individual experiments. Data 
was analysed using Students paired T-test (GraphPad Prism 4).  Means were compared to 
wild type GPR41 * = p<0.05 
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Figure 5.12 Localisation of GPR41 mutants visualised using eYFP fluorescence  
HEK293T cells were transiently transfected to express (a) GPR41-eYFP, (b) GPR41 
Arg71Ala-eYFP, (c) GPR41 His146Ala-eYFP or (d) GPR41 Arg185Ala-eYFP.  Cells were 
directly imaged using fluorescence microscopy.  Results shown are of a single experiment, 
representative of three experiments performed. 
Leigh Ann Stoddart, 2007   195 
0 60 120 180 240 300
0.9
1.0
1.1
1.2
1.3
1.4
1.5
1.6
1.7
GPR40-YFP
GPR40 Lys
62
Ala-YFP
GPR40 His
137
Ala-YFP
GPR40 Arg
183
Ala-YFP
100µM lauric acid
Time (s)
F
u
ra
-2
 r
a
ti
o
 
Figure 5.13 Activation of wild type and single point mutant GPR40 receptors by 
lauric acid in single cell [Ca
2+
]i assays 
Wild type and single point mutant GPR40 receptors were transiently transfected into 
HEK293T cells.  Cells were loaded with Fura-2 and changes in fluorescence monitored 
upon the addition of 100µM lauric acid after 60s.  Images were collected every 2s for a 
total of 300s.  Data shown represents means±SEM from at least 20 cells positively 
transfected with GPR40-eYFP (black line), GPR40 Lys62Ala-eYFP (blue line), GPR40 
His137Ala-eYFP (red line) or GPR40 Arg183Ala-eYFP (green line) selected on the basis of 
eYFP fluorescence.   
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GPR40-YFP
GPR40 
Lys
62
Ala -YFP
GPR40 
His
137
Ala -
YFP
GPR40 
Arg
183
Ala -
YFP
Caproic Acid 4.0±0.1 inactive inactive inactive
Caprylic Acid 4.3±0.3   3.1±0.1* inactive 3.8±1.0
Capric Acid 5.5±0.6 inactive inactive 5.5±0.3
Lauric Acid 5.3±0.4 4.9±0.3 4.8±0.5 5.0±0.1
Myristic Acid 5.4±0.5 5.0±0.4 inactive 4.6±0.4
Palmitic Acid 5.5±0.8 4.7±0.7 5.4±0.7 inactive
Stearic Acid 4.9±0.7   6.3±0.1* inactive 5.5±0.5
Palmitoleic Acid 5.3±0.3 4.9±0.3 4.9±0.1 5.2±0.4
Linolenic Acid 5.6±0.3     5.2±0.2 *** 4.8±1.0   5.3±0.1 *
γ-Linolenic Acid 5.5±0.2 5.3±0.2 5.2±0.3 5.4±0.2
Linoleic Acid 5.6±0.2    5.1±0.1 ** 5.3±0.1     5.1±0.2 **
Elaidic Acid 5.2±0.2   4.9±0.1 * inactive inactive
Retinoic Acid 5.3±0.4   4.7±0.1 *   4.6±0.5 *   5.0±0.1 *
Arachidonic 
Acid
5.4±0.3 5.1±0.3   4.9±0.1 * 5.2±0.2
Docosapent -
aenoic Acid
5.3±0.2 5.0±0.2 4.9±0.1 5.2±0.2
 
Table 5.3 Potency of fatty acids agonists at GPR40 single mutants  
HEK293 MSRII cells were transiently transfected to express the GPR40-eYFP or the 
indicated GPR40 mutant.  24h post transfection cells were seeded at 15,000 cells per well 
into 384 well microtitre plates.  Cells were loaded with the Ca2+ sensitive dye, Fluo-4.  
Changes in [Ca2+]i levels were measured using the FLIPR apparatus following challenge 
with the indicated fatty acid added at the 10 second time point and data collected for a 
further 110 seconds.  Data represents mean±SEM of pEC50 from three individual 
experiments performed in duplicate.  Data was analysed using Students paired T-test 
(GraphPad Prism 4).  Means were compared to wild type GPR40, * = p<0.05, ** = p<0.01, 
***=p<0.001. 
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GPR40-YFP
GPR40 
Lys
62
Ala -YFP
GPR40 
His
137
Ala -
YFP
GPR40 
Arg
183
Ala -
YFP
Rosiglitazone 5.7±0.3 inactive inactive inactive
Troglitazone 5.9±0.1 inactive inactive inactive
GW839508X 7.6±0.3     5.6±0.5 *** inactive inactive
GSK250089A 7.0±0.2    5.2±0.1 ** inactive inactive
GSK223112A 5.7±0.7 inactive inactive inactive
 
Table 5.4 Potency of thiazolidinediones and small molecule agonists at GPR40 single 
mutants 
HEK293 MSRII cells were transiently transfected to express the GPR40-eYFP or the 
indicated GPR40 mutant.  24h post transfection cells were seeded at 15,000 cells per well 
into 384 well microtitre plates.  Cells were loaded with the Ca2+ sensitive dye, Fluo-4.  
Changes in intracellular calcium levels were measured using the FLIPR apparatus 
following challenge with the indicated test compound added at the 10 second time point 
and data collected for a further 110 seconds.  Data represent mean±SEM of pEC50 from 
three individual experiments performed in duplicate.  Data was analysed using Students 
paired T-test (GraphPad Prism 4).  Means were compared to wild type GPR40, ** = 
p<0.01, ***=p<0.001. 
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Figure 5.14 The addition of fatty acid free BSA can reduce the basal [
35
S]GTPγS 
loading of GPR40 mutant-Gαq fusion proteins 
HEK293T cells were transiently transfected with GPR40-Gαq, GPR40 Lys
62Ala-Gαq or 
GPR40 Arg183Ala-Gαq and membranes prepared.  [
35S]GTPγS binding studies were 
performed in the absence (black bars) or presence (white bars) of 10µM fatty acid free 
BSA. All assay samples were immunoprecipitated with the Gαq/11 antiserum CQ before 
scintillation counting.  Data shown is representative of results obtained for three individual 
experiments performed in triplicate.  Data points represent means±SEM.  
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Figure 5.15 Comparison of [
35
S]GTPγS concentration response curves to different 
ligands generated by wild type GPR40-Gαq, GPR40 Lys
62
Ala-Gαq and GPR40 
Arg
183
Ala-Gαq  
HEK293T cells were transiently transfected to express GPR40-Gαq (black squares), 
GPR40 Lys62Ala-Gαq (red triangles), or GPR40 Arg
183Ala-Gαq (blue circles).  [
35S]GTPγS 
binding studies were performed on the resulting membranes in the presence of 10µM fatty 
acid free BSA and increasing concentrations of (a) palmitic acid, (b) troglitazone or (c) 
GSK250089A.  Assay samples were immunoprecipitated with the anti-Gαq antiserum CQ 
before scintillation counting.  Graphs shown are representative of results obtained from 
three individual experiments performed in triplicate.  Data points indicate means±SEM. 
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GPR40-Gαq
GPR40 Lya
62
Ala -
Gαq
GPR40 Arg
183
Ala 
-Gαq
Palmitic Acid 4.6±0.1 4.9±0.1 3.5±0.4*
Troglitazone 6.5±0.3 5.3±0.1* inactive
GSK250089A 7.6±0.2 5.4±0.2* inactive
 
Table 5.5 Potency of palmitic acid, troglitazone and GSK250089A at GPR40 
Lys
62
Ala-Gαq and GPR40 Arg
183
Ala-Gαq measured in a [
35
S]GTPγS binding assay 
[35S]GTPγS binding studies were performed on membranes expressing GPR40-Gαq 
GPR40 Lys62Ala-Gαq or GPR40 Arg
183Ala-Gαq in the presence of increasing 
concentrations of the indicated test compound.  Data represent mean±SEM of pEC50 from 
three individual experiments.  Data was analysed using Students paired T-test (GraphPad 
Prism 4).  Means were compared to wild type GPR40, * = p<0.05 
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Figure 5.16 Localisation of GPR40 single mutants visualised by eYFP fluorescence 
HEK293T cells were transiently transfected to express (a) GPR40-eYFP, (b) GPR40 
Lys62Ala-eYFP, (c) GPR40 His137Ala-eYFP or (d) GPR40 Arg183Ala-eYFP.  Cells were 
directly imaged using fluorescence microscopy.  Results shown are of a single experiment, 
representative of three experiments performed.   
Leigh Ann Stoddart, 2007   203 
0 60 120 180 240 300
0.9
1.0
1.1
1.2
1.3
1.4
1.5
1.6
1.7
GPR40-YFP
GPR40 His
137
Ala, Arg
183
Ala-YFP
GPR40 Lys
62
Ala, His
137
Ala-YFP
GPR40 Lys
62
Ala, Arg
183
Ala-YFP
Time (s)
F
u
ra
-2
 r
a
ti
o
 
Figure 5.17 Lauric acid mediated rise in [Ca
2+
]i via GPR40 double mutants 
HEK293T cells were transiently transfected with GPR40-eYFP (black line), GPR40 
Lys62Ala, His137Ala-eYFP (grey line), GPR40 Lys62Ala, Arg183Ala-eYFP (orange line) or 
GPR40 His137Ala, Arg183Ala-eYFP (purple line).  Cells were loaded with Fura-2 and the 
change in fluorescence measured in response to the addition of 100µM lauric acid at the 
60s time point.  Images were collected every 2s for a total of 300s.  Data represent 
means±SEM from at least 20 positively transfected cells selected on the basis of eYFP 
fluorescence.   
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GPR40-YFP
GPR40 
Lya
62
Ala, 
His
137
Ala -
YFP
GPR40 
Lya
62
Ala, 
Arg
183
Ala -
YFP
GPR40 
His137Ala, 
Arg
183
Ala -
YFP
Caproic Acid 4.0±0.1 inactive inactive inactive
Caprylic Acid 4.3±0.3 3.2±0.3 3.2±0.2 * inactive
Capric Acid 5.5±0.6 5.4±0.2 inactive inactive
Lauric Acid 5.3±0.4 4.9±0.1 5.0±0.2 inactive
Myristic Acid 5.4±0.5 5.3±0.3 4.9±0.3 inactive
Palmitic Acid 5.5±0.8 4.9±0.1 4.8±0.1 inactive
Stearic Acid 4.9±0.7 4.3±0.8 4.1±0.2 inactive
Palmitoleic Acid 5.3±0.3 inactive 5.0±0.1 inactive
Linolenic Acid 5.6±0.3  5.1±0.2 *      5.2±0.2*** 5.1±0.9
γ-Linolenic Acid 5.5±0.2 5.3±0.4  5.3±0.2 5.3±0.1
Linoleic Acid 5.6±0.2   5.2±0.2 **    5.1±0.1 * 5.1±0.3
Elaidic Acid 5.2±0.2 inactive 4.9±0.2 inactive
Retinoic Acid 5.3±0.4 5.2±0.2 inactive inactive
Arachidonic 
Acid
5.4±0.3   5.2±0.3 * 5.2±0.1 inactive
Docosapent -
aenoic Acid
5.3±0.2 4.9±0.1 5.2±0.2 5.1±0.3
 
Table 5.6 Potency of fatty acids agonists at GPR40 double mutants  
HEK293 MSRII cells were transiently transfected to express the GPR40-eYFP or the 
indicated GPR40 double mutant.  24h post transfected cells were seeded at 15,000 cells per 
well into 384 well microtitre plates.  Cells were loaded with the Ca2+ sensitive dye, Fluo-4.  
Changes in intracellular calcium levels were measured using the FLIPR apparatus 
following challenge with the indicated fatty acid added at the 10 second time point and 
data collected for a further 110 seconds.  Data represent mean±SEM of pEC50 from three 
individual experiments performed in duplicate.  Data was analysed using Students paired 
T-test (GraphPad Prism 4).  Means were compared to wild type GPR40, * = p<0.05, ** = 
p<0.01, ***=p<0.001. 
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GPR40-
YFP
GPR40 
Lys
62
Ala, 
His
137
Ala -
YFP
GPR40 
Lys
62
Ala, 
Arg
183
Ala -
YFP
GPR40 
His
137
Ala, 
Arg
183
Ala -
YFP
Rosiglitazone 5.7±0.3 5.7±0.5 5.3±0.5 inactive
Troglitazone 5.9±0.1 inactive inactive inactive
GW839508X 7.6±0.3      6.3±0.1 ***    4.7±0.2 *** inactive
GSK250089A 7.0±0.2   6.1±0.3 * inactive inactive
GSK223112A 5.7±0.7 inactive inactive inactive
 
Table 5.7 Potency of thiazolidinediones and small molecule agonists at GPR40 double 
mutants 
HEK293 MSRII cells were transiently transfected to express the GPR40-eYFP or the 
indicated GPR40 double mutant.  24h post transfected cells were seeded at 15,000 cells per 
well into 384 well microtitre plates.  Cells were loaded with the Ca2+ sensitive dye, Fluo-4.  
Changes in intracellular calcium levels were measured using the FLIPR apparatus 
following challenge with the indicated test compound added at the 10 second time point 
and data collected for a further 110 seconds.  Data represent mean±SEM of three 
individual experiments performed in duplicate.  Data was analysed using Students paired 
T-test (GraphPad Prism 4).  Means were compared to wild type GPR40, ** = p<0.01, 
***=p<0.001. 
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(a) (b)
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Figure 5.18 Cellular localisation of GPR40 double mutants visualised using eYFP 
fluorescence 
HEK293T cells were transiently transfected to express (a) GPR40-eYFP, (b) GPR40 
Lys62Ala, His137Ala-eYFP, (c) GPR40 Lys62Ala, Arg183Ala-eYFP or (d) GPR40 His137Ala, 
Arg183Ala-eYFP.  Cells were directly imaged using fluorescence microscopy.  Results 
shown are of a single experiment, representative of three experiments performed.   
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Figure 5.19 Responses to various chain length fatty acids by GPR40 GGG
93-95
STW 
HEK293T cells were transiently transfected with GPR40-eYFP (black line) or GPR40 
GGG93-95STW-eYFP (purple line).  Cells were loaded with Fura-2 and exposed to 100µM 
(a) palmitic acid, (b) lauric acid, (c) oleic acid or (d) 10mM propionate after 60s of basal 
readings and alterations in fluorescence were monitored  Images were collected every 2s 
for a total of 300s.  Data represents means±SEM from at least 20 positively transfected 
cells selected on the basis of eYFP fluorescence (GPR40-eYFP response to propionate 
represents means±SEM from 7 positively transfected cells).   
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Figure 5.20 GPR40 GGG
93-95
STW can mediate a rise in [Ca
2+
]i when challenged with 
acetate  
HEK293T cells were transiently transfected with GPR40-eYFP (black line) or GPR40 
GGG93-95STW-eYFP (purple line).  Cells were loaded with Fura-2 and exposed to 10mM 
acetate after 60s of basal readings and alteration in Fura-2 fluorescence monitored.  Images 
were collected every 2s for a total of 300s.  Data represents means±SEM from at least 30 
positively transfected cells selected on the basis of eYFP fluorescence.   
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GPR40-
YFP
GPR40 
GGG
93-
95
STW-YFP 
GPR43-
YFP
GPR43 
Trp
98
Gly-
YFP 
GPR43 
Thr
97
Gly, 
Trp
98
Gly-
YFP
GPR43 
Ser,Thr, 
Trp
96-
98
Gly,Gly,Gly-
YFP
Formate inactive inactive 2.8±1.0 inactive inactive inactive
Acetate inactive inactive 4.6±0.2 4.4±0.9 inactive inactive
Propionate inactive inactive 4.9±0.2 4.7±0.6 inactive inactive
Butyrate inactive inactive 4.4±0.5 4 inactive inactive
Caproic Acid 4.0±0.1 inactive inactive inactive inactive inactive
Caprylic Acid 3.9±0.9 3.9±0.4 inactive inactive inactive inactive
Capric Acid 5.5±0.6 5.1±0.9 inactive inactive inactive inactive
Lauric Acid 5.3±0.4 5.0±0.3 inactive inactive 7 7.4
Myristic Acid 5.4±0.5 5.0±0.4 inactive 5.2 6.2±2.5 5
Palmitic Acid 5.5±0.8 inactive inactive inactive inactive inactive
Stearic Acid 4.9±0.7 5.1±0.4 inactive inactive inactive inactive
Palmitoleic 
Acid
5.3±0.3 inactive inactive inactive 6.2±1.4 inactive
Linolenic Acid 5.6±0.2   5.1±0.2 * inactive 5.1±0.9 inactive inactive
γ-Linolenic 
Acid
5.4±0.1 5.1±0.2 inactive 5.3±0.1 inactive inactive
Linoleic Acid 5.6±0.2   5.1±0.1 * inactive 5.1±0.3 inactive inactive
Elaidic Acid 5.0±0.1 inactive inactive inactive 6.2±2.4 4.5±0.2
Retinoic Acid 5.3±0.4 inactive inactive inactive inactive inactive
Arachidonic 
Acid
5.4±0.3 5.0±0.1 inactive inactive inactive inactive
Docosapent -
aenoic Acid
5.3±0.2   5.1±0.1 * inactive 5.1±0.3 inactive inactive
 
Table 5.8 Potency of a range of fatty acids at TM3 mutants of GPR40 and GPR43 
HEK293 MSRII cells were transiently transfected to express the indicated wild type or 
mutant receptor.  24h post transfected cells were seeded at 15,000 cells per well into 384 
well microtitre plates.  Cells were loaded with the Ca2+ sensitive dye, Fluo-4.  Changes in 
intracellular calcium levels were measured using the FLIPR apparatus following challenge 
with the indicated test compound added at the 10 second time point and data collected for a 
further 110 seconds.  Data represent mean±SEM of three individual experiments 
performed in duplicate.  Data was analysed using Students paired T-test (GraphPad Prism 
4).  * = p<0.05.  Dashes indicate that no signal was observed when the test fatty acid was 
added.   
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(a) (b)
 
Figure 5.21 Cellular localisation of GPR40 GGG
93-95
STW visualised using eYFP 
fluorescence  
HEK293T cells were transiently transfected to express (a) GPR40-eYFP or (b) GPR40 
GGG93-95STW-eYFP.  Cells were directly imaged using fluorescence microscopy.  Results 
shown are of a single experiment, representative of three experiments performed. 
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Figure 5.22 Amino acid positions differing between GPR41 and GPR42 
Amino acid sequences corresponding to GPR41 and GPR42 were aligned using the 
ClustalX algorithm.  Residues are coloured as follows; small and hydrophobic residues are 
coloured red, acidic residues coloured blue, basic residues coloured magenta, hydroxyl and 
amine containing residues are coloured green.  Conserved basic transmembrane residues 
and area within TM3 proposed to confer fatty acid chain length specificity boxed with a 
continuous line.  Residues that differ between GPR41 and GPR42 are indicated by arrows.  
Accession numbers are as follows: human GPR41, NP005295; human GPR42, NP005296.   
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Figure 5.23 GPR40 homology model showing positions of Tyr
91
 and Phe
191
 in relation 
to proposed binding site of small molecule agonists 
The homology model of GPR40 was generated by GlaxoSmithKline using the 
GPCR_Builder programme based on the crystal structure of rhodopsin.  GPR40 was 
aligned with rhodopsin on the basis of highly conserved residues found in family A 
GPCRs.  The model shows the residues implicated in forming a salt bridge with the fatty 
acid agonists; Lys62, Gly93-95, His137 and Arg183 (coloured blue).  It also shows a synthetic 
small molecule agonist (coloured red) co-ordinated by Arg183 and Tyr91 and Phe191 
(coloured green).   
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6 Detection of GPR40 and GPR43 homo-oligomers 
using a variety of techniques 
6.1 Introduction 
The ability of family A GPCRs to form homo- and hetero-oligomers has become widely 
accepted (Bulenger et al., 2005; Milligan, 2006).  The role of oligomerisation is unclear but 
it has been proposed to be involved in protein folding, correct membrane delivery and 
interaction with G proteins.  There are a growing number of studies on the effects of 
hetero-oligomerisation on ligand pharmacology and function.  Hetero-oligomerisation has 
been shown to switch the G protein coupling of MOP and DOP receptors when co-
expressed (George et al., 2000; Fan et al., 2006) and to affect the potency of orexin A at 
the orexin-1 receptor when it is co-expressed with the CB1 receptor (Hilairet et al., 2003). 
An obvious requirement for hetero-oligomerisation is that both receptors are expressed in 
the same cell.  Although GPR40, GPR41 and GPR43 have distinct expression patterns, 
they have been reported to be co-expressed in certain tissues.  Xiong et al., (2004) were 
able to detect both GPR41 and GPR43 mRNA in adipocytes and all three receptors have 
been found to be expressed in immune cells (Briscoe et al., 2003; Brown et al., 2003; Le 
Poul et al., 2003).  Examination of different immune cells suggests that there is a greater 
overlap of the expression of GPR40 and GPR43.  Recent patents by Arena Pharmaceuticals 
indicated that expression of all three receptors could be detected in pancreatic islet cells.  
The overlap of expression suggests that interactions between these receptors may occur in 
vivo, and this may modulate their function and/or pharmacology.   
To date, there have been no studies into the potential for the receptors to form homo- or 
hetero-oligomers.  From expression studies, GPR40 and GPR43 have the most overlapping 
expression pattern.  Before studies into their ability to form hetero-oligomers can be 
undertaken, their capacity to assemble into homo-oligomers had to be determined.  This 
was achieved using three complementary techniques, co-immunoprecipitation, FRET and 
Tr-FRET.   
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6.2 Co-immunoprecipitation allows detection of GPR40 
and GPR43 homo-oligomers 
To investigate the potential homo-oligomerisation of GPR40, GPR40-Flag and GPR40-c-
Myc were transiently expressed individually or co-expressed in HEK293T cells.  Cells 
were harvested 24h post-transfection and solubilised by the addition of 1x RIPA buffer.  
Mock-transfected HEK293T cells were included as a control, as was a control composed of 
cells individually expressing the two constructs that were mixed prior to 
immunoprecipitation.  Samples were incubated with anti-Flag antibody and 
immunoprecipitated material resolved by SDS-PAGE.  Proteins were transferred onto 
nitrocellulose membrane and a western blot performed using anti-c-Myc antibody.  Figure 
6.1 demonstrates the co-immunoprecipitation of GPR40-Flag and GPR40-c-Myc only in 
the sample where the differentially tagged receptors were co-expressed.  A band 
representing the 32kDa GPR40-c-Myc receptor can be observed in the co-expressed 
sample, which is consistent with an interaction between GPR40-Flag and GPR40-c-Myc.  
Higher molecular mass species were also detected and this suggested that a fraction of the 
immunoprecipitated oligomer was not efficiently separated by the SDS-PAGE conditions 
used.  No immunoreactivity could be detected in samples where each of the constructs was 
expressed individually.  Mixing of samples individually expressing GPR40-Flag and 
GPR40-c-Myc prior to immunoprecipitation did not result in co-immunoprecipitation, 
implying that expression of both epitope tagged receptors within the same cell was 
required to allow interaction.  To confirm expression of the tagged receptors, lysates from 
each of the samples were also subjected to western blot analysis using both the anti-Flag 
and anti-c-Myc antibodies.   
A similar experimental protocol was followed to investigate the formation of GPR43 
homo-oligomers (Figure 6.2).  Immunoreactivity at 33kDa corresponding to GPR43-c-Myc 
was observed in the lane where the differentially epitope tagged receptors were co-
expressed.  No immunoreactivity was observed in the sample in which the individually 
expressed receptors were mixed prior to immunoprecipitation or when each construct was 
expressed individually.  A larger fraction of the co-immunoprecipitated anti-c-Myc 
immunoreactivty remained as a dimer and higher order oligomers.   
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6.3 Investigation of homo-oligomerisation of GPR40 and 
GPR43 using FRET imaging in living cells 
As GPCR immunoprecipitation studies require solubilisation of the membrane surrounding 
the receptors, the formation of GPR40 and GPR43 homo-oligomers in living cells was 
investigated.  This was achieved by the attachment of either eCFP or eYFP at the C-
terminus of the receptor, expression of the modified receptors in HEK293T cells and the 
quantification of the resulting FRET signal as eCFP and eYFP are well established FRET 
partners.  Expression of either GPR40-eYFP or GPR40-eCFP allowed selective imaging of 
each construct and quantification of the bleed-through values to be calculated due to the 
overlapping spectral properties of the two fluorescent proteins.  Co-expression of GPR40-
eCFP and GPR40-eYFP resulted in a FRETNORM signal of 0.82±0.07 (Figure 6.3).  
Previous studies performed within the Milligan group have demonstrated that co-
expression of the isolated forms of eCFP and eYFP did not result in significant levels of 
FRET (Carrillo et al., 2004), which suggest that the FRETNORM signal is from direct 
protein-protein interactions involving GPR40.   
The specificity of the FRET signal was investigated using the histamine H1 receptor.  
There is no overlap between the expression pattern of this receptor and GPR40 or GPR43.  
The interactions between GPR40 and histamine H1 receptor were monitored by expression 
of GPR40-eCFP and H1-eYFP in HEK293T cells and quantification of the resulting FRET 
signal.  The FRETNORM signal was 0.30±0.02, which demonstrated significantly lower 
levels of energy transfer between these two receptor than the GPR40 homo-oligomer.  
Imaging of individual cells confirmed their co-expression in the same cell (Figure 6.3 (d)). 
Homo-oligomerisation of GPR43 was also investigated using this technique (Figure 6.4).  
GPR43-eCFP and GPR43-eYFP were co-expressed and resulted in a FRETNORM of 
0.75±0.04.  The specificity of the interaction was investigated by co-expression of GPR43-
eCFP and H1-eYFP, which yielded a FRETNORM of 0.34±0.03.  The FRETNORM value 
obtained upon co-expression of GPR43-eCFP and H1-eYFP is significantly less than that 
observed with the GPR43 homo-oligomer and imaging confirmed expression of both 
receptors in the same cell.   
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6.4 Demonstration of homo-oligomerisation of GPR40 
and GPR43 using Tr-FRET 
A further technique, Tr-FRET, was used to confirm the homo-oligomerisation of GPR40 
and GPR43.  GPR40-Flag and GPR40-c-Myc were expressed transiently in HEK293T 
cells.  As a control, mixed cells expressing the differentially tagged constructs individually 
were also used.  Membranes were prepared and incubated with an anti-c-Myc antibody 
conjugated to Europium (Eu3+), which acts the energy donor, and an anti-Flag antibody 
conjugated to allophycocyanin (APC), which acts as the energy acceptor.  The energy 
transfer signal obtained when GPR40-c-Myc and GPR40-Flag were co-expressed was 
0.017±0.003.  A low energy transfer signal of 0.004±0.0008 was obtained for the mixed 
sample.  The energy transfer observed using membranes expressing GPR43-c-Myc and 
GPR43-Flag was 0.012±0.0005 (Figure 6.5).  The mixed control of the GPR43 constructs 
also yielded a low energy transfer of 0.002±0.0005. 
6.5 Discussion 
Using a variety of techniques it was found that GPR40 and GPR43 could form homo-
oligomers.  The first technique used in this study to investigate the ability of GPR40 and 
GPR43 to homo-oligomerise was co-immunoprecipitation.  This technique has been used 
as a starting point for many of the studies into the oligomerisation of GPCRs (Milligan and 
Bouvier. 2005).  Despite its widespread use there have been questions raised about its 
validity due the requirement for cell lysis and solubilisation.  It has been suggested that this 
may result in artefactual positive results due to the hydrophobic nature of GPCRs (Salim et 
al., 2002).  To address this, a mixed cell control can be utilised, in which cells expressing 
each tagged receptor alone are mixed prior to immunoprecipitation (Wilson et al., 2005).  
This control was included in my studies and yielded no immunoreactivity, confirming that 
the positive results obtained were not an artefact of the experimental procedure.  Another 
issue that may yield false positive results is if the membranes are not fully solubilised prior 
to immunoprecipitation (Milligan and Bouvier, 2005).  In many studies, the samples are 
only subjected to a short period in a microcentrifuge, in which the force is not enough to 
ensure that the remaining membrane fragments are removed from the soluble fraction.  
This can be overcome by increasing the centrifuge duration and speed.  In my study, 
samples were centrifuged for 60 mins at 100,000 x g, which should ensure the complete 
removal of any remaining membrane fragments.   
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Figures 6.1 and 6.2 demonstrate that a portion of the immunoprecipitated oligomer was not 
fully separated by the SDS-PAGE conditions used.  Immunoreactivity corresponding to the 
predicted weight for the homo-dimer of GPR40 and GPR43, along with higher order 
oligomers was observed.  This indicates that a fraction of both the GPR40 and GPR43 
homo-oligomers exist through non-covalent interactions. The occurrence of SDS-resistant 
oligomers has been observed for a variety of other receptors including the α1b receptor 
(Carrillo et al., 2004), CXCR1 and CXCR2 chemokine receptors (Wilson et al., 2005), and 
MOR and DOR opioid receptors (George et al., 2000).  The formation of SDS-resistant 
oligomers may be due to over-expression of the receptors.  Using the oxytocin receptor, 
Devost and Zingg (2004) demonstrated that at low levels of receptor expression the 
formation of SDS-resistant oligomer is favoured while at high levels of receptor expression 
(400 fmol/mg) the formation of SDS-sensitive oligomers was observed.   
The use of single cell FRET allows protein-protein interactions to be measured in living 
cells.  Using this technique confirmed the ability of GPR40 and GPR43 to form 
constitutive homo-oligomers (Figures 6.3, 6.4).  It has been found that some wild type 
GFPs have the tendency to oligomerise, which may cause aggregation of receptors they are 
fused to.  The use of eCFP and eYFP reduces the possibility of artefactual results as they 
have less affinity for one another than wild type GFP.  A study carried out by Carrillo et 
al., (2004) in which they co-expressed isolated forms of eCFP and eYFP did not result in a 
significant amount of FRET.  This confirms that the FRET observed in the present study is 
not due to the properties of the fluorescent proteins.   
The specificity of the homo-oligomers was investigated by measuring the amount of FRET 
upon co-expression with the histamine H1 receptor.  For both GPR40 and GPR43, co-
expression with this distantly related receptor resulted in significantly less FRET than that 
observed with the homo-oligomer.  Although this suggests that the GPR40/H1 and 
GPR43/H1 oligomers have less affinity to form it may be due to conformation of the 
hetero-oligomer being such that there is a large distance between the donor and acceptor 
fluorescent moieties that prevents energy transfer from taking place.  Although the FRET 
values obtained with the H1 receptor was reduced compared to the homo-oligomer, it does 
indicate that the receptors can form hetero-oligomers.  To gain a greater understanding of 
the relative affinity of the homo-oligomer versus a hetero-oligomer, saturation BRET 
experiments could be employed.  Saturation BRET studies have been used to determine the 
relative affinity a variety of homo- and hetero-oligomers including, CXCR1/CXCR2 
homo- and hetero-oligomers (Wilson et al., 2005), the adenosine A2A receptor (Canals et 
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al., 2004), adenosine A2A-dopamine D2 hetero-oligomers (Canals et al., 2003) and β2-β3 
adrenergic receptor hetero-oligomers (Breit et al., 2004).   
Using Tr-FRET confirmed the observations from the co-immunoprecipitation and FRET 
studies that GPR40 and GPR43 could form homo-oligomers.  Tr-FRET utilises antibodies 
that recognise specific epitope tags and are conjugated to energy transfer donor and 
acceptor moieties.  It has been suggested that the binding of antibodies may cause receptor 
aggregation that would give a false positive result (McVey et al., 2001).  Although the 
antibodies used are bivalent, any antibody mediated aggregation would only occur between 
receptors expressing the same epitope tag.  As the technique relies on the energy transfer 
between two different moieties conjugated to the antibodies, any clustering is unlikely to 
have any effect on the energy transfer.  This is confirmed by the inclusion of a control in 
which cells individually expressing the different epitope tagged receptors were mixed prior 
to membrane preparation and very low levels of energy transfer were observed, ruling out 
the possibility of antibody mediated aggregation.   
Tr-FRET is normally utilised to demonstrate the formation of GPCR oligomers at the cell 
surface.  This is achieved by attaching the epitope tag to the N-terminus of the receptor; 
therefore only receptors at the cell surface are available for the antibodies to bind to.  
Unfortunately, I found that GPR43 did not tolerate the attachment of the c-Myc epitope tag 
to its N-terminus (see Figure 3.5).  This may have been due to low levels of receptor 
expression or that the attachment of the epitope sequence prevents the receptor from 
expressing.  It was concluded that the N-terminally epitope tagged versions of GPR43 were 
not suitable to be used in these experiments.  The attachment of an epitope tag to the N-
terminus of GPR40 was not attempted.  Therefore, the Tr-FRET experiments in this study 
were carried out on membranes rather than whole cells.  As the receptors cannot be N-
terminally tagged this makes the detection of oligomers at the cell surface difficult.  The 
attachment of the Flag epitope did not appear to have as large effect on the function of 
GPR43 but further experiments would need to be carried out to confirm this.  This suggests 
that different epitope tags have different effects on the function and expression of GPR43.  
The attachment of other epitope such as VSV or HA at the N-terminus may not affect the 
function of the receptors and could be used to assess their ability to form cell surface 
delivered oligomers.   
Time constraints prevented the investigation into the ability of GPR40 and GPR43 to form 
a hetero-oligomer.  The data obtained with the histamine H1 receptor suggests that the 
receptors are able to form a hetero-oligomer with a distantly related receptor; therefore it is 
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likely that they will be able to form hetero-oligomers with each other as they are more 
closely related.  These studies show that GPR40 and GPR43 homo-oligomers exist and can 
be monitored easily using a variety of techniques.  The construction of epitope tagged 
receptors and receptor-fluorescent protein fusions will make the investigation of hetero-
oligomers a relatively simple process.   
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Figure 6.1 Co-immunoprecipitation of differentially epitope-tagged forms of the 
human GPR40 receptor 
HEK293T cells were transiently transfected to express GPR40-Flag (lane 2), GPR40-c-
Myc (lane 3) or co-transfected to transiently express GPR40-Flag and GPR40-c-Myc (lane 
4).  Lane 1 represents non-transfected HEK293T cells.  Lane 5 represents a mixed cell 
control in which cells individually expressing the constructs were mixed prior to 
immunoprecipitation.  Cell lysates were prepared and immunoprecipitated with anti-Flag 
antibody.  The resulting immunoprecipitates were resolved by SDS-PAGE and 
immunoblotted with anti-c-Myc antibody (upper panel).  Immunoblot analysis of original 
cell lysates using anti-Flag and anti-c-Myc antibodies was also performed to ensure correct 
protein expression (lower panels).  One experiment representative of three experiments is 
shown.   
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Figure 6.2 Co-immunoprecipitation of differentially epitope-tagged forms of the 
human GPR43 receptor 
HEK293T cells were transiently transfected to express GPR43-c-Myc (lane 2), GPR43-
Flag (lane 3) or co-transfected to transiently express GPR43-Flag and GPR43-c-Myc (lane 
4).  Lane 1 represents non-transfected HEK293T cells.  Lane 5 represents a mixed cell 
control in which cells individually expressing the constructs were mixed prior to 
immunoprecipitation.  Cell lysates were prepared and immunoprecipitated with anti-Flag 
antibody.  The resulting immunoprecipitates were resolved by SDS-PAGE and 
immunoblotted with anti-c-Myc antibody (a).  Immunoblot analysis of original cell lysates 
using anti-Flag (b) and anti-c-Myc (c) antibodies was also performed to ensure correct 
protein expression.  One experiment representative of three experiments is shown.  
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Figure 6.3 FRET imaging of GPR40 homo-oligomerisation in single cells 
HEK293T cells were transiently transfected to co-express GPR40-eCFP and GPR40-eYFP 
(a) or to express either GPR40-eCFP (b) or GPR40-eYFP (c) individually.  Control 
interactions with the histamine H1 receptor were recorded.  H1-eYFP was co-expressed 
with GPR40-eCFP (d).  Images were obtained individually for eYFP, eCFP and FRET 
filter channels using an Optoscan monochromator and a dichroic mirror 86002v2bs.  Left 
hand panels represent eCFP images, centre panels represent eYFP images and right hand 
panels represent FRET.  MetaMorph imaging software was used to quantify the FRET 
images as described in section 2.8.7 and are shown in (e).  Data shown are means±SEM 
from three experiments.  *** = p<0.005 versus homo-oligomer FRET. 
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Figure 6.4 FRET imaging of GPR43 homo-oligomerisation in single cells 
HEK293T cells were transiently transfected to co-express GPR43-eCFP and GPR43-eYFP 
(a) or to express either GPR43-eCFP (b) or GPR43-eYFP (c) individually.  Control 
interactions with the histamine H1 receptor were recorded.  H1-eYFPwas co-expressed with 
GPR43-eCFP (d).  Images were obtained individually for eYFP, eCFP and FRET filter 
channels using an Optoscan monochromator and a dichroic mirror 86002v2bs.  Left hand 
panels represent eCFP images, centre panels represent eYFP images and right hand panels 
represent FRET.  MetaMorph imaging software was used to quantify the FRET images as 
described in section 2.8.7, and are shown in (e).  Data shown are means±SEM from three 
experiments.  *** = p<0.005 versus homo-oligomer FRET. 
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Figure 6.5 GPR40 homo-oligomer detected using Tr-FRET 
HEK293T cells were transiently transfected to express GPR40-Flag or GPR40-c-Myc 
individually and were mixed prior to membrane preparation (mix).  Cells were also 
transiently transfected to co-express both GPR40-Flag and GPR40-c-Myc and membranes 
prepared (co).  The resulting membranes were incubated with anti-c-Myc-Eu3+ antibody 
alone or both anti-c-Myc-Eu3+ and anti-Flag-APC antibodies.  Tr-FRET was measured and 
calculated as detailed in section 2.8.6.  Data shown are representative of three individual 
experiments.   
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Figure 6.6 GPR43 homo-oligomer detected using Tr-FRET 
HEK293T cells were transiently transfected to express GPR43-Flag or GPR43-c-Myc 
individually and were mixed prior to membrane preparation.  Cells were also transiently 
transfected to co-express both GPR43-Flag and GPR43-c-Myc (co) and membranes 
prepared.  The resulting membranes were incubated with anti-c-Myc-Eu3+ antibody alone 
or both anti-c-Myc-Eu3+ and anti-Flag-APC antibodies.  Tr-FRET was measured and 
calculated as detailed in section 2.8.6.  Data shown are representative of three individual 
experiments.   
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7 Final Discussion 
GPR40, GPR41 and GPR43 are a small family of GPCRs that are able to respond to fatty 
acids (Covenington et al., 2006; Milligan et al., 2006).  GPR40 responds to long chain fatty 
acids (Briscoe et al., 2003; Itoh et al., 2003; Kotarsky et al., 2003) whereas GPR41 and 
GPR43 are activated by short chain fatty acids (Brown et al., 2003; Le Poul et al., 2003; 
Nilsson et al., 2003).  Their expression pattern, along with the plethora of disease states in 
which fatty acids have been shown to play an important role, has lead to a requirement for 
a fuller understanding of their function and pharmacology.   
Due to the recent identification of fatty acids as the ligands for GPR40-43, assays to 
monitor activation of the receptors are poorly developed.  When GPR41 was expressed 
with Gαi3 only a small concentration-dependent increase of [
35S]GTPγS binding could be 
observed in response to the short chain fatty acid propionate.  The signal to background 
ratio was greatly increased when a GPR41-Gαi3 fusion protein was used.  A GPR40-Gαq 
fusion protein was also utilised but it was found that the addition of long chain fatty acids 
were unable to generate a significant increase of [35S]GTPγS binding.  The high basal 
[35S]GTPγS binding at GPR40 could be reduced, in a concentration-dependent manner, by 
the addition of fatty acid free BSA.  Using fatty acid free BSA to reduce the basal 
[35S]GTPγS binding at GPR40-Gαq allowed the pharmacology of a variety of fatty acids to 
be determined and the potencies obtained were in agreement with potencies measured in 
different assay systems (Briscoe et al., 2003; Itoh et al., 2003; Nilsson et al., 2003).  
Briscoe et al., (2003) and Itoh et al., (2003) found that GPR40 could respond to a wide 
range of fatty acids, with varying chain lengths and degrees of saturation.  Both studies 
measured the potencies of the fatty acids in Ca2+ based assay systems.  The development of 
a [35S]GTPγS binding assay with this receptor could be used to confirm the potencies of a 
wide range of fatty acids as time constraints only allowed the potency of four fatty acids to 
be determined.  There appears to be no relationship between chain length and degree of 
saturation to the ability of a fatty acid to activate GPR40.  Subtle difference may be more 
apparent in the [35S]GTPγS binding assay and may allow full and partial agonists to be 
defined. 
One of the original reports on GPR40 found that the thiazolidinedione, rosiglitazone, acted 
as an agonist at GPR40 (Kotarsky et al., 2003).  I found that rosiglitazone and the related 
compound, troglitazone, both acted as agonists at GPR40 in the [35S]GTPγS binding assay 
and in a FLIPR based Ca2+ mobilisation assay.  The thiazolidinediones are known agonists 
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of PPARγ and are currently used clinically in the treatment of NIDDM.  There is a growing 
body of evidence showing that not all of the effects of thiazolidinediones can be explained 
through action on PPARγ.  The finding that some of these compounds can act as agonists 
at GPR40 may provide an explanation to some of their PPARγ independent effects.  
Further use of the GPR40-eYFP inducible cell line generated in my work will help define 
the action of thiazolidinediones at GPR40, as expression of the receptor can be controlled.  
I found that troglitazone was able to mediate a rise in [Ca2+]i in the β cell line, INS-1E, that 
expresses GPR40 endogenously.  It has been found that β cells also express PPARγ 
(Braissant et al., 1996) and this complicates interpretation of the results.  Both Shapiro et 
al., (2005) and Schnell et al., (2006) were able to reduce the expression of GPR40 
significantly in INS-1E cells by siRNA treatment.  Reducing the expression of GPR40 will 
allow the effects of the thiazolidinediones in these cells to be uncovered.   
Small molecule agonists (Garrido et al., 2006; Briscoe et al., 2006) and an antagonist 
(Briscoe et al., 2006) of GPR40 have recently been described.  I was able to test six of the 
small molecule agonists (Figure 1.2) in the [35S]GTPγS binding assay and in the FLIPR 
based Ca2+ mobilisation assay.  Garrido et al., (2006) reported that a carboxylate group was 
not required for agonist activation of GPR40.  In the [35S]GTPγS assay, the non-carboxyl 
containing agonists were found to be essentially inactive.  This may be due to problems 
with compound solubility and needs to be examined further.  The GPR40 antagonist, 
GW1100 is useful tool in studying the receptor.  It was able to block troglitazone and 
GSK250089A mediated activation of GPR40 and to reduce the high basal [35S]GTPγS 
binding in a concentration-dependent manner.  Time constraints prevented its ability to 
block fatty acid mediated activation of the receptor to be investigated.  Briscoe et al., 
(2006) found that in MIN-6 cells it was unable to fully block linolenic acid potentiation of 
glucose stimulated insulin secretion but could fully block the effects of GW839508X.  
Although attributed to non-GPR40 pathways it may also indicate that the antagonist, and 
small molecule agonists, may bind and activate the receptor slightly differently than fatty 
acids. 
Homology modelling and sequence alignment of GPR40, GPR41 and GPR43 indicated 
that an Arg residue in TM domain 5 could be important in co-ordinating the carboxylate 
group of the fatty acids.  Mutagenesis studies confirmed that the Arg in TM5 was critical 
for activation of GPR41 and GPR43 by fatty acids.  In GPR40, neutralisation of the charge 
in TM5 did not abolish the receptors ability to respond to fatty acids although the mutant 
receptor was unable to be activated by the small molecule agonists or thiazolidinediones.  
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Further mutants were generated which suggested a His in TM4 also plays a role in the 
binding of ligands to GPR40.  The data suggests that the His in TM4 can compensate for 
the loss of the charge in TM5 and vice versa.  It should be noted that the models are static 
images of the initial binding of the ligand to the receptor.  Activation of a receptor is a 
dynamic process and causes significant changes in receptor conformation.  In rhodopsin, 
the covalently bound ligand, 11-cis-retinal, interacts with a range of residues within the 
TM regions.  These interactions are thought to be disrupted due to the conformational 
changes that occur with the isomerisation of 11-cis-retinal to all-trans-retinal.  The 
disruption of these interactions is a prerequisite to receptor activation (Meng and Bourne, 
2001).  Further mutagenesis studies need to be undertaken to gain a fuller understanding of 
the residues important in ligand binding and activation of GPR40.   
It is important to consider the apparent difference between rat and human GPR40.  Using 
membranes prepared from INS-1E cells, it was found that GSK250089A was unable to 
increase [35S]GTPγS binding in the presence of fatty acid free BSA.  Briscoe et al., (2003) 
also found that the related compound GW839508X was unable to potentiate glucose 
stimulated insulin release in isolated rat or mouse islets.  Figure 7.1 shows the sequence 
alignment of rat and human GPR40.  Rat and human GPR40 share 82% homology and 
none of the residues mutated in this study differ between the species.  When placed onto 
the homology model of GPR40 (Figure 7.2), it can be seen that the majority of the residues 
that appear on the model are concentrated at the top of the TM helices and the extracellular 
loops.  Three residues, Val141, Leu186 and Val237, which in rat GPR40 are Ala, Ile and Leu 
respectively, occur close to the proposed binding site.  The difference in the binding sites 
may prevent the synthetic ligands from binding and activating the receptors.  These 
residues could also be mutated in human GPR40 to further characterise the binding site of 
the receptor.  The differences between rat and human GPR40 needs to be examined further, 
with the pharmacology of the small molecule human GPR40 agonists at rat GPR40 
determined.  If these compounds display very different characteristics at the different 
species it will impede the study of the receptor in animal models and the development of 
clinically relevant compounds.    
In light of the findings from the mutagenesis studies it is also important to examine the 
position of the polymorphisms found in GPR40.  There have been two polymorphisms 
recorded within the open reading frame of GPR40, Arg211His (Hamid et al., 2005; Ogawa 
et al., 2005) and Asp175Asn (Hamid et al., 2005).  It is unclear what effect these 
polymorphisms have on the function of GPR40.  Hamid et al., (2005) reported a reduction 
in efficacy towards eicosatriynoic acid for GPR40 Asp175Asn but no change in potency.  
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They found no change in potency or efficacy for this fatty acid at GPR40 Arg211His.  
However, studies on Japanese men have indicated that the Arg211His polymorphism is 
linked to insulin secretory capacity (Ogawa et al., 2005).  Asp175 occurs at the very top of 
TM5, which is close to the proposed binding site but is not expected to make any contacts 
with the agonists.  Arg211His is found within intracellular loop 3, which therefore may 
affect the receptors ability to activate G proteins or other effectors.  Although Hamid et al., 
(2005) studied the effects of the polymorphisms in a recombinant system; it would be 
interesting to carry out a more detailed examination of their effects.  The polymorphisms 
could be incorporated into the GPR40-Gαq fusion protein to allow [
35S]GTPγS binding 
studies to be performed.  This may uncover more subtle changes in the potency or efficacy 
of a variety of ligands.  Wenzel-Seifert and Seifert (2003) used a receptor-G protein fusion 
to study the consequence of the Arg389Gly polymorphism of the β1-adrenoceptor.  This 
polymorphism has been linked to heart function and to the therapeutic effects of β-blocker 
treatment (Liggett et al., 2006).  Using a β1-adrenoceptor-Gαs fusion protein they could not 
detect any difference between the two receptor variants (Wenzel-Seifert and Seifert, 2003).   
Due to time constraints, I was unable to test the GPR40 antagonist, GW1100, at the GPR40 
mutants.  Antagonists do not always share the same binding site as agonists.  In the case of 
α1b adrenergic receptor antagonists, such as pentolamine and WB4101, they do not make 
the same interactions as agonists (Zhao et al., 1996).  Agonists of this receptor bind within 
a crevice formed by the transmembrane helices, whereas these antagonists are thought to 
interact with residues in extracellular loop 2.  In the case of the β2 adrenergic receptor 
antagonists, alprenolol and propranolol, they have been shown to interact with the aspartic 
acid residue in TM3 (Asp113), which is conserved in the biogenic amine receptors, but 
other key interactions differ (Suryanarayana et al., 1991).  The two GPR40-Gαq mutants 
displayed high basal [35S]GTPγS binding which could be reduced by treatment with fatty 
acid free BSA.  GW1100 was able to reduce the basal [35S]GTPγS binding in the wild type 
GPR40-Gαq fusion protein in a concentration dependent manner.  Therefore, testing the 
ability of GW1100 to reduce the basal [35S]GTPγS at the GPR40 mutants would give an 
indication if it could still act as an antagonist. 
The models of GPR40, GPR41 and GPR43 were built based on homology of the receptors 
to bovine rhodopsin.  The mutagenesis studies on the receptors have demonstrated some of 
the shortcomings with drawing conclusions only from homology modelling.  In the case of 
GPR41 and GPR43 the models predicted that the Arg in TM5 was in a position to co-
ordinate the carboxylate group of the fatty acid and this was supported by the mutagenesis 
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studies.  A similar mechanism was suggested from the model of GPR40 but this was not 
confirmed by the data generated from the mutant receptors.  The receptors share low 
sequence homology with bovine rhodopsin therefore a model based on the structure of 
rhodopsin may not be entirely accurate.  Unfortunately, bovine rhodopsin is the only 
GPCR for which high-resolution structural data exists.  The models of GPR40, GPR41 and 
GPR43 now need to be refined to take into account the finding of the mutagenesis studies.   
The small size of the ligands of GPR41 and GPR43 make their positioning into the models 
difficult as they can be accommodated in a variety of ways.  It is possible that more than 
one fatty acid needs to be bound for activation of the receptor.  This will be a hard question 
to answer as no small molecule agonists exist for either GPR41 or GPR43, and as seen 
with GPR40, they may not even bind in a similar manner to the fatty acids.  There is a 
range of radioactively labelled fatty acids i.e.3H-palmitic acid, and fluorescent labelled 
fatty acids available commercially i.e. BODIPY labelled fatty acids (Molecular Probes).  In 
the case of fluorescent fatty acids, the fluorescent moiety is attached to the end of the 
carbon chain that leaves the carboxyl group intact.  Fluorescent probes have been used to 
investigate the BLT1 receptor whose ligands also contain a carboxyl group.  In this case, 
the fluorescent moiety was attached to the carboxyl end, which helped show that a 
carboxyl group was not essential for activation of the receptor and provided clues to the 
binding of the ligand to the receptor (Sabrish et al., 2005; Sabrish et al., 2006).  The 
possible problem with fluorescent and radioactive fatty acids is that they may become 
incorporated into the membrane and render any specific binding impossible to detect.  
Fatty acids are not very potent ligands and this would impact on the level of specific 
binding, which in turn makes the fluorescent or radioactive fatty acids unsuitable to 
monitor ligand binding at these receptors.   
The limitations of studying the pharmacology of GPR40, GPR41 and GPR43 are wide 
ranging, especially for GPR41 and GPR43 as there has been no small molecule agonists or 
antagonists described for either receptor.  With the mutagenesis studies it is impossible to 
determine if the fatty acids or other ligands are actually binding the receptor.  As discussed 
above, it is unlikely that a modified fatty acid would be of use in a ligand-binding assay.  
In this study I have shown that rosiglitazone and troglitazone act as agonists of GPR40 and 
troglitazone was more potent than any of the fatty acids tested.  Radiolabelled rosiglitazone 
(3H-rosiglitazone – American Radiolabeled Chemicals) is available commercially and may 
prove to be a useful compound to investigate the ligand binding properties of wild type 
GPR40 and the GPR40 mutants.   
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The majority of studies into GPR40, GPR41 and GPR43 have used one fatty acid to 
activate the receptor.  A recent study by Dass et al., (2007) examined the effects of short 
chain fatty acids on intestinal motility and the possible contribution of GPR43.  Although 
they showed that fatty acid mediated intestinal contraction was unlikely to be due to 
activation of GPR43, they did test in vivo concentrations of fatty acids.  They determined 
the concentrations of short chain fatty acids in rat intestine and found acetate to be the most 
predominant fatty acid, followed by propionate then butyrate, with a molar ratio of 59:7:34 
and a maximum concentration of 115mmol L-1.  When testing a combination of fatty acids 
at in vivo concentrations they found they exerted highly significant effects on intestinal 
motility compared to the individual fatty acids (Dass et al., 2007).  It would be of interest 
to test a combination of fatty acids at in vivo concentrations in a recombinant system and 
the [35S]GTPγS binding assay developed for GPR41 would be a obvious starting point.   
As shown in chapter 6, GPR40 and GPR43 were able to form homo-oligomers.  They were 
also able to form hetero-oligomers with the histamine H1 receptor, albeit with apparent 
lower affinity than the homo-oligomers.  The potential for the receptors to form hetero-
oligomers with a receptor that they share little homology with, makes the probability of 
them forming hetero-oligomers with each other high.  There is a growing amount of 
interest into the functional significance of hetero-oligomers and how it may alter the 
pharmacology of receptors.  It would be interesting to determine the ability of GPR40, 
GPR41 and GPR43 to form hetero-oligomers and how this may alter their pharmacology.   
In conclusion, this study has led to a fuller understanding of the pharmacology, function 
and oligomerisation of GPR40, GPR41 and GPR43 and uncovered some unusual 
properties of GPR40 in particular.  This study will provide a good basis for further 
investigations into the function and physiological relevance of these receptors.   
Leigh Ann Stoddart, 2007   235 
 
 
Figure 7.1 Amino acid sequence alignment of human and rat GPR40 
Amino acid sequences corresponding to human GPR40 and rat GPR40 were aligned using 
the ClustalX algorithm.  Residues are coloured as follow; small and hydrophobic residues 
are coloured red, acidic residues coloured blue, basic residues coloured magenta, hydroxyl 
and amine containing residues are coloured green.  The residues mutated in human GPR40 
during the mutagenesis studies are boxed.  Accession numbers of the sequences used are as 
follows: human GPR40, NP005294; rat GPR40, NP695216. 
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Figure 7.2 Position of residues that differ between human and rat GPR40 
The homology model of GPR40 was generated by GlaxoSmithKline using the 
GPCR_Builder programme based on the structure of rhodopsin.  GPR40 was aligned with 
rhodopsin on the basis of highly conserved residues found in family A GPCRs.  The model 
shows the residues mutated in human GPR40 during the mutagenesis studies, which are 
coloured red, and the residues that differ in rat GPR40, which are coloured yellow. 
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9 Additional Material 
The following paper was published as a result of the studies carried out for this thesis.   
